

# **Children's Hospital Medical Center and Affiliates**

Title 2 U.S. Code of Federal Regulations  
Part 200 (Uniform Guidance) Reports for the  
Year Ended June 30, 2024

# CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

## TABLE OF CONTENTS

---

|  | <b>Page</b> |
|--|-------------|
| INDEPENDENT AUDITOR'S REPORT   | 1-2         |
| CONSOLIDATED FINANCIAL STATEMENTS FOR THE<br>YEARS ENDED JUNE 30, 2024 AND 2023:   |             |
| Consolidated Balance Sheets  | 3           |
| Consolidated Statements of Operations and Changes in Net Assets  | 4-5         |
| Consolidated Statements of Cash Flows  | 6           |
| Notes to Consolidated Financial Statements   | 7-32        |
| SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS<br>FOR THE YEAR ENDED JUNE 30, 2024   | 33-47       |
| NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF<br>FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2024  | 48          |
| REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND<br>ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF<br>FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH<br><i>GOVERNMENT AUDITING STANDARDS</i> | 49-50       |
| REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM;<br>REPORT ON INTERNAL CONTROL OVER COMPLIANCE;<br>AND REPORT ON THE SCHEDULE OF EXPENDITURES OF<br>FEDERAL REQUIRED BY THE UNIFORM GUIDANCE             | 51-53       |
| SCHEDULE OF FINDINGS AND QUESTIONED COSTS  | 54-55       |

## **INDEPENDENT AUDITOR'S REPORT**

To the Board of Trustees  
Children's Hospital Medical Center and Affiliates  
Cincinnati, Ohio

### **Report on the Audit of the Financial Statements**

#### ***Opinion***

We have audited the consolidated financial statements of Children's Hospital Medical Center and Affiliates (the "Company"), which comprise the consolidated balance sheets as of June 30, 2024 and 2023, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### ***Basis for Opinion***

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### ***Responsibilities of Management for the Financial Statements***

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date that the financial statements are issued.

### ***Auditor's Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

### ***Other Reporting Required by Government Auditing Standards***

In accordance with *Government Auditing Standards*, we have also issued our report dated September 30, 2024 on our consideration of the Company's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control over financial reporting and compliance.

*Deloitte + Touche LLP*

September 30, 2024

## Children's Hospital Medical Center and Affiliates

Consolidated Balance Sheets  
June 30, 2024 and 2023 (dollars in thousands)

|  | <u>2024</u>          | <u>2023</u>         |
|--|----------------------|---------------------|
| <b>CURRENT ASSETS:</b>                                     |                      |                     |
| Cash and cash equivalents                                  | \$ 189,507           | \$ 200,381          |
| Marketable securities                                      | 1,335,526            | 1,298,639           |
| Cash, cash equivalents and marketable securities           | <u>1,525,033</u>     | <u>1,499,020</u>    |
| Patient receivables, net                                   | 704,875              | 588,455             |
| Other receivables  | 236,163              | 165,009             |
| Inventories and prepaid expenses                           | 93,336               | 86,765              |
| Total current assets                                       | <u>2,559,407</u>     | <u>2,339,249</u>    |
| ASSETS LIMITED AS TO USE - Funds in trust                  | 40,186               | 36,482              |
| PROPERTY AND EQUIPMENT,<br>net of accumulated depreciation | 1,650,130            | 1,556,549           |
| GOODWILL   | 5,579                | 6,437               |
| OPERATING LEASE RIGHT-OF-USE ASSETS                        | 20,696               | 15,926              |
| PENSION BENEFIT ASSET                                      | 132,504              | 185,998             |
| OTHER LONG-TERM ASSETS                                     | 126,626              | 92,995              |
| INTEREST IN NET ASSETS OF SUPPORTING ORGANIZATIONS         | 5,527,851            | 4,869,148           |
| Total assets   | <u>\$ 10,062,979</u> | <u>\$ 9,102,784</u> |
| <b>CURRENT LIABILITIES:</b>                                |                      |                     |
| Accounts payable and accrued expenses                      | \$ 532,445           | \$ 483,353          |
| Current portion of long-term debt and lease obligations    | 20,063               | 18,856              |
| Commercial paper   | 100,000              | 100,000             |
| Bonds payable subject to remarketing, net                  | 70,023               | 78,270              |
| Total current liabilities                                  | <u>722,531</u>       | <u>680,479</u>      |
| SELF-INSURANCE RESERVES                                    | 17,443               | 31,020              |
| LONG-TERM DEBT:  |                      |                     |
| Tax-exempt bonds payable                                   | 301,036              | 315,187             |
| Taxable bonds payable                                      | 596,637              | 596,407             |
| Finance lease obligations                                  | 41,202               | 48,275              |
| Operating lease obligations                                | 18,484               | 13,439              |
| OTHER LONG-TERM LIABILITIES                                | 15,283               | 15,095              |
| Total liabilities  | <u>1,712,616</u>     | <u>1,699,902</u>    |
| COMMITMENTS AND CONTINGENCIES (Note 11)                    | -                    | -                   |
| <b>NET ASSETS:</b>   |                      |                     |
| Without donor restrictions                                 | 2,602,373            | 2,310,909           |
| With donor restrictions                                    | 5,747,990            | 5,091,973           |
| Total net assets   | <u>8,350,363</u>     | <u>7,402,882</u>    |
| Total liabilities and net assets                           | <u>\$ 10,062,979</u> | <u>\$ 9,102,784</u> |

See accompanying notes to Consolidated Financial Statements.

## Children's Hospital Medical Center and Affiliates

Consolidated Statements of Operations and Changes in Net Assets  
For the Years Ended June 30, 2024 and 2023 (dollars in thousands)

|   | <u>2024</u>       | <u>2023</u>      |
|---|-------------------|------------------|
| <b>OPERATING REVENUES, GAINS AND OTHER SUPPORT:</b>                               |                   |                  |
| Net patient service revenue   | \$ 2,765,941      | \$ 2,508,408     |
| Net assets released from restriction used for operations-                         |                   |                  |
| Grant revenue   | 254,163           | 247,146          |
| Other restricted net assets used to support operations                            | 160,880           | 139,133          |
| Other revenue   | 196,719           | 207,854          |
| Total operating revenues, gains and other support                                 | <u>3,377,703</u>  | <u>3,102,541</u> |
| <b>OPERATING EXPENSES:</b>  |                   |                  |
| Salaries  | 1,668,703         | 1,510,665        |
| Employee benefits   | 431,024           | 388,496          |
| Supplies, drugs and other   | 599,215           | 570,020          |
| Purchased services  | 376,866           | 339,535          |
| Depreciation and amortization   | 152,764           | 149,767          |
| Utilities   | 22,028            | 21,615           |
| Interest  | 32,860            | 32,531           |
| Total operating expenses  | <u>3,283,460</u>  | <u>3,012,629</u> |
| Operating income  | 94,243            | 89,912           |
| <b>NONOPERATING GAINS:</b>  |                   |                  |
| Net investment return   | 127,935           | 42,160           |
| Net benefit gain other than service cost  | 37,863            | 14,674           |
| Net nonoperating gains  | <u>165,798</u>    | <u>56,834</u>    |
| Revenue and gains in excess of expenses   | 260,041           | 146,746          |
| <b>OTHER CHANGES IN NET ASSETS WITHOUT DONOR RESTRICTIONS:</b>                    |                   |                  |
| Receipts and receipts due from supporting organizations                           | 53,292            | 3,272            |
| Net assets released from restrictions used for purchase of property and equipment | 21,585            | 12,844           |
| Consolidation of sole member entity   | 4,017             | -                |
| Transfers to supporting organizations   | (4,185)           | (3,269)          |
| Pension and post-retirement health liability adjustment                           | (43,286)          | (61,577)         |
| Increase in net assets without donor restrictions                                 | <u>\$ 291,464</u> | <u>\$ 98,016</u> |

(Continued on next page)

## Children's Hospital Medical Center and Affiliates

Consolidated Statements of Operations and Changes in Net Assets  
For the Years Ended June 30, 2024 and 2023 (dollars in thousands)

|  | <u>2024</u>         | <u>2023</u>         |
|--|---------------------|---------------------|
| NET ASSETS WITH DONOR RESTRICTIONS:  |                     |                     |
| Contributions and investment income-   |                     |                     |
| Grant receipts   | \$ 255,744          | \$ 247,837          |
| Gifts and contributions of financial assets and other income                   | 176,011             | 160,507             |
|  | <u>431,755</u>      | <u>408,344</u>      |
| Net assets released from restriction-  |                     |                     |
| Grant expenditures   | (254,163)           | (247,146)           |
| Net assets with donor restrictions used to support operations                  | (160,880)           | (139,133)           |
| Net assets with donor restrictions used for purchase of property and equipment | (21,585)            | (12,844)            |
|  | <u>(436,628)</u>    | <u>(399,123)</u>    |
| Gain in interest in net assets of supporting organizations                     | 658,703             | 406,357             |
| Consolidation of sole member entity  | 2,187               | -                   |
|  | <u>656,017</u>      | <u>415,578</u>      |
| Increase in net assets with donor restrictions                                 |                     |                     |
|  | <u>656,017</u>      | <u>415,578</u>      |
| INCREASE IN NET ASSETS   | 947,481             | 513,594             |
| NET ASSETS, beginning of year  | <u>7,402,882</u>    | <u>6,889,288</u>    |
| NET ASSETS, end of year  | <u>\$ 8,350,363</u> | <u>\$ 7,402,882</u> |

See accompanying notes to Consolidated Financial Statements.

## Children's Hospital Medical Center and Affiliates

### Consolidated Statements of Cash Flows

For the Years Ended June 30, 2024 and 2023 (dollars in thousands)

|   | <u>2024</u>       | <u>2023</u>       |
|---|-------------------|-------------------|
| <b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>  |                   |                   |
| Increase in net assets  | \$ 947,481        | \$ 513,594        |
| Adjustments to reconcile increase in net assets to net cash provided by operating activities- |                   |                   |
| Depreciation and amortization   | 151,914           | 149,340           |
| Loss on disposal of property and equipment  | 752               | 1,031             |
| Proceeds from sale of donated securities  | 466               | 874               |
| Receipts from supporting organizations  | (3,292)           | (3,272)           |
| Contributions of financial assets to supporting organizations                                 | 4,185             | 3,269             |
| Contributions of financial assets restricted for purchase of property and equipment           | (21,585)          | (12,844)          |
| Gain in interest in net assets of supporting organizations                                    | (658,703)         | (406,357)         |
| Unrealized and realized gains on marketable securities, net                                   | (84,076)          | (1,288)           |
| Loss (gain) on interest rate swap   | 1,013             | (1,182)           |
| Increase in receivables   | (187,574)         | (99,774)          |
| Increase in inventories and prepaid expenses and other assets                                 | (41,215)          | (25,841)          |
| Decrease in pension benefit asset   | 53,494            | 95,045            |
| Increase in accounts payable and accrued expenses, net  | 33,818            | 7,833             |
| Decrease in operating lease obligations   | (3,062)           | (2,847)           |
| (Decrease) increase in self-insurance reserves and other long-term liabilities                | (4,889)           | 1,354             |
| Net cash provided by operating activities   | <u>188,727</u>    | <u>218,935</u>    |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>  |                   |                   |
| Expenditures for property and equipment   | (239,464)         | (257,602)         |
| Purchases of marketable securities  | (1,079,864)       | (944,601)         |
| Sales and maturities of marketable securities   | 1,126,586         | 905,586           |
| Cash withdrawn from funds in trust  | 3,620             | 5,813             |
| Cash invested in funds in trust   | (8,673)           | (9,427)           |
| Net cash used in investing activities   | <u>(197,795)</u>  | <u>(300,231)</u>  |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>  |                   |                   |
| Issuance of bonds and notes payable   | 66,155            | -                 |
| Repayment of bonds, notes payable, and finance lease obligations                              | (90,002)          | (23,938)          |
| Contributions restricted for purchase of property and equipment                               | 21,585            | 12,844            |
| Receipts from supporting organizations  | 3,292             | 3,272             |
| Contributions to supporting organizations   | (4,185)           | (3,269)           |
| Net cash used in financing activities   | <u>(3,155)</u>    | <u>(11,091)</u>   |
| Net decrease in cash, cash equivalents, and restricted cash                                   | (12,223)          | (92,387)          |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, beginning of year                                | <u>209,959</u>    | <u>302,346</u>    |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, end of year                                      | <u>\$ 197,736</u> | <u>\$ 209,959</u> |
| <b>SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES:</b>                              |                   |                   |
| Capital expenditures in accounts payable and accrued expenses                                 | \$ 36,409         | \$ 29,635         |
| Acquisition of property through finance leases  | -                 | 7,192             |
| Acquisition of property through operating leases  | 7,897             | 1,540             |

See accompanying notes to Consolidated Financial Statements.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

(1) Accounting Policies –

- (a) Basis of Consolidation – Children's Hospital Medical Center (Cincinnati Children's), River City Insurance Limited (River City), CHMC Community Health Services Network (CHSN), HealthVine LLC (HealthVine), Every Child Succeeds (ECS), and other investment holding entities are included in the accompanying Consolidated Financial Statements and are collectively referred to as Cincinnati Children's. The previously named entities are all wholly own subsidiaries of Cincinnati Children's whose intercompany transactions and balances have been eliminated.

Cincinnati Children's is an Ohio not-for-profit corporation providing pediatric healthcare services, education, and research. River City is a captive insurance company. CHSN's purpose is to manage primary care practices in a community setting. HealthVine supports the population health and care coordination initiatives of Cincinnati Children's. ECS is a not-for-profit organization designed to optimize child development for first-time, at-risk mothers.

Effective August 2023, Cincinnati Children's became the sole member of ECS with no consideration paid. Consequently, Cincinnati Children's assumed the fair value of assets of \$7,920 and the fair value of associated liabilities of \$1,716 resulting in an increase in Net assets without donor restrictions of \$4,017 and an increase in Net assets with donor restrictions of \$2,187.

- (b) Supporting Organizations – The Children's Hospital (TCH) and Convalescent Hospital Fund for Children (CHFC) are both Ohio not-for-profit corporations that provide financial support to Cincinnati Children's. The TCH and CHFC purpose clauses both specify the support of Cincinnati Children's as the organization's sole purpose. Additionally, certain endowment funds of these supporting organizations are restricted by the donors for specific operating purposes of Cincinnati Children's. As such, the assets of TCH and CHFC are recorded in Cincinnati Children's Consolidated Financial Statements as Interest in net assets of supporting organizations and as Net assets with donor restrictions. Changes in the fair value of Interest in net assets of supporting organizations are recorded as a Gain in interest in net assets of supporting organizations in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

The majority of receipts are from TCH and CHFC donor-restricted endowment funds or are other receipts that are designated by the supporting organizations' Boards of Trustees for specific operating purposes. The receipts are reflected in Gifts and contributions of financial assets and other income with donor restrictions in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Upon spending, such funds are reflected in Other restricted net assets used to support operations in the Consolidated Statements of Operations and Changes in Net Assets.

Other receipts from TCH are designated by the supporting organization's Board of Trustees to provide general support. The receipts are reflected in Receipts and receipts due from supporting organizations without donor restriction in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

- (c) Support Received from Supporting Organizations – TCH and CHFC provide annual support to Cincinnati Children's through transfers of dividend and interest earnings on investments, net of investment management fees, administrative expenses, and donor-required income reinvestments.

The supporting organizations' respective Boards of Trustees may also make certain pledges of principal without donor restriction in support of key projects or initiatives at Cincinnati Children's. In January 2020, CHFC's Board of Trustees made a gift in the amount of \$36,000 to support the

## Children’s Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

construction of a new facility at the College Hill Campus and programmatic support of Cincinnati Children’s *Pursuing our Potential in Mental Health* initiative. The agreement has certain criteria that represent donor-imposed conditions that must be overcome before Cincinnati Children’s is entitled to the assets promised. Contributions of \$10,000 were made for each of the years ended June 30, 2024 and June 30, 2023. The receipts are reflected in Gifts and contributions of financial assets and other income with donor restrictions and in Net assets released from restrictions used for purchase of property and equipment in the Consolidated Statements of Operations and Changes in Net Assets.

During fiscal year 2024, TCH’s Board of Trustees approved a request from Cincinnati Children’s for \$200,000. This represents a return of funds previously transferred to TCH from Cincinnati Children’s Net assets without donor restrictions. The commitment will be distributed over four years in the amount of \$50,000 each year and is intended to support research capital projects. The first \$50,000 distribution was approved by TCH’s Board of Trustees prior to June 30, 2024, and the transfer was made subsequent to year-end. At June 30, 2024, the transaction was recorded as an Other receivable and as a Receipt due from supporting organizations without donor restrictions. The remainder of the commitment is revocable at the discretion of TCH’s Board of Trustees, and therefore a receivable is not recorded to the Consolidated Balance Sheet for such amounts.

The following table details transfers between Cincinnati Children’s and Supporting Organizations in the Consolidated Statements of Operations and Changes in Net Assets:

|  | <u>2024</u>       | <u>2023</u>       |
|--|-------------------|-------------------|
| Transfers of net assets with donor restrictions included in    |                   |                   |
| Gifts and contributions of financial assets and other income:  |                   |                   |
| Cincinnati Children’s from TCH                                 | \$ 125,215        | \$ 116,861        |
| Cincinnati Children’s from CHFC                                | 16,360            | 15,585            |
| Total  | <u>\$ 141,575</u> | <u>\$ 132,446</u> |
| Transfers of net assets without donor restrictions included in |                   |                   |
| Receipts from (Transfers to) supporting organizations:         |                   |                   |
| Cincinnati Children’s from TCH                                 | \$ 3,292          | \$ 3,272          |
| Cincinnati Children’s due from TCH                             | 50,000            | -                 |
| Cincinnati Children’s to TCH (1)                               | (4,185)           | (3,269)           |
| Total  | <u>\$ 49,107</u>  | <u>\$ 3</u>       |

(1) The purpose of this transfer is to establish funds designated to support divisional activities and strategic priorities.

(d) Revenue Recognition – The following revenue streams are subject to the revenue recognition guidance in Accounting Standards Codification No. 606 (ASC 606) “Revenue from Contracts with Customers”:

|                             | <u>2024</u>         | <u>2023</u>         |
|-----------------------------|---------------------|---------------------|
| Net patient service revenue | \$ 2,765,941        | \$ 2,508,408        |
| Other revenue               | 196,719             | 207,854             |
|                             | <u>\$ 2,962,660</u> | <u>\$ 2,716,262</u> |

### Net Patient Service Revenue

Cincinnati Children’s net patient service revenue generally relates to contracts with patients in which the performance obligations are to provide health care services to patients. As patients simultaneously

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

receive and consume the benefits of health care provided by Cincinnati Children's, the performance obligations meet the criteria to be satisfied over time. Net patient service revenue is recorded as services are provided. Payment for such services is due between thirty to forty-five days from payer receipt of claim. Consideration for patient service revenue is variable. Agreements with payers typically provide for payments at amounts less than established charges.

Cincinnati Children's has an agreement with an Ohio Medicaid managed care company in which performance obligations are to stand-ready to provide care for approximately 98,000 children. The performance obligation to stand-ready is satisfied over time. Cincinnati Children's is reimbursed under a variable capitation methodology for hospital services. All physician and home care services are reimbursed based on provider fee schedules. The hospital services are reimbursed through a variable capitation payment which represents the amount remaining after payment has been made for (a) Cincinnati Children's physician services, (b) Cincinnati Children's home care services, (c) services provided to members by facilities outside the Cincinnati Children's network, and (d) an actuarially determined accrual for incurred but not reported claims (see Note 1h). Under delegation agreements, Cincinnati Children's receives fixed payments to perform the required medical management, care management and care coordination functions. Medicaid managed care organizations retain risk for payments to providers. The amount of net patient service revenue recorded under this arrangement in fiscal year 2024 and 2023 was \$98,311 and \$121,666, respectively.

Laws and regulations concerning government programs, including Medicaid and Medicare, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from related programs. There can be no assurance that regulatory authorities will not challenge Cincinnati Children's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon Cincinnati Children's. In addition, the contracts Cincinnati Children's has with third party payers also provide for retroactive audit and review of claims. At June 30, 2024, Cincinnati Children's has settled all Medicaid cost reports through 2018 and all Medicare cost reports through 2021.

Settlements with third party payers for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of estimated transaction price for providing patient care. These settlements are based on the terms of the payment agreement with the payer, correspondence from the payer, and Cincinnati Children's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Estimated settlements are adjusted in future periods as adjustments become known based on new information or as years are settled and no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in transaction price were not material in fiscal years 2024 and 2023.

Generally, patients who are covered by third party payers are responsible for related deductibles and coinsurance, which vary in amount. Cincinnati Children's also provides services to uninsured patients and offers those uninsured patients a discount, either by policy or law, from standard charges. Cincinnati Children's estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by established

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of change.

Consistent with Cincinnati Children's mission, care is provided to patients regardless of their ability to pay. Therefore, Cincinnati Children's has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances. The implicit price concessions included in estimating the transaction price represent the difference between the amounts billed to patients and the amounts Cincinnati Children's expects to collect based on its collection history with those patients.

Patients who meet Cincinnati Children's criteria for charity care are provided care without charge or at amounts less than established rates. Amounts determined to qualify as charity care are not reported as net patient service revenue.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, Cincinnati Children's has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the fiscal year. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the fiscal year. The performance obligations for these contracts are generally completed when patients are discharged, which generally occurs shortly after the end of the fiscal year.

In both fiscal years 2024 and 2023, substantially all net patient service revenue is derived from third-party payment programs (Medicaid, insurance companies and various managed care agreements). Cincinnati Children's classifies its patients by payer. The following table disaggregates Cincinnati Children's net patient service revenue by payer categories for the fiscal year ended June 30, 2024 and 2023:

|                                      | <b>2024</b> |                     | <b>2023</b> |                     |
|--------------------------------------|-------------|---------------------|-------------|---------------------|
| Managed care and commercial insurers | 63%         | \$ 1,743,742        | 64%         | \$ 1,605,381        |
| Government (HMO and third party)     | 30%         | 821,469             | 30%         | 752,522             |
| International                        | 4%          | 116,154             | 3%          | 75,252              |
| Specialty contracts <sup>1</sup>     | 2%          | 55,898              | 2%          | 50,168              |
| Self-pay                             | 1%          | 28,678              | 1%          | 25,085              |
|                                      |             | <u>\$ 2,765,941</u> |             | <u>\$ 2,508,408</u> |

The following details the percentage of accounts receivable by payer category as of June 30, 2024 and 2023:

|                                      | <b>2024</b> | <b>2023</b> |
|--------------------------------------|-------------|-------------|
| Managed care and commercial insurers | 52%         | 58%         |
| Government (HMO and third party)     | 25%         | 23%         |
| International                        | 17%         | 14%         |
| Specialty contracts <sup>1</sup>     | 3%          | 2%          |
| Self-pay                             | 3%          | 3%          |

<sup>1</sup> Specialty contracts are single case agreements or contracts for specialty services, such as transplants.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

#### **Other Revenue**

Cincinnati Children's other revenue generally relates to contracts with external organizations in which the performance obligations are to provide research services or other various fee-for-service arrangements outside the scope of healthcare services.

Revenue from industry contracts and certain government contracts is earned based on performance obligations to provide research services to the external organizations. License and royalty revenue relates to contracts with other organizations in which our performance obligations are to provide intellectual property to the organization. Revenue is also earned for various other contracted fee-for-service arrangements where services are performed for external organizations outside the scope of healthcare services for Cincinnati Children's patients. Performance obligations for industry and government contracts, license and royalty contracts, and various other fee-for-service arrangements are satisfied over time. Consideration is fixed based on contracted price, and there is no significant variable consideration related to these agreements.

A contract liability exists when an entity has an obligation to transfer goods or services to a customer. Cincinnati Children's has contract liabilities of \$67,954 and \$66,354 recorded within Accounts payable and accrued expenses for the years ended June 30, 2024 and 2023, respectively. The balance of contract liabilities on July 1, 2022 was \$60,289.

- (e) Graduate Medical Education – Cincinnati Children's receives Federal graduate medical education funding. Other revenue of \$12,532 and \$12,111 was recognized for the years ended June 30, 2024 and 2023, respectively.
- (f) Tax Exempt Status – Cincinnati Children's, CHSN and ECS are exempt from federal income taxes under Section 501(a) of the Internal Revenue Code as organizations described in Section 501(c)(3). HealthVine is a single-member LLC wholly owned by Cincinnati Children's treated as a disregarded entity of Cincinnati Children's for income tax purposes. River City is a captive insurance corporation wholly owned by Cincinnati Children's. Cincinnati Children's, CHSN, ESC, HealthVine and River City are generally not subject to federal or state income tax obligations. Other investment holding entities' income is taxable to Cincinnati Children's. The income tax provisions recorded in the accompanying Consolidated Financial Statements are immaterial for the years ended June 30, 2024 and 2023.

Cincinnati Children's accounts for income taxes in accordance with Accounting Standards Codification Topic (ASC) 740 "Income Taxes". It is Cincinnati Children's policy to classify the expense related to interest and penalties, if any, to be paid on underpayments of income taxes within other expenses. There were no material penalties or interest recognized in fiscal years 2024 and 2023. Cincinnati Children's paid \$852 and \$2,171 in income taxes for unrelated business income during the year ended June 30, 2024 and 2023, respectively.

Fiscal years 2021 through 2024 are subject to examination by both the Federal and State tax jurisdictions.

- (g) Cash Equivalents – Cash equivalents consist primarily of money market and money market mutual funds, demand deposits, and commercial paper investments with maturities of three months or less. Cash is held primarily in two financial institutions.
- (h) Inventories and Prepaid Expenses – Inventories consist primarily of medical supplies and pharmaceuticals and are valued on an average cost method.

## Children’s Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

As part of Cincinnati Children’s variable capitation agreement, reimbursement is reduced by an actuarially determined estimate for incurred but not reported claims. Cincinnati Children’s recorded incurred but not reported claims of approximately \$20,555 and \$19,441 for the years ended June 30, 2024 and 2023, respectively. The estimate is recorded as an increase in Prepaid expenses and an increase in Accounts payable and accrued expenses.

- (i) Marketable Securities – Cincinnati Children’s accounts for its investments under ASC 958-320 “Not-for-Profit Entities – Investments – Debt Securities” and ASC 958-321 “Not-for-Profit Entities – Investments – Equity Securities.” Cincinnati Children’s carries its marketable securities at fair value with unrealized gains and losses included in Net investment return in the accompanying Consolidated Statements of Operations and Changes in Net Assets.
- (j) Property and Equipment – Property and equipment are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, ranging from three to forty years, as follows:

|                                     |            |
|-------------------------------------|------------|
| Land Improvements                   | 3-25 years |
| Buildings and Building Improvements | 5-40 years |
| Equipment                           | 3-25 years |

Cincinnati Children’s evaluates long-lived assets under the provisions of ASC 360 “Property Plant and Equipment.” During fiscal years 2024 and 2023, Cincinnati Children’s did not incur any losses related to impairment of property and equipment.

- (k) Goodwill – Goodwill is the excess of the purchase price over the fair value of the net assets of an entity acquired. Cincinnati Children’s elected to apply the accounting alternatives available for not-for-profit entities. Goodwill is amortized over a 10-year period and tested for impairment at the entity level when a triggering event occurs. During the years ended June 30, 2024 and 2023, no amounts were recorded to goodwill and no impairment losses were recognized. During fiscal year 2024 and 2023, \$858 and \$859 of amortization expense was recognized to Depreciation and amortization, respectively.
- (l) Leases – Cincinnati Children’s leases property and equipment under finance and operating leases. Cincinnati Children’s determines if an arrangement is a lease at inception. Right-of-use assets and lease obligations are recognized for leases with terms greater than 12 months based on the net present value of the future minimum lease payments over the lease term at commencement date. When readily determinable, Cincinnati Children’s uses the interest rate implicit in the lease to determine the present value of future minimum lease payments. However, most of Cincinnati Children’s leases do not have a readily determinable implicit interest rate. For these leases, Cincinnati Children’s uses a collateralized incremental borrowing rate based on the period and cash payment stream comparable with that of each lease. The right-of-use asset and lease obligations include a value for options to extend a lease if it is reasonably certain that the option will be exercised.

The current portion of operating lease obligations is included in the Current portion of long-term debt and lease obligations and the non-current portion is separately stated as Operating lease obligations on the Consolidated Balance Sheets. The related right-of-use assets are included in Operating lease right-of-use assets on the Consolidated Balance Sheets. Operating lease expense is recognized on a straight-line basis over the lease term and is included in Purchased services in the Consolidated Statements of Operations and Changes in Net Assets.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

The current portion of finance lease obligations is included in Current portion of long-term debt and lease obligations and the non-current portion is separately broken out as Finance lease obligations on the Consolidated Balance Sheets. The related finance lease right-of-use assets are included in Property and equipment, net on the Consolidated Balance Sheets. Finance lease right-of-use assets are amortized using the straight-line method over the shorter period of the lease term or the estimated useful life of the property or equipment. Such amortization expense is included in Depreciation in the Consolidated Statements of Operations and Changes in Net Assets.

- (m) Costs of Borrowing – Interest incurred on borrowed funds, net of interest earned on restricted bond funds, during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. In fiscal years 2024 and 2023, Cincinnati Children's capitalized \$6,032 and \$5,759 of interest related to construction in progress, respectively. Total cash paid for interest was approximately \$38,046 and \$37,210 in fiscal years 2024 and 2023, respectively.

Deferred bond issuance costs and issuance premiums are amortized using the effective interest method over the period the related obligation is outstanding.

- (n) Interest Rate Swap Agreement – Cincinnati Children's has an interest rate swap agreement to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. The swap agreement is measured at fair value and recognized in the Consolidated Balance Sheets within Other long-term assets. Cincinnati Children's recognizes gains and losses from the changes in fair value of the interest rate swap agreement as Non-operating gains within Net investment return on the Consolidated Statements of Operations and Changes in Net Assets.

- (o) Net Asset Classifications – Cincinnati Children's reports its financial position and activities according to the following net asset classifications:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objective of the organization are classified as Net assets without donor restrictions. These net assets may be used at the discretion of Cincinnati Children's management.

Net assets with donor restrictions – Net assets subject to stipulations imposed by donors or supporting organizations are classified as Net assets with donor restrictions. Some restrictions are temporary in nature; those restrictions will be met by fulfilling a certain purpose or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the principal be maintained in perpetuity.

Net assets with donor restrictions are comprised of the following:

|   | <u>2024</u>    | <u>2023</u>    |
|---|----------------|----------------|
| Subject to expenditure for specified purpose: |                |                |
| Clinical                                      | \$ 42,014      | \$ 43,299      |
| Research                                      | 94,949         | 99,297         |
| Education                                     | 19,165         | 16,305         |
| General Administration and Other              | 32,054         | 37,020         |
|   | <u>188,182</u> | <u>195,921</u> |

(Continued on next page)

## Children’s Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

|  | <u>2024</u>         | <u>2023</u>         |
|--|---------------------|---------------------|
| Subject to expenditure for specified purpose, held at supporting organizations:  |                     |                     |
| Research   | 16,850              | 15,295              |
| Education  | 1,242               | 1,127               |
| General Administration and Other   | 5,000               | 4,539               |
|  | <u>23,092</u>       | <u>20,961</u>       |
| Subject to expenditure based on Board discretion of the supporting organization, held at supporting organizations      | <u>2,664,502</u>    | <u>2,372,530</u>    |
|  | 2,664,502           | 2,372,530           |
| Investment in perpetuity, the income from which is expendable for specified purpose, held at Cincinnati Children’s:    |                     |                     |
| Clinical   | 1,676               | 1,410               |
| Research   | 23,800              | 19,971              |
| Education  | 1,789               | 1,521               |
| General Administration and Other   | 4,692               | 4,002               |
|  | <u>31,957</u>       | <u>26,904</u>       |
| Investment in perpetuity, the income from which is expendable for specified purpose, held at supporting organizations: |                     |                     |
| Clinical   | 68,357              | 60,003              |
| Research   | 2,560,685           | 2,232,474           |
| Education  | 112,747             | 97,242              |
| General Administration and Other   | 96,405              | 83,649              |
|  | <u>2,838,194</u>    | <u>2,473,368</u>    |
| Subject to appropriation and expenditure when a specified event occurs:  |                     |                     |
| Upon death of insured party  | 2,063               | 2,289               |
|  | <u>2,063</u>        | <u>2,289</u>        |
| Total net assets with donor restrictions   | <u>\$ 5,747,990</u> | <u>\$ 5,091,973</u> |

- (p) Revenue and Gains in Excess of Expenses – The Consolidated Statements of Operations and Changes in Net Assets subtotals operating revenues, gains and other support, operating expenses and nonoperating gains as Revenue and gains in excess of expenses. Other changes in net assets without donor restrictions are receipts from and transfers to supporting organizations, pension and post-retirement health liability adjustments, and Net assets released from restrictions used for purchase of property and equipment, which are excluded from Revenue and gains in excess of expenses.
- (q) Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
- (r) New Accounting Pronouncements – In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments” which amends “Financial Instruments—Credit Losses”

## Children’s Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

(Topic 326). ASU 2016-13 provides guidance for measuring credit losses on financial instruments. Early adoption is permitted. The amendments in this ASU should be applied retrospectively. This ASU is effective for annual and interim periods in fiscal years beginning after December 15, 2022. The standard has been adopted and there are no material impacts to our Consolidated Financial Statements.

In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” The ASU amends ASC 805 to require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination and is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those years, with early adoption permitted. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The standard has been adopted and there are no material impacts to our Consolidated Financial Statements.

In August 2023, the FASB issued ASU No 2023-05, “Business Combinations — Joint Venture Formations” (Subtopic 805-60). The amendments in this ASU are effective prospectively for all joint ventures with a formation date on or after January 1, 2025, and early adoption is permitted. Additionally, a joint venture that was formed before the effective date of the ASU may elect to apply the amendments retrospectively if it has sufficient information. The standard’s impact to the Consolidated Financial Statements is currently being evaluated.

#### (2) Liquidity and Availability –

Financial assets available for general expenditure within one year of the balance sheet date consist of the following:

|  | <u>2024</u>         | <u>2023</u>         |
|--|---------------------|---------------------|
| Amounts available for general expenditure          |                     |                     |
| Cash and cash equivalents                          | \$ 189,507          | \$ 200,381          |
| Marketable securities                              | 1,335,526           | 1,298,639           |
| Patient receivables, net                           | 704,875             | 588,455             |
| Other receivables                                  | 236,163             | 165,009             |
|  | <u>2,466,071</u>    | <u>2,252,484</u>    |
| Less: Board-designated assets                      | 150,000             | 150,000             |
| Financial assets available for general expenditure | <u>\$ 2,316,071</u> | <u>\$ 2,102,484</u> |

Cincinnati Children’s has cash and cash equivalents, marketable securities (more fully described in Note 4), patient receivables and certain other receivables which are liquid and available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the quantitative information above. During fiscal year 2021, the Board of Trustees designated \$100,000 plus interest and earnings from net assets without donor restrictions to be used to support Cincinnati Children’s community pillar of the *Pursuing Our Potential Together* strategic plan. During fiscal year 2023, the Board of Trustees designated \$50,000 for employee benefit initiatives. Cincinnati Children’s has other assets limited to use for professional liability, self-insurance health care and debt service, as well as perpetual endowments with donor restrictions. These assets limited to use, which are more fully described in Notes 4 and 6, are not available for general expenditure within the next year and are not reflected in the amounts above.

## Children’s Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

Cincinnati Children’s has \$170,023 in outstanding obligations for which liquid funds must be available for payment in the event of a failed remarketing. Cincinnati Children’s maintains certain balances in cash and investments and has access to a \$100,000 line of credit, as discussed in more detail in Note 9.

Additionally, Cincinnati Children’s is required to maintain certain liquidity ratios as outlined in bond covenants. As of June 30, 2024 and 2023, Cincinnati Children’s was in compliance with all such covenants.

Cincinnati Children’s forecasts its future cash flows and monitors liquidity on an ongoing basis.

#### (3) Reconciliation of Cash, Cash Equivalents, and Restricted Cash –

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statement of Cash Flows for the fiscal years ending June 30, 2024 and 2023:

|  | <u>2024</u>       | <u>2023</u>       |
|--|-------------------|-------------------|
| Cash and cash equivalents  | \$ 189,507        | \$ 200,381        |
| Restricted cash included in assets limited as to use                                   | 8,229             | 9,578             |
| Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | <u>\$ 197,736</u> | <u>\$ 209,959</u> |

#### (4) Fair Value Measurements –

Cincinnati Children’s accounts for its assets and liabilities under ASC 820 “Fair Value Measurements.” As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three broad levels, which are described below:

Level 1: Quoted Prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date for assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. These include quoted prices for identical or similar assets or liabilities in markets that are not active, that is, markets in which there are a few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers, or in which little information is released publicly and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Unobservable inputs, developed using Cincinnati Children’s estimates and assumptions, which reflect those that the market participants would use. Such inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

Determining where an asset or liability falls within the hierarchy depends on the lowest level input that is significant to the fair value measurement as a whole. In determining fair value, Cincinnati Children's utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in the assessment of fair value.

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2024.

|  | Level 1    | Level 2    | Level 3 | Total        |
|--|------------|------------|---------|--------------|
| <b>Marketable Securities:</b>  |            |            |         |              |
| U.S. Government and agency securities  | \$ -       | \$ 193,301 | \$ -    | \$ 193,301   |
| Foreign bonds  | -          | 56,915     | -       | 56,915       |
| Municipal bonds  | -          | 3,173      | -       | 3,173        |
| Common stock   | 300,187    | -          | -       | 300,187      |
| Corporate obligations  | -          | 349,932    | -       | 349,932      |
| ETFs   | 219,084    | -          | -       | 219,084      |
| Commercial paper   | -          | 35,259     | -       | 35,259       |
| Total marketable securities measured in the fair value hierarchy                               | 519,271    | 638,580    | -       | 1,157,851    |
| Full discretion fixed income <sup>2</sup>  | -          | -          | -       | 177,675      |
|  | 519,271    | 638,580    | -       | 1,335,526    |
| <b>Assets Limited As To Use:</b>   |            |            |         |              |
| Money market mutual funds  | 8,267      | -          | -       | 8,267        |
| Common stock   | 31,919     | -          | -       | 31,919       |
|  | 40,186     | -          | -       | 40,186       |
| <b>Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets):</b> |            |            |         |              |
| Common stock   | 11,351     | -          | -       | 11,351       |
| Mutual funds:  |            |            |         |              |
| Money market   | 247        | -          | -       | 247          |
| Equity   | 1,097      | -          | -       | 1,097        |
| International equity   | 356        | -          | -       | 356          |
| Bond   | 633        | -          | -       | 633          |
| Lifecycle  | 6,514      | -          | -       | 6,514        |
| Variable annuities   | -          | 25         | -       | 25           |
| Guaranteed insurance contract  | -          | -          | 718     | 718          |
|  | 20,198     | 25         | 718     | 20,941       |
| <b>Derivative Investments (included in Other-Long-term Assets):</b>                            |            |            |         |              |
| Interest rate swap agreement   | -          | 4,500      | -       | 4,500        |
| Total investments at fair value  | \$ 579,655 | \$ 643,105 | \$ 718  | \$ 1,401,153 |

<sup>2</sup> Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheets.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2023.

|  | <u>Level 1</u>    | <u>Level 2</u>    | <u>Level 3</u>  | <u>Total</u>        |
|--|-------------------|-------------------|-----------------|---------------------|
| <b>Marketable Securities:</b>  |                   |                   |                 |                     |
| U.S. Government and agency securities  | \$ -              | \$ 327,874        | \$ -            | \$ 327,874          |
| Foreign bonds  | -                 | 42,895            | -               | 42,895              |
| Municipal bonds  | -                 | 19,131            | -               | 19,131              |
| Common stock   | 254,333           | -                 | -               | 254,333             |
| Corporate obligations  | -                 | 408,148           | -               | 408,148             |
| ETFs   | 76,600            | -                 | -               | 76,600              |
| Total marketable securities measured in the fair value hierarchy                               | 330,933           | 798,048           | -               | 1,128,981           |
| Full discretion fixed income <sup>3</sup>  | -                 | -                 | -               | 169,658             |
|  | <u>330,933</u>    | <u>798,048</u>    | <u>-</u>        | <u>1,298,639</u>    |
| <b>Assets Limited As To Use:</b>   |                   |                   |                 |                     |
| Money market mutual funds  | 9,753             | -                 | -               | 9,753               |
| Common stock   | 26,729            | -                 | -               | 26,729              |
|  | <u>36,482</u>     | <u>-</u>          | <u>-</u>        | <u>36,482</u>       |
| <b>Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets):</b> |                   |                   |                 |                     |
| Common stock   | 8,933             | -                 | -               | 8,933               |
| Mutual funds:  |                   |                   |                 |                     |
| Money market   | 297               | -                 | -               | 297                 |
| Equity   | 736               | -                 | -               | 736                 |
| International equity   | 319               | -                 | -               | 319                 |
| Bond   | 697               | -                 | -               | 697                 |
| Lifecycle  | 4,877             | -                 | -               | 4,877               |
| Variable annuities   | -                 | 28                | -               | 28                  |
| Guaranteed insurance contract  | -                 | -                 | 1,032           | 1,032               |
|  | <u>15,859</u>     | <u>28</u>         | <u>1,032</u>    | <u>16,919</u>       |
| <b>Derivative Investments (included in Other-Long-term Assets):</b>                            |                   |                   |                 |                     |
| Interest rate swap agreement   | -                 | 5,603             | -               | 5,603               |
| Total investments at fair value  | <u>\$ 383,274</u> | <u>\$ 803,679</u> | <u>\$ 1,032</u> | <u>\$ 1,357,643</u> |

The valuation methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in different fair value measurement at the reporting date.

The carrying amount and fair value of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.

<sup>3</sup> Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheets.

**Children’s Hospital Medical Center and Affiliates**

Consolidated Financial Statements  
 For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

Cincinnati Children’s uses quoted market prices in active markets to determine the fair value of common stock, mutual funds and ETFs; such items are classified as Level 1 in the fair value hierarchy.

Cincinnati Children’s primarily bases fair value for investments in fixed income securities, including U.S. government securities, municipal bonds and corporate obligations on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate). Commercial paper is valued using broker quotes that utilize observable market inputs. Consideration is also given to the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy.

Cincinnati Children’s interest rate swap agreement (Note 14) is a derivative instrument valued using the income approach, which uses market inputs to discount future cash flows to a single present amount based on market expectations.

Cincinnati Children’s investment in Full Discretion Fixed Income is an investment in a limited liability company whose investment objective is to invest in marketable and non-marketable securities with issue and industry diversification. As set forth in the LLC agreement, the LLC will dissolve on May 22, 2047, but may dissolve earlier under certain conditions. Any Investing Member may elect to withdraw, in whole or in part from the LLC if the Member notifies of intent to withdraw sixty calendar days in advance. The Full Discretion Fixed Income is measured at fair value using the net asset value per share practical expedient.

The guaranteed insurance contract is recorded based on discounted cash flows, which is an approximation of fair value, and is classified as Level 3 based on time restrictions for redemption.

Activity and transfers into and out of Level 3 and the reasons for those transfers are as follows:

|   |  |
|---|--|
| <p><b><u>2024</u></b><br/>                 Purchases \$ 117<br/>                 Issues -</p> | <p><b><u>Guaranteed Insurance Contracts</u></b><br/>                 \$ 117<br/>                 -</p> |
| <p><b><u>2023</u></b><br/>                 Purchases \$ 118<br/>                 Issues -</p> | <p><b><u>Guaranteed Insurance Contracts</u></b><br/>                 \$ 118<br/>                 -</p> |

Cincinnati Children’s policy is to recognize transfers in and out as of the actual date of the event or change in circumstances that caused the transfer. For the years ended June 30, 2024 and 2023, there were no material transfers in or out of Levels 1, 2 or 3.

(5) Losses on the Provision of Uncompensated Care –

In accordance with its mission and purpose, Cincinnati Children’s maintains a policy of providing medically necessary services to pediatric patients within its primary service area regardless of ability to pay. This primary service area has been defined to include the four counties in Ohio, three counties in Kentucky and one county in Indiana that geographically surround Cincinnati. Under certain circumstances, Cincinnati Children’s accepts patients from outside the primary service area regardless of their ability to pay. Cincinnati Children’s defines uncompensated care as services rendered to patients whose families’ annual income or net worth falls below certain minimum standards. As such, losses absorbed by Cincinnati Children’s in rendering services to patients who are covered under governmental programs which are designed to aid low-income families (primarily the Medicaid program) are considered uncompensated care.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

The following information summarizes uncompensated care provided during the years ended June 30, 2024 and 2023:

| <b>CHARGES</b>   | <b>2024</b>         | <b>2023</b>         |
|--|---------------------|---------------------|
| Charges under Medicaid and other entitlement programs                                | \$ 2,562,854        | \$ 2,489,227        |
| Charity care not eligible for Medicaid assistance, at established charges            | 25,803              | 21,928              |
| Other uncollectible self-pay, at established charges                                 | 33,346              | 28,060              |
| Total Medicaid, charity care and other uncollectible self-pay charges                | <u>\$ 2,622,003</u> | <u>\$ 2,539,215</u> |
| <br>   |                     |                     |
| <b>COSTS/LOSSES</b>  |                     |                     |
| Estimated costs to provide uncompensated care  | \$ (1,144,535)      | \$ (1,101,844)      |
| Reimbursement from Medicaid programs   | 724,594             | 692,387             |
| Losses on the provision of uncompensated care  | (419,941)           | (409,457)           |
| Funds received from Hospital Care Assurance Program (HCAP) <sup>4</sup> and tax levy | 67,801              | 55,751              |
| Losses on provision of uncompensated care, net of HCAP and tax levy                  | <u>\$ (352,140)</u> | <u>\$ (353,706)</u> |

The 2024 and 2023 cost amounts reflected in the tables above are calculated using cost to charge ratios calculated from preliminary cost reports because the current year cost report is not yet available. Management does not believe the use of preliminary data would have a material impact on the amounts calculated above.

(6) Funds in Trust –

Cincinnati Children's has certain funds, which are invested and held in trust for various specified purposes. Funds are carried at fair value with unrealized gains and losses included in Net investment return in the accompanying Consolidated Statements of Operations and Changes in Net Assets. The amounts of such funds, at carrying value, and the specified purposes for which such funds may be used, are set forth below:

|   | <b>June 30,</b>  |                  |
|---|------------------|------------------|
|   | <b>2024</b>      | <b>2023</b>      |
| Self-insurance Funds:                     |                  |                  |
| Professional liability                    | \$ 158           | \$ 159           |
| Employee health and workers' compensation | 453              | 140              |
| Bond interest and principal escrow funds  | 7,618            | 9,279            |
| Endowment funds held in perpetual trust   | 31,957           | 26,904           |
|   | <u>\$ 40,186</u> | <u>\$ 36,482</u> |

<sup>4</sup> The Hospital Care Assurance Program (HCAP) is a State of Ohio program created to financially assist hospitals that care for a disproportionate share of low-income patients who are unable to pay for their own care.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

(7) Property and Equipment –

Property and equipment consists of the following:

|                                     | <b>June 30,</b>     |                     |
|-------------------------------------|---------------------|---------------------|
|                                     | <b>2024</b>         | <b>2023</b>         |
| Land                                | \$ 47,033           | \$ 45,663           |
| Land improvements                   | 37,636              | 37,826              |
| Buildings and building improvements | 2,232,333           | 2,033,672           |
| Equipment                           | 829,528             | 794,350             |
| Construction in progress            | 144,998             | 247,228             |
|                                     | <u>3,291,528</u>    | <u>3,158,739</u>    |
| Accumulated depreciation            | (1,641,398)         | (1,602,190)         |
| Property and equipment, net         | <u>\$ 1,650,130</u> | <u>\$ 1,556,549</u> |

(8) Professional Liability –

Cincinnati Children's insurance program includes a self-insured retention for losses arising out of healthcare professional liability claims. The current self-insured retention for asserted claims is \$10,000 (\$25,000 in aggregate). Cincinnati Children's regularly purchases excess healthcare professional liability insurance on a claims made basis at varying levels.

The actuarial present value of expected costs (including incurred, but not reported claims) for the healthcare professional liability program of \$25,943 and \$31,020 for 2024 and 2023, respectively, is accrued in the accompanying Consolidated Balance Sheets. At June 30, 2024, \$8,500 of the total accrued liability is reported in Accounts payable and accrued expenses as the current portion. Accrued healthcare professional liability losses are discounted at a rate of 4% at June 30, 2024 and 2023. The costs of Cincinnati Children's healthcare professional liability program, including premiums paid for excess re-insurance, legal fees, settlements, judgments, and other administrative costs are included in Supplies, drugs and other in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Accrued losses funding levels are actuarially determined based on management's estimation of potential outstanding loss liabilities, payout patterns, and various other assumptions, and then adjusted to reflect its best estimate of the present value of expected costs for the healthcare professional liability claims. Healthcare professional liability expense is \$13,034 and \$13,964 for fiscal years 2024 and 2023, respectively.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

#### (9) Debt –

Debt at June 30, 2024 and 2023 is summarized as follows:

|   | <u>2024</u>       | <u>2023</u>       |
|---|-------------------|-------------------|
| Series 2018BB commercial paper, variable interest 5.42% to 5.45% at June 30, 2024), taxable               | \$ 100,000        | \$ 100,000        |
| Bonds payable:  |                   |                   |
| Series 2014S, 3.0% to 5.0% due through 2034, net of unamortized premium of \$1,407 in 2023                | -                 | 75,932            |
| Series 2014T, 4.268% due 2044, taxable  | 298,090           | 297,995           |
| Series 2016X, 5.00%, due through 2032, net of unamortized premium of \$6,208 in 2024 and \$7,078 in 2023  | 57,546            | 58,367            |
| Series 2016Y, 2.853% due 2026, taxable  | 99,817            | 99,730            |
| Series 2018Z*, variable interest (3.93% at June 30, 2024), due through 2037                               | 27,517            | 30,759            |
| Series 2018AA*, variable interest (3.87% at June 30, 2024), due through 2037                              | 42,506            | 47,511            |
| Series 2019CC, 5.0% due through 2049, net of unamortized premium of \$53,062 in 2024 and \$55,494 in 2023 | 187,565           | 189,948           |
| Series 2020DD, 2.82% due 2050, taxable  | 198,730           | 198,681           |
| Series 2024EE, 2.934% due 2034  | 66,155            | -                 |
| Total   | <u>1,077,926</u>  | <u>1,098,923</u>  |
| Less:   |                   |                   |
| Current portion of bonds and notes payable  | (10,230)          | (9,059)           |
| Commercial paper notes  | (100,000)         | (100,000)         |
| Bonds payable subject to remarketing, net   | <u>(70,023)</u>   | <u>(78,270)</u>   |
| Bonds payable and notes payable - long-term   | <u>\$ 897,673</u> | <u>\$ 911,594</u> |

\*Denotes variable rate bonds subject to remarketing agreements

- (a) Bonds Payable – Cincinnati Children's has pledged gross revenues to secure the payment of 2014T, 2016X, 2016Y, 2018Z, 2018AA, 2019CC, 2020DD, and 2024EE bonds. Cincinnati Children's is bound by certain financial covenants included in the bond indentures, and related agreements, including a requirement to maintain a minimum Debt Service Coverage Ratio.

The 2018Z and 2018AA tax-exempt bonds are subject to mandatory tender purchase seven days after notice from bondholders and may be remarketed. If the bonds are not remarketed, Cincinnati Children's must repay the bonds. The 2018Z and 2018AA bonds are classified as Current liabilities in Bonds payable subject to remarketing, net in the accompanying Consolidated Balance Sheets. The interest rates on the 2018Z and 2018AA variable rate bonds are reset weekly by a rate-setting agent.

Cincinnati Children's refunded and retired the outstanding principal of its Series 2014S bonds of \$65,820 through the issuance of hospital facilities bond Series 2024EE of \$66,155. The new bond series is issued through Hamilton County, Ohio at a fixed rate of 2.934%. The closing of the refunding and issuance occurred on May 15, 2024.

- (b) Commercial Paper – The Series 2018BB taxable commercial paper was issued in the original aggregate principal amount of \$100,000 and outstanding at any one time in a principal amount not to exceed \$100,000. The notes shall mature no later than May 15, 2048. The commercial paper notes have a maximum maturity period of 270 days and are resold at maturity. In the event the notes have not been

## Children’s Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

resold, Cincinnati Children’s must repay the notes. The 2018BB commercial paper is recorded in Current liabilities in the accompanying Consolidated Balance Sheets. The interest rates on the 2018BB commercial paper are reset with each remarketing by a rate-setting agent.

- (c) Future Debt Maturities – The following is a schedule of future debt maturities, excluding discounts/premiums and deferred issuance costs:

|            |              |
|------------|--------------|
| 2024       | \$ 180,620   |
| 2025       | 10,295       |
| 2026       | 110,160      |
| 2027       | 10,120       |
| 2028       | 16,270       |
| Thereafter | 696,355      |
|            | \$ 1,023,820 |

- (d) Line of Credit – Cincinnati Children’s maintains an agreement for a line of credit of \$100,000. The line of credit agreement was amended in May 2024 to extend the maturity date to May 2027. The line of credit bears interest at the greater of the Overnight Bank Funding Rate plus 50 basis points, the Prime Rate or the Daily Simple SOFR Rate plus 100 basis points. \$2,550 of the line of credit has been committed to secure letters of credit as required by a payer arrangement, leaving \$97,450 available. There were no draws on the line of credit during fiscal year 2024 or 2023.

- (10) Employee Benefit Plans –

Cincinnati Children’s maintains non-contributory retirement plans covering substantially all employees. Among these plans is a defined benefit plan where benefits are based on a formula which reflects years of service and salary levels. Cincinnati Children’s funding policy for its defined benefit plan meets the funding standards established by the Employee Retirement Income Security Act of 1974 (ERISA).

Cincinnati Children’s investment strategy with respect to pension assets is designed to achieve a moderate level of overall portfolio risk in keeping with desired risk objective, which is established through careful consideration of plan liabilities, plan funded status, and corporate financial condition. Cincinnati Children’s adopted an Investment Policy that adjusts allocations between return-seeking assets and liability-hedging assets based on the funded status of the Plan and prevailing yields. As the funded ratio improves, allocations to liability-hedging assets increase accordingly.

Cincinnati Children’s seeks to maintain diversified portfolios and has adopted allocation targets within the return-seeking and liability hedging portfolios as follows:

|   |                    |
|---|--------------------|
| Return-Seeking Allocation:                  | Min - Target - Max |
| Global Equity                               | 60% - 70% - 80%    |
| Private Equity                              | 5% - 10% - 15%     |
| Private Real Estate                         | 5% - 10% - 15%     |
| Multi-Asset Credit                          | 5% - 10% - 15%     |
| Opportunity Allocation                      | 0% - 0% - 10%      |
| Liability-Hedging Allocation:               |                    |
| Long Credit                                 | 50% - 75% - 100%   |
| STRIPS (Long Duration Treasury Instruments) | 0% - 25% - 50%     |

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

In order to maintain the portfolio's actual asset allocation in line with the target allocations specified above, rebalancing will occur periodically.

Cincinnati Children's defined benefit plan investment allocation at the actuarial measurement date of June 30, 2024 and 2023 by asset category is as follows:

|                              | <u>2024</u>   | <u>2023</u>   |
|------------------------------|---------------|---------------|
| Cash and cash equivalents    | 3.1%          | 1.1%          |
| Corporate bonds              | 13.7%         | 13.5%         |
| Government bonds             | 2.4%          | 2.0%          |
| Investment Partnerships:     |               |               |
| Equity                       | 4.7%          | 5.0%          |
| Real estate                  | 2.5%          | 2.6%          |
| Commingled Investment Funds: |               |               |
| Equity                       | -             | 12.5%         |
| Bond                         | 51.4%         | 44.6%         |
| Government                   | 22.2%         | 18.0%         |
| Real estate                  | -             | 0.7%          |
|                              | <u>100.0%</u> | <u>100.0%</u> |

The fair values of Level 1 investments are based on quoted prices in active markets.

The fair value for investments in fixed income securities, including U.S. government securities and corporate obligations, is based on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate) and considers the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy.

Investments in partnerships – U.S. equities and real estate – are valued using the net asset value reported by the managers of the funds and as supported by the unit prices of actual purchase and sale transactions. The investments in investment partnerships generally are associated with liquidation restrictions that may range from 91 days to the life of the fund (up to fifteen years) and may require redemption penalties.

Commingled investment funds are private funds for institutional investors valued at net asset value. The commingled funds primarily invest in actively traded equity mutual funds, bond mutual funds, and US Treasury STRIPS with daily liquidity and no lockup period.

There were no transfers between levels in fiscal year 2024 or fiscal year 2023.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

At June 30, 2024, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

|  | <u>Level 1</u>   | <u>Level 2</u>    | <u>Level 3</u> | <u>Total</u>        |
|--|------------------|-------------------|----------------|---------------------|
| Cash and cash equivalents                              | \$ 38,616        | \$ -              | \$ -           | \$ 38,616           |
| Corporate bonds  | -                | 169,040           | -              | 169,040             |
| Government bonds                                       | -                | 29,668            | -              | 29,668              |
| Total assets in the fair value hierarchy               | <u>38,616</u>    | <u>198,708</u>    | <u>-</u>       | <u>237,324</u>      |
| Investments measured at net asset value <sup>5</sup> : |                  |                   |                |                     |
| Investment Partnerships:                               |                  |                   |                |                     |
| Equity   | -                | -                 | -              | 57,968              |
| Real estate  | -                | -                 | -              | 31,018              |
| Commingled Investment Funds:                           |                  |                   |                |                     |
| Bond   | -                | -                 | -              | 636,962             |
| Government   | -                | -                 | -              | 275,419             |
| Total assets at fair value                             | <u>\$ 38,616</u> | <u>\$ 198,708</u> | <u>\$ -</u>    | <u>\$ 1,238,691</u> |

At June 30, 2023, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

|  | <u>Level 1</u>   | <u>Level 2</u>    | <u>Level 3</u> | <u>Total</u>        |
|--|------------------|-------------------|----------------|---------------------|
| Cash and cash equivalents                              | \$ 13,767        | \$ -              | \$ -           | \$ 13,767           |
| Corporate bonds  | -                | 172,710           | -              | 172,710             |
| Government bonds                                       | -                | 25,666            | -              | 25,666              |
| Total assets in the fair value hierarchy               | <u>13,767</u>    | <u>198,376</u>    | <u>-</u>       | <u>212,143</u>      |
| Investments measured at net asset value <sup>5</sup> : |                  |                   |                |                     |
| Investment Partnerships:                               |                  |                   |                |                     |
| Equity   | -                | -                 | -              | 64,121              |
| Real estate  | -                | -                 | -              | 32,792              |
| Commingled Investment Funds:                           |                  |                   |                |                     |
| Equity   | -                | -                 | -              | 160,126             |
| Bond   | -                | -                 | -              | 570,384             |
| Government   | -                | -                 | -              | 230,646             |
| Real estate  | -                | -                 | -              | 9,438               |
| Total assets at fair value                             | <u>\$ 13,767</u> | <u>\$ 198,376</u> | <u>\$ -</u>    | <u>\$ 1,279,650</u> |

<sup>5</sup> Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Change in Plan Assets disclosure.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

As of June 30, 2024, Cincinnati Children's has made \$93,900 in funding commitments in nine investment partnerships, of which \$76,800 has been funded. Additionally, Cincinnati Children's has made \$72,500 in funding commitments in nine real estate investment partnerships, of which \$68,900 has been funded. It is anticipated that these commitments will be funded from liquid investments of the plan.

The following table reflects the weighted average assumptions utilized to determine benefit obligations:

|   | <u>2024</u> | <u>2023</u> |
|---|-------------|-------------|
| Discount rate used to determine actuarial present value of the projected benefit obligation | 5.73%       | 5.53%       |
| Assumed rate of increase in compensation levels   | 3.50%       | 4.00%       |
| Long-term rate of return  | 6.00%       | 6.00%       |

The following table sets forth the funded status of the plan and amounts recognized in the accompanying Consolidated Balance Sheets as of June 30, 2024 and 2023, utilizing actuarial measurement dates as of June 30, 2024 and 2023.

|  | <u>2024</u>         | <u>2023</u>         |
|--|---------------------|---------------------|
| Change in projected benefit obligation:                          |                     |                     |
| Projected benefit obligation at beginning of year                | \$ 1,093,652        | \$ 1,144,529        |
| Service cost   | 48,165              | 48,122              |
| Interest cost  | 58,430              | 56,318              |
| Other actuarial gain   | (39,608)            | (12,082)            |
| Benefits paid  | (54,452)            | (21,249)            |
| Settlements  | -                   | (121,986)           |
| Projected benefit obligation at end of year                      | <u>\$ 1,106,187</u> | <u>\$ 1,093,652</u> |
| Change in plan assets:   |                     |                     |
| Fair value of plan assets at beginning of year                   | \$ 1,279,650        | \$ 1,425,572        |
| Actual return (loss) on plan assets                              | 13,493              | (2,687)             |
| Benefits paid  | (54,452)            | (21,249)            |
| Settlements  | -                   | (121,986)           |
| Fair value of plan assets at end of year                         | <u>1,238,691</u>    | <u>1,279,650</u>    |
| Funded status  | 132,504             | 185,998             |
| Net accrued pension benefit asset in Consolidated Balance Sheets | <u>\$ 132,504</u>   | <u>\$ 185,998</u>   |

For the Retirement Plan, the overall actuarial gain in plan obligation of \$39,608 is primarily attributable to an increase in the discount rate between June 30, 2023 and June 30, 2024. The discount rate increase of 20 basis points resulted in a decrease in benefit obligation of approximately \$31,471.

Pension benefit payments for the period July 1, 2022 to June 30, 2023 exceeded the threshold for which settlement accounting is required. As such, Cincinnati Children's recorded a charge representing accelerated recognition of certain net losses in fiscal year 2023. The settlement cost of \$28,468 is recorded in Net benefit gain other than service cost on the Consolidated Statements of Operations and Changes in Net Assets.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

In 2024 and 2023, the mortality tables utilized by actuaries to value the pension liability were updated based on current experience. The impact of the change in mortality assumptions is included in other actuarial gain in fiscal years 2024 and 2023.

Amounts included in Net Assets without donor restrictions but not yet recognized in pension cost consist of:

|                                      | <b>2024</b>       | <b>2023</b>       |
|--------------------------------------|-------------------|-------------------|
| Net actuarial loss                   | \$ 304,807        | \$ 273,242        |
| Net prior service credit             | (41,788)          | (53,539)          |
| Accumulated other comprehensive loss | <u>\$ 263,019</u> | <u>\$ 219,703</u> |

The table below reflects the following weighted average assumptions utilized to determine benefit costs were:

|  | <b>2024</b> | <b>2023</b> |
|--|-------------|-------------|
| Discount rate used to determine benefit costs:   |             |             |
| July – March                                     | 5.53%       | 5.06%       |
| April – June                                     | 5.53%       | 5.38%       |
| Assumed rate of increase in compensation levels  | 4.00%       | 4.00%       |
| Expected long-term rate of return on plan assets | 6.00%       | 5.50%       |

The Cincinnati Children's expected long-term rate of return on plan assets is based on the expected average returns based on the portfolio mix of plan assets and is reassessed on an annual basis.

Net periodic pension cost for 2024 and 2023 related to the defined benefit plan consisted of the following components:

|                                      | <b>2024</b>      | <b>2023</b>     |
|--------------------------------------|------------------|-----------------|
| Service cost                         | \$ 48,165        | \$ 48,122       |
| Interest cost                        | 58,430           | 56,318          |
| Expected return on plan assets       | (84,667)         | (87,860)        |
| Amortization of prior service credit | (11,751)         | (11,751)        |
| Net periodic pension cost            | <u>\$ 10,177</u> | <u>\$ 4,829</u> |

Based on preliminary estimates, we do not expect any required fiscal year 2024 contributions for the qualified defined benefit plan under the current funding regulations.

The accumulated benefit obligation for the pension plan was \$1,066,845 and \$1,042,259 at June 30, 2024 and 2023, respectively.

## Children’s Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

Cincinnati Children’s estimated benefit payments in each of the next five fiscal years and in aggregate for the five fiscal years thereafter are as follows:

|           |           |
|-----------|-----------|
| 2025      | \$ 80,929 |
| 2026      | 78,432    |
| 2027      | 79,178    |
| 2028      | 79,434    |
| 2029      | 80,411    |
| 2030-2034 | 417,268   |

All other retirement plans maintained by Cincinnati Children’s are defined contribution plans. Cincinnati Children’s contributions to these plans are generally based on ten percent of salaries up to established ERISA limits. Total expense, net of forfeitures, related to these other plans was approximately \$35,876 and \$32,236 in fiscal years 2024 and 2023, respectively.

Cincinnati Children’s provides individual nonqualified deferred compensation benefits to key employees with varying terms. Accounts are participant-directed, and the amounts are at a substantial risk of forfeiture and revert back to the Cincinnati Children’s if the employee does not meet certain criteria as established by the plan. The amount of deferred compensation income and expense resulting from changes in market value of underlying investments are recognized in fiscal years 2024 and 2023 was \$3,420 and \$538, respectively. The current portion of plan accounts are included in Other receivables with a corresponding liability in Accounts payable and accrued expenses on the Consolidated Balance Sheets. The long-term portion of plan accounts are included in Other long-term assets with a corresponding liability in Other long-term liabilities on the Consolidated Balance Sheets.

The following table displays the nonqualified deferred compensation plans assets and liabilities as of June 30, 2024 and 2023:

|                              | <u>2024</u>      | <u>2023</u>      |
|------------------------------|------------------|------------------|
| Current portion              | \$ 52            | \$ 1,009         |
| Long-term portion            | 20,889           | 15,910           |
| Total assets and liabilities | <u>\$ 20,941</u> | <u>\$ 16,919</u> |

#### (11) Commitments and Contingencies –

- (a) Litigation – Cincinnati Children’s is engaged from time to time in a variety of litigation and regulatory compliance matters in addition to professional and general liability matters. Management assesses the probable outcome of unresolved litigation and records estimated reserves consistent with ASC 450, “Contingencies.” After consultation with legal counsel, management believes that all such currently existing matters will be resolved without material adverse impact to the consolidated financial position or results of operations of Cincinnati Children’s.
- (b) Laws and Regulations – The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations guide the healthcare industry in many domains such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient service, and Medicare and Medicaid fraud and abuse to name a few. Compliance with these laws and regulations, specifically those relating to the Medicare and Medicaid programs, is complex and can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time. Management believes that Cincinnati Children’s is in compliance, in all material respects, with fraud and abuse as well as other applicable government

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

laws and regulations. Cincinnati Children's has recorded reserves for routine regulatory compliance issues and believes these reserves are adequate to cover any potential repayment of previously billed and collected revenue from patient service.

- (c) **Capital Commitments** – Cincinnati Children's has entered into agreements with general contractors for several new construction projects, renovations, equipment, and information system technology projects. Approximately \$935,840 has been spent through June 30, 2024 and approximately \$479,555 is expected to be spent in connection with current active projects. The commitments have expected completion dates ranging from fiscal year 2025 through fiscal year 2029.
- (d) **Funding Commitments** – The Board of Trustees of Cincinnati Children's approved revocable commitments for up to \$20,000 in non-recourse loans to Uptown Consortium Inc. Cincinnati Children's has provided \$17,867 of funding in relation to these commitments through June 30, 2024. Management does not anticipate any additional funding. These funds are used to invest in commercial and residential projects in the uptown area. During fiscal year 2024, none of the loans were repaid. Cincinnati Children's expects to receive an additional \$3,773 related to the loans which is recorded to Other long-term assets.
- (e) **Investment Commitments** – Cincinnati Children's has made commitments to invest \$45,500 in nine limited partnerships that focus on investing in venture capital funds or provide venture capital for companies in the high-growth sectors of the economy, including life sciences, information technology, advanced manufacturing, and healthcare. Cincinnati Children's has made commitments to invest \$26,573 in fifteen limited liability companies that focus on investing in early-stage venture capital funds regionally and nationally with the goals of making the Cincinnati region the place for entrepreneurs and investors to launch new ideas and driving capital into scalable technology companies in southwest Ohio. Investment values are included in Other assets in the Consolidated Balance Sheets. Cincinnati Children's occasionally receives distributions from these investments which reduce investment values.

The following displays the amounts funded and investment values at June 30, 2024 and 2023:

|   | <b>2024</b> | <b>Funded</b>    | <b>Value</b>     |
|---|-------------|------------------|------------------|
| Investment in Limited Partnerships            |             | \$ 29,670        | \$ 15,286        |
| Investments in Limited Liability Corporations |             | 16,605           | 20,953           |
| Total   |             | <u>\$ 46,275</u> | <u>\$ 36,239</u> |
|   | <b>2023</b> | <b>Funded</b>    | <b>Value</b>     |
| Investment in Limited Partnerships            |             | \$ 23,499        | \$ 10,882        |
| Investments in Limited Liability Corporations |             | 13,507           | 19,210           |
| Total   |             | <u>\$ 37,006</u> | <u>\$ 30,092</u> |

(12) **Leases** –

Cincinnati Children's leases certain property and equipment. Cincinnati Children's determines if an arrangement is a lease at inception of a contract.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

The following table presents expenses recorded related to lease arrangements for the years ended June 30, 2024 and 2023:

|                                       | <u>2024</u>      | <u>2023</u>      |
|---------------------------------------|------------------|------------------|
| Operating lease expense               | \$ 3,806         | \$ 3,532         |
| Finance leases:                       |                  |                  |
| Amortization of right-of-use assets   | 8,150            | 7,431            |
| Interest on finance lease obligations | 1,871            | 1,890            |
| Short-term and variable lease expense | 5,461            | 5,153            |
| Total lease expense                   | <u>\$ 19,288</u> | <u>\$ 18,006</u> |

Other information related to leases for the years ended June 30, 2024 and 2023 is as follows:

#### Supplemental cash flow information

Cash paid for amounts included in the measurement of lease liabilities:

|  | <u>2024</u> | <u>2023</u> |
|--|-------------|-------------|
| Operating cash flows from operating leases | \$ 3,062    | \$ 2,847    |
| Financing cash flows from finance leases   | 6,827       | 6,772       |

#### Weighted average remaining lease term (in years)

|                  | <u>2024</u> | <u>2023</u> |
|------------------|-------------|-------------|
| Operating leases | 9.0         | 7.1         |
| Finance leases   | 7.5         | 8.3         |

#### Weighted average discount rate

|                  | <u>2024</u> | <u>2023</u> |
|------------------|-------------|-------------|
| Operating leases | 5.55%       | 3.52%       |
| Finance leases   | 3.61%       | 3.61%       |

The aggregate future lease payments for operating and finance leases as of June 30, 2024 are as follows:

|  | <u>Operating</u> | <u>Finance</u>  |
|--|------------------|-----------------|
| 2025   | \$ 3,898         | \$ 8,698        |
| 2026   | 3,312            | 8,196           |
| 2027   | 2,688            | 7,107           |
| 2028   | 2,582            | 6,053           |
| 2029   | 2,594            | 5,351           |
| Thereafter   | 12,808           | 19,803          |
| Total lease payments   | <u>27,882</u>    | <u>55,208</u>   |
| <u>Present values:</u>   |                  |                 |
| Current lease liabilities  | 2,760            | 7,073           |
| Long-term lease liabilities  | 18,484           | 41,202          |
| Total lease liabilities  | <u>21,244</u>    | <u>48,275</u>   |
| Difference between undiscounted cash flows and discounted cash flows | <u>\$ 6,638</u>  | <u>\$ 6,933</u> |

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

- (13) Functional Expenses –The costs of providing Cincinnati Children's services are summarized on a functional basis in the following tables. Accordingly, certain costs have been allocated among functions. Such allocations are determined by management on an equitable basis. The expenses that are allocated include the following:

| <u>Expense</u>    | <u>Method of Allocation</u> |
|-------------------|-----------------------------|
| Employee benefits | Full Time Equivalent        |
| Depreciation      | Square footage              |
| Utilities         | Square footage              |

The following presents expenses by both their nature and function for the year ended June 30, 2024:

|                               | <u>Clinical</u>     | <u>Research</u>   | <u>Education</u> | <u>Fundraising</u> | <u>Management and General</u> | <u>TOTAL</u>        |
|-------------------------------|---------------------|-------------------|------------------|--------------------|-------------------------------|---------------------|
| Salaries                      | \$ 1,089,638        | \$ 221,048        | \$ 69,932        | \$ 4,641           | \$ 283,444                    | \$ 1,668,703        |
| Employee benefits             | 247,466             | 54,287            | 17,202           | 1,290              | 110,779                       | 431,024             |
| Supplies, drugs and other     | 457,823             | 42,980            | 3,613            | 568                | 94,231                        | 599,215             |
| Purchased services            | 132,109             | 61,566            | 3,018            | 737                | 179,436                       | 376,866             |
| Depreciation and amortization | 82,879              | 35,140            | 168              | 375                | 34,202                        | 152,764             |
| Utilities                     | 11,951              | 5,067             | 24               | 54                 | 4,932                         | 22,028              |
| Interest                      | -                   | -                 | -                | -                  | 32,860                        | 32,860              |
|                               | <u>\$ 2,021,866</u> | <u>\$ 420,088</u> | <u>\$ 93,957</u> | <u>\$ 7,665</u>    | <u>\$ 739,884</u>             | <u>\$ 3,283,460</u> |

The following presents expenses by both their nature and function for the year ended June 30, 2023:

|                               | <u>Clinical</u>     | <u>Research</u>   | <u>Education</u> | <u>Fundraising</u> | <u>Management and General</u> | <u>TOTAL</u>        |
|-------------------------------|---------------------|-------------------|------------------|--------------------|-------------------------------|---------------------|
| Salaries                      | \$ 981,042          | \$ 211,292        | \$ 63,169        | \$ 4,380           | \$ 250,782                    | \$ 1,510,665        |
| Employee benefits             | 200,122             | 66,617            | 16,245           | 1,090              | 104,422                       | 388,496             |
| Supplies, drugs and other     | 433,579             | 42,851            | 4,116            | 525                | 88,949                        | 570,020             |
| Purchased services            | 122,956             | 57,022            | 3,054            | 753                | 155,750                       | 339,535             |
| Depreciation and amortization | 83,249              | 32,404            | 86               | 373                | 33,655                        | 149,767             |
| Utilities                     | 12,015              | 4,677             | 12               | 54                 | 4,857                         | 21,615              |
| Interest                      | -                   | -                 | -                | -                  | 32,531                        | 32,531              |
|                               | <u>\$ 1,832,963</u> | <u>\$ 414,863</u> | <u>\$ 86,682</u> | <u>\$ 7,175</u>    | <u>\$ 670,946</u>             | <u>\$ 3,012,629</u> |

- (14) Interest Rate Swap Agreement –

In August 2019, Cincinnati Children's entered into a 10-year interest rate swap agreement in which Cincinnati Children's and the counterparty agree to exchange the difference between fixed rate and variable rate interest amounts calculated by reference to specified notational principal amounts during the agreement period. The objective is to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. Parties to interest rate swap agreements are subject to market risk for changes in interest rates and risk of credit loss in the event of nonperformance by the counterparty.

## Children's Hospital Medical Center and Affiliates

### Consolidated Financial Statements

For the Years Ended June 30, 2024 and 2023, respectively (dollars in thousands)

---

The following table summarizes the general terms of Cincinnati Children's fixed payment swap agreement as of June 30, 2024:

| <u>Effective</u> | <u>Expiration</u> | <u>Counterparty</u> | <u>Interest Rate Paid</u> | <u>Interest Rate Received</u>                                  | <u>Notational Amount</u> |
|------------------|-------------------|---------------------|---------------------------|--|--------------------------|
| August 2019      | August 2029       | Fifth Third Bank    | 1.38%                     | USD-SIFMA Municipal Swap Index, 3.88% at June 30 <sup>th</sup> | \$ 70,390,000            |

As of June 30, 2024 and 2023 the swap fair value of \$4,500 and \$5,603 was recorded in Other long-term assets in the accompanying Consolidated Balance Sheets, respectively.

(15) Subsequent Events –

Cincinnati Children's announced an amendment to the defined benefit plan in September 2024. The amendment will freeze the defined benefit plan for new entrants effective January 1, 2025. The defined benefit plan will also be frozen to current participants effective December 31, 2025, at which time benefits will cease to accrue in the defined benefit plan. As such, a remeasurement is anticipated to occur in fiscal year 2025. New eligible employees will be offered a 401(a) defined contribution plan beginning January 1, 2025, while current defined benefit plan participants will be eligible to participate in the defined contribution plan beginning January 1, 2026.

Management reviewed subsequent events through September 30, 2024, the date the Consolidated Financial Statements were issued, noting no changes are required to the Consolidated Financial Statements or footnotes.

**Children's Hospital Medical Center and Affiliates**

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency                 | Division                      | Government Branch                                | Award Title   | Pass-Through Grantor                     | Subrecipient Name                        | Identifying Number | Federal Grant Number      | ALN                     | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |           |
|-----------------------------------|-------------------------------|--|---|--|--|--------------------|---------------------------|-------------------------|--------------------------|---------------------|-------------------|-----------|
| Department of Defense             | DOD                           | Military Medical Research and Development        | Cardiac Rhabdomyomas as Biom  |  |  |                    | HT94252310212             | 12.420                  | \$ -                     | \$ 93,767           | \$ 93,767         |           |
|                                   | DOD                           | Military Medical Research and Development        | Regulating Together in Tubero   | Univ of North Carolina at Chapel Hill    |  | 5128118            | HT94252310344             | 12.420                  | -                        | 150,619             | 150,619           |           |
|                                   | DOD                           | Military Medical Research and Development        | Combinatorial targeting of hig  |  |  |                    | HT94252310453             | 12.420                  | -                        | 89,468              | 89,468            |           |
|                                   | DOD                           | Military Medical Research and Development        | Spreading depolarizations as a  | University of Cincinnati                 |  | 015141-00002       | HT94252310483             | 12.420                  | -                        | 22,122              | 22,122            |           |
|                                   | DOD                           | Military Medical Research and Development        | Novel RAC Pathway Inhibitors f  |  |  |                    | HT94252310960             | 12.420                  | -                        | 143,883             | 143,883           |           |
|                                   | DOD                           | Military Medical Research and Development        | Multicenter Randomized Trial of Everolimus in Pediatric Heart Transplantation | Children's Hospital Boston               |  |                    | W81XWH1710532             | 12.420                  | -                        | 1,819               | 1,819             |           |
|                                   | DOD                           | Military Medical Research and Development        | Preemptive Rituximab to Preven  | University of Minnesota                  |  | N006814103         | W81XWH1810577             | 12.420                  | -                        | 9,504               | 9,504             |           |
|                                   | DOD                           | Military Medical Research and Development        | Antioxidant Therapy with N-Ace  |  |  |                    | W81XWH2010139             | 12.420                  | -                        | 305,968             | 305,968           |           |
|                                   | DOD                           | Military Medical Research and Development        | Merlin-ASPP2 Tumor Suppressor   |  |  |                    | W81XWH2010377             | 12.420                  | -                        | 185,077             | 185,077           |           |
|                                   | DOD                           | Military Medical Research and Development        | Inflammatory vigor in heteroge  |  |  |                    | W81XWH2010392             | 12.420                  | -                        | 538,672             | 538,672           |           |
|                                   | DOD                           | Military Medical Research and Development        | Inflammatory vigor in heteroge  |  |  |                    | W81XWH2010393             | 12.420                  | -                        | 56,423              | 56,423            |           |
|                                   | DOD                           | Military Medical Research and Development        | Mitochondrial ALR protein defi  |  |  |                    | W81XWH2010477             | 12.420                  | 13,408                   | 55,987              | 69,395            |           |
|                                   | DOD                           | Military Medical Research and Development        | The role of mitochondria in bo  |  |  |                    | W81XWH2010689             | 12.420                  | -                        | 110,187             | 110,187           |           |
|                                   | DOD                           | Military Medical Research and Development        | Ribosome Biogenesis Defects As  | The Univ of Texas Hlth Sci Ctr @ San Ant |  |                    | W81XWH2110148             | 12.420                  | -                        | 169,290             | 169,290           |           |
|                                   | DOD                           | Military Medical Research and Development        | Role of endoplasmic reticulum   |  |  |                    | W81XWH2110907             | 12.420                  | -                        | 34,379              | 34,379            |           |
|                                   | DOD                           | Military Medical Research and Development        | CHIPS (CHILled Platelet Study)  | University of Pittsburgh                 |  |                    | FY2022-18477-SVC          | 12.420                  | -                        | 116,520             | 116,520           |           |
|                                   | DOD                           | Military Medical Research and Development        | Regulating Together: Randomize  |  |  |                    | W81XWH2210168             | 12.420                  | 49,629                   | 554,195             | 603,824           |           |
|                                   | DOD                           | Military Medical Research and Development        | Regulation of Translation by N  |  |  |                    | W81XWH2210196             | 12.420                  | -                        | 78,482              | 78,482            |           |
|                                   | DOD                           | Military Medical Research and Development        | Trial of Indication-based Tran  | Children's Hospital Boston               |  |                    | W81XWH2210301             | 12.420                  | -                        | 42,068              | 42,068            |           |
|                                   | DOD                           | Military Medical Research and Development        | Defects in the transition from  |  |  |                    | W81XWH2210410             | 12.420                  | 79,880                   | 112,545             | 192,425           |           |
|                                   | DOD                           | Military Medical Research and Development        | Is There a Point of Convergen   |  |  |                    | W81XWH2210533             | 12.420                  | -                        | 356,827             | 356,827           |           |
|                                   | DOD                           | Military Medical Research and Development        | Establishing Network Connectiv  |  |  |                    | W81XWH2210633             | 12.420                  | -                        | 203,994             | 203,994           |           |
|                                   | DOD                           | Military Medical Research and Development        | Human and mouse models of DDX4  |  |  |                    | W81XWH2210805             | 12.420                  | -                        | 109,158             | 109,158           |           |
|                                   | DOD                           | Military Medical Research and Development        | Delayed outcome mechanisms in   |  |  |                    | W81XWH2211075             | 12.420                  | -                        | 379,808             | 379,808           |           |
|                                   | DOD                           | Military Medical Research and Development        | Military Medical Research and Development                                     | Neurofibromatosis Research Pro           | University of Alabama-Birmingham         |                    | 000533783-SC010           | W81XWH2230001           | 93.RD                    | -                   | 32,816            | 32,816    |
|                                   |                               |  | Military Medical Research and Development Total                               |  |  |                    |                           |                         |                          | 142,917             | 3,953,578         | 4,096,495 |
|                                   |                               | DARPA  | Research and Technology Development   | Systems biological assessment            | Stanford University Medical Center       |                    | 63182657-245431           | W91NF2320019            | 12.910                   | -                   | 129,415           | 129,415   |
|                                   |                               |  | Research and Technology Development Total                                     |  |  |                    |                           |                         |                          | -                   | 129,415           | 129,415   |
|                                   | Department of Defense Total   |  |   |  |  |                    |                           |                         |                          | 142,917             | 4,082,993         | 4,225,910 |
|                                   | Department of Education       | DOE  | Education Research, Development and Dissemination                             | Longitudinal Evaluation of Slu           |  |                    |                           | R305A200028             | 84.305                   | -                   | 380,443           | 380,443   |
|                                   |                               |  | Education Research, Development and Dissemination Total                       |  |  |                    |                           |                         |                          | -                   | 380,443           | 380,443   |
|                                   | Department of Education Total |  |   |  |  |                    |                           |                         |                          | -                   | 380,443           | 380,443   |
|                                   | Department of Justice         | DOJ  | Crime Victim Assistance   | VOCA Mayerson 2023                       |  |                    |                           | 2023-VOCA-135104917     | 16.575                   | -                   | 59,945            | 59,945    |
|                                   |                               | DOJ  | Crime Victim Assistance   | VOCA 2024                                |  |                    |                           | 15POVC-23-GG-00458-ASSI | 16.575                   | -                   | 172,225           | 172,225   |
|                                   |                               |  | Crime Victim Assistance Total   |  |  |                    |                           |                         |                          | -                   | 232,170           | 232,170   |
|                                   |                               | DOJ  | Edward Byrne Memorial Justice Assistance Grant Program                        | BJA Police Response Training f           | The Arc of The United States INC         |                    | BJA Police Response Riddl | BJA Police Response     | 16.738                   | -                   | 36,972            | 36,972    |
|                                   |                               |  | Edward Byrne Memorial Justice Assistance Grant Program Total                  |  |  |                    |                           |                         |                          | -                   | 36,972            | 36,972    |
|                                   | Department of Justice Total   |  |   |  |  |                    |                           |                         |                          | -                   | 269,142           | 269,142   |
| National Science Foundation       | NSF                           | Biological Sciences                              | NSF/MCB-BSF: Modeling the mec   |  | University of Cincinnati                 |                    | 2114950                   | 47.074                  | 55,178                   | 229,809             | 284,987           |           |
|                                   |                               | Biological Sciences Total                        |   |  |  |                    |                           |                         | 55,178                   | 229,809             | 284,987           |           |
|                                   | NSF                           | Engineering Grants                               | Collaborative Research: Unders  |  |  |                    | 2140441                   | 47.041                  | -                        | 46,271              | 46,271            |           |
|                                   |                               | Engineering Grants Total                         |   |  |  |                    |                           |                         | -                        | 46,271              | 46,271            |           |
|                                   | NSF                           | Social, Behavioral, and Economic Sciences        | A Contextual Analysis of Peer   | University of Buffalo                    |  | R1352161           | 2234666                   | 47.075                  | -                        | 52,900              | 52,900            |           |
|                                   |                               | Social, Behavioral, and Economic Sciences Total  |   |  |  |                    |                           |                         | -                        | 52,900              | 52,900            |           |
| National Science Foundation Total |                               |  |   |  |  |                    |                           |                         | 55,178                   | 328,980             | 384,158           |           |
| Dept of Health and Human Serv     | NIH                           | Aging Research                                   | Role of skeletal muscle stem c  |  |  |                    | R01AG059605               | 93.866                  | -                        | 14,478              | 14,478            |           |
|                                   | NIH                           | Aging Research                                   | Novel mechanism of intestinal   | Tulane University                        |  |                    | R01AG063967               | 93.866                  | -                        | 487,785             | 487,785           |           |
|                                   | NIH                           | Aging Research                                   | Accelerating research to advan  |  |  |                    | R01AG077497               | 93.866                  | -                        | 577,446             | 577,446           |           |
|                                   | NIH                           | Aging Research                                   | Coordinated mechanisms to resc  |  | Univer of Texas Medical Branch Galveston |                    | R01AG078174               | 93.866                  | 27,707                   | 480,351             | 508,058           |           |
|                                   | NIH                           | Aging Research                                   | Myonuclear dynamics during ske  |  |  |                    | R01AG082697               | 93.866                  | -                        | 294,154             | 294,154           |           |
|                                   | NIH                           | Aging Research                                   | Investigating the role of CSF   | University of Cincinnati                 |  | 015438-00002       | R01AG083164               | 93.866                  | -                        | 23,218              | 23,218            |           |
|                                   | NIH                           | Aging Research                                   | Mechanisms in Lamin A function  |  |  |                    | R33AG054770               | 93.866                  | -                        | 158,441             | 158,441           |           |
|                                   | NIH                           | Aging Research                                   | Sub to Tulane -Transfer from R  | Tulane University                        |  |                    | R33AG057983               | 93.866                  | -                        | 300,578             | 300,578           |           |
|                                   | NIH                           | Aging Research                                   | Regulation and function of imm  |  |  |                    | R56AG065327               | 93.866                  | -                        | 19,257              | 19,257            |           |
|                                   |                               | Aging Research Total                             |   |  |  |                    |                           |                         | 27,707                   | 2,355,708           | 2,383,415         |           |
|                                   | NIH                           | Allergy, Immunology and Transplantation Research | Immunological identity redefined by genetically foreign                       |  |  |                    | DP1AI131080               | 93.855                  | -                        | 158,099             | 158,099           |           |
|                                   | NIH                           | Allergy, Immunology and Transplantation Research | Silencer Control of T cell Hom  |  |  |                    | F30AI157421               | 93.855                  | -                        | 40,794              | 40,794            |           |
|                                   | NIH                           | Allergy, Immunology and Transplantation Research | Single cell analysis of allere  |  |  |                    | F30AI167482               | 93.855                  | -                        | 47,688              | 47,688            |           |
|                                   | NIH                           | Allergy, Immunology and Transplantation Research | Adipose Tissue Inflammation in  |  |  |                    | F31AI169757               | 93.855                  | -                        | 41,412              | 41,412            |           |

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division | Government Branch                                | Award Title   | Pass-Through Grantor                    | Subrecipient Name   | Identifying Number         | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|----------|--|---|---|---|----------------------------|----------------------|--------|--------------------------|---------------------|-------------------|
|                   | NIH      | Allergy, Immunology and Transplantation Research | Maternal B cells enforce fetal                            |   |   |                            | K08AI180350          | 93.855 | \$ -                     | \$ 140,643          | \$ 140,643        |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Improving Anaphylaxis Outcomes                            |   |   |                            | K23AI175525          | 93.855 | -                        | 1,166               | 1,166             |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Combinatory Effects of Genetic                            |   |   |                            | K99AI158660          | 93.855 | -                        | 930                 | 930               |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Molecular Mechanisms of the Dy                            | Univ of Texas Medical Branch-Galveston  |   | 21-85495-01                | P01AI150585          | 93.855 | -                        | 176,596             | 176,596           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Combinatory Effects of Genetic                            |   |   |                            | R00AI158660          | 93.855 | -                        | 210,540             | 210,540           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Genetic Linkage in Lupus                                  |   | Cinti Foundatn Biomedical Resrch & Educ<br>LaJolla Inst for Allergy and Immunology  |                            | R01AI024717          | 93.855 | 148,500                  | 703,986             | 906,345           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Regulation of Gastrointestinal                            |   |   |                            | R01AI045898          | 93.855 | -                        | 642,564             | 642,564           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Epidemiologic Impact of HPV Va                            |   | Indiana University<br>Univ of California  |                            | R01AI104709          | 93.855 | 45,151                   | 327,121             | 393,681           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Innate mechanisms of regulatio                            |   |   |                            | R01AI123176          | 93.855 | -                        | 482,604             | 482,604           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Genetic and Immunological Diss                            |   |   |                            | R01AI124355          | 93.855 | -                        | 613,049             | 613,049           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Functional immune tolerance to non-inherited maternal an  |   |   |                            | R01AI124657          | 93.855 | -                        | 93,058              | 93,058            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Role and Regulation of TSLP in Childhood Allergic Disease |   |   |                            | R01AI127392          | 93.855 | -                        | 17,927              | 17,927            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Food Allergy Outcomes Related                             | Northwestern University Medical School  |   | 60061589 CC                | R01AI130348          | 93.855 | -                        | 137,291             | 137,291           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Non-Invasive Diagnosis of Pedi                            | Arkansas Children's Hospital            |   | #034146-006/R01AI139032    | R01AI139032          | 93.855 | -                        | 2,968               | 2,968             |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Early life factors, gene-envir                            | Wake Forest University Health Sciences  |   | R01AI139126                | R01AI139126          | 93.855 | -                        | 90,713              | 90,713            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Translational Regulation of CD                            |   |   |                            | R01AI139675          | 93.855 | -                        | 232,166             | 232,166           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Role of TET1 in airway epithel                            | University of California-Davis          |   | A20-0494S001               | R01AI141569          | 93.855 | -                        | 54,567              | 54,567            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Progesterone induced immune mo                            |   |   |                            | R01AI145840          | 93.855 | 162,566                  | 1,110,942           | 1,273,508         |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Rapid, safe suppression of IgE                            | University of Cincinnati                |   | 012329-00005               | R01AI145991          | 93.855 | -                        | 90,476              | 90,476            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Targeting natural killer cells                            |   | Duke University   |                            | R01AI148080          | 93.855 | 121,990                  | 345,254             | 467,244           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Roles of FFAR 3-SCFA axis in T                            |   |   |                            | R01AI148138          | 93.855 | -                        | 407,979             | 407,979           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Genomics of Inflammatory Bowel                            |   | Emory University<br>University of Cincinnati<br>Brigham and Women's Hospital  |                            | R01AI148276          | 93.855 | 18,313                   | 365,171             | 448,490           |
|                   |          |  |   |   |   |                            |                      |        | 17,616                   | -                   | -                 |
|                   |          |  |   |   |   |                            |                      |        | 47,390                   | -                   | -                 |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Viral and Cellular Determinant                            |   |   |                            | R01AI150486          | 93.855 | -                        | 135,365             | 135,365           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | An experimentally-refined, dyn                            |   |   |                            | R01AI153442          | 93.855 | -                        | 751,891             | 751,891           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Immunobiology of Influenza Vir                            | Children's Hospital Boston              |   | GENF0002024871             | R01AI154470          | 93.855 | -                        | 1,280               | 1,280             |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Proteasome targeting for allor                            | University of Pennsylvania              |   | 580121                     | R01AI154932          | 93.855 | -                        | 306,316             | 306,316           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Regulation of TLR signaling, I                            | Univ of Texas Southwestern              |   |                            | R01AI155426          | 93.855 | 245,678                  | 458,724             | 704,402           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Regulation of C. difficile col                            | University of Cincinnati                |   | 013939-00002               | R01AI158451          | 93.855 | -                        | 10,443              | 10,443            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Pay-it-forward gonorrhea testi                            | University of North Carolina            |   | 5123479/1R01AI158826-01    | R01AI158826          | 93.855 | -                        | 43,078              | 43,078            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Multi-Center Molecular Diagnos                            | Arkansas Children's Hospital            |   | VIPEER_ACRI_Danziger-Isako | R01AI159684          | 93.855 | -                        | 2,569               | 2,569             |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Mechanisms of staphylococcal s                            | University of Nebraska Medical Center   |   | 34-5301-2210-201           | R01AI162964          | 93.855 | -                        | 195,833             | 195,833           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Leveraging Health Information                             | Children's National Medical Center      |   | 30007046                   | R01AI163232          | 93.855 | -                        | 17,812              | 17,812            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Hyperhydration to Improve Kidn                            | University of Calgary                   |   | R01AI165327                | R01AI165327          | 93.855 | -                        | 67,304              | 67,304            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Malaria associated pathogenesi                            | Indiana University                      |   | 9671_CCHMC                 | R01AI165946          | 93.855 | -                        | 13,343              | 13,343            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Commensal Candida albicans pri                            |   | Brown University  |                            | R01AI168222          | 93.855 | 238,565                  | 351,692             | 590,257           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Kruppel-like factor-2 CD4+ T c                            |   |   |                            | R01AI172960          | 93.855 | -                        | 441,628             | 441,628           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Gene regulatory network modeli                            |   | University of California Irvine   |                            | R01AI173314          | 93.855 | 313,361                  | 392,629             | 705,990           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Biochemical mechanisms for sust                           | University of Pennsylvania              |   | 587137                     | R01AI175185          | 93.855 | -                        | 26,044              | 26,044            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Pregnancy induced deacetylato                             |   |   |                            | R01AI175431          | 93.855 | -                        | 191,832             | 191,832           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Blocking granzyme-mediated immn                           |   | Emory University  |                            | R01AI176519          | 93.855 | 150,799                  | 655,581             | 806,380           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | The TNF Superfamily Control of                            |   |   |                            | R01AI177359          | 93.855 | -                        | 604,447             | 604,447           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Sialylated antibody defense ag                            |   |   |                            | R01AI181778          | 93.855 | -                        | 122,079             | 122,079           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Viral and Cellular Determinant                            |   |   |                            | R01AI186611          | 93.855 | -                        | 16,943              | 16,943            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Genetic ancestry differences i                            |   |   |                            | R21AI157363          | 93.855 | -                        | 67,370              | 67,370            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Decoding human T-cell allospec                            | University of Notre Dame                |   | 204631CCHMC                | R21AI169863          | 93.855 | -                        | 101,929             | 101,929           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Early life dysbiosis, and skin                            | University of Cincinnati                |   | 015692-00002               | R21AI176276          | 93.855 | -                        | 67,657              | 67,657            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Role of Innate Lymphocytes in                             |   |   |                            | R21AI178517          | 93.855 | -                        | 48,046              | 48,046            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Copper tolerance and homeostas                            |   |   |                            | R21AI143467          | 93.855 | 17,151                   | -                   | 17,151            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | USIDNET: A resource for clinic                            | Children's Hospital of Philadelphia     |   | GRT-00002464               | R24AI171055          | 93.855 | -                        | 37,702              | 37,702            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Biomarker-enhanced Artificial                             | Computer Technology Associates, Inc     |   | STTR - Resubmission - 1    | R41AI167224          | 93.855 | -                        | 10,230              | 10,230            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Dr. Ming Tan sub on an NIH STT                            | Scaled Microbiomics, LLC                |   | SMB-CCHMC- 2023-001        | R41AI172485          | 93.855 | -                        | 59,525              | 59,525            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | A Nanoparticle-Based Multivale                            |   | Virginia Tech   |                            | R56AI148426          | 93.855 | 791                      | 1,943               | 2,734             |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Vaccinology Training Program                              |   |   |                            | T32AI165396          | 93.855 | -                        | 269,540             | 269,540           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Gene therapy for SCID-X1 with                             | Children's Hospital Boston              |   | GENF00020491271            | U01AI125051          | 93.855 | -                        | 8,980               | 8,980             |
|                   | NIH      | Allergy, Immunology and Transplantation Research | A Phase II study by the Primar                            | Children's Hospital Los Angeles         |   | 1801                       | U01AI126612          | 93.855 | -                        | 5,437               | 5,437             |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Controlling and Preventing Asthma Progression and Severi  | Children's Hospital Boston              |   | GENF00001867991            | U01AI126614          | 93.855 | -                        | 264,895             | 264,895           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Impact of the Initial Influenz                            |   | Emory University<br>University of Cincinnati  |                            | COVID-19 U01AI144673 | 93.855 | 1,309,301                | 3,498,130           | 5,161,258         |
|                   |          |  |   |   |   |                            |                      |        | 353,827                  | -                   | -                 |
|                   | NIH      | Allergy, Immunology and Transplantation Research | SEAL: (Stopping Atopic dermati                            | Harvard and Fellows of Harvard College, |   | 113159-5130587             | U01AI147462          | 93.855 | -                        | 202,000             | 202,000           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Dynamic regulatory network mod                            | University of California, Irvine        |   | 2023-1986                  | U01AI150748          | 93.855 | -                        | 562,663             | 562,663           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Atopic dermatitis: mechanisms                             |   |   |                            | U01AI152034          | 93.855 | -                        | 410,536             | 410,536           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Genomics of Nephrotic Syndrome                            | Duke University                         |   | UAI152585A                 | U01AI152585          | 93.855 | -                        | 408                 | 408               |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Randomized trial of viral spec                            |   |   |                            | U01AI157620          | 93.855 | -                        | 668,573             | 668,573           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Multi-omics of the Frequent Ex                            |   |   |                            | U01AI159087          | 93.855 | -                        | 444,261             | 444,261           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Advancing Transplantation Outc                            | Harvard Medical School                  |   | GENF0002098919/U01AI1630   | U01AI163072          | 93.855 | -                        | 46,104              | 46,104            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Itacimib to reduce lung infl                              | Duke University                         |   | A03-5348/1U01AI163099-01   | U01AI163099          | 93.855 | -                        | 47,101              | 47,101            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Comparison of High versus Stan                            | Vanderbilt University Medical Center    |   | VUMC114005                 | U01AI167799          | 93.855 | -                        | 77,477              | 77,477            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | HIP-III ImmuneSignatures IOF                              | La Jolla Institute for Immunology       |   | 20012-01-156-284           | U01AI167892          | 93.855 | -                        | 116,844             | 116,844           |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Consortium of Food Allergy Res                            |   |   |                            | U01AI181966          | 93.855 | -                        | 90,622              | 90,622            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Epithelial Genes in Allergic I                            |   |   |                            | U19AI070235          | 93.855 | -                        | 1,598,217           | 1,598,217         |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Systems biological assessment                             | Stanford University Medical Center      |   | 62927133-229950            | U19AI167903          | 93.855 | -                        | 17,708              | 17,708            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | i-AKC: Integrated AIRR Knowled                            | University of Texas at Dallas           |   | GMO240908 PO000003119      | U24AI177622          | 93.855 | -                        | 79,192              | 79,192            |
|                   | NIH      | Allergy, Immunology and Transplantation Research | Consortium of Eosinophilic Gas                            |   | Ann & Robert H Lurie Children's Hospital<br>Arkansas Children's Hospital<br>Baylor College of Medicine.<br>Children's Hospital of Philadelphia<br>ICAHN School of Medicine at Mount Sinai<br>Mayo Clinic Arizona<br>Northwestern University<br>Research Inst. at Nationwide Hos |                            | U54AI117804          | 93.855 | 48,895                   | 473,222             | 1,748,319         |
|                   |          |  |   |   |   |                            |                      |        | 17,707                   | -                   | -                 |
|                   |          |  |   |   |   |                            |                      |        | 22,581                   | -                   | -                 |
|                   |          |  |   |   |   |                            |                      |        | 65,776                   | -                   | -                 |
|                   |          |  |   |   |   |                            |                      |        | 73,648                   | -                   | -                 |
|                   |          |  |   |   |   |                            |                      |        | 42,853                   | -                   | -                 |
|                   |          |  |   |   |   |                            |                      |        | 321,378                  | -                   | -                 |
|                   |          |  |   |   |   |                            |                      |        | 16,383                   | -                   | -                 |

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division | Government Branch   | Award Title  | Pass-Through Grantor                   | Subrecipient Name   | Identifying Number | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|----------|---|--|--|---|--------------------|----------------------|--------|--------------------------|---------------------|-------------------|
|                   |          |   |  |  | University of Alabama at Birmingham                               |                    |                      |        | \$ 21,845                | \$ -                | \$ -              |
|                   |          |   |  |  | University of California  |                    |                      |        | 28,104                   | -                   | -                 |
|                   |          |   |  |  | University of Colorado  |                    |                      |        | 293,552                  | -                   | -                 |
|                   |          |   |  |  | University of North Carolina-Chapel Hill                          |                    |                      |        | 99,504                   | -                   | -                 |
|                   |          |   |  |  | University of Pennsylvania  |                    |                      |        | 95,216                   | -                   | -                 |
|                   |          |   |  |  | University of Utah  |                    |                      |        | 111,239                  | -                   | -                 |
|                   |          |   |  |  | Vanderbilt University Medical Center                              |                    |                      |        | 11,512                   | -                   | -                 |
|                   |          |   |  |  | Wake Forest Univ School of Medicine                               |                    |                      |        | 4,904                    | -                   | -                 |
|                   | NIH      | Allergy, Immunology and Transplantation Research            | Vaccine and Treatment Evaluati                           |  | Henry M. Jackson Foundation for the Nationwide Childrens Hospital |                    | UM1A1148372          | 93.855 | 199,973                  | 1,528,093           | 1,728,150         |
|                   |          |   |  |  | University of Cincinnati  |                    |                      |        | 84                       | -                   | -                 |
|                   |          |   |  |  | COVID-19 UMI1A1148372   |                    |                      |        | 17,586                   | 916,657             | 934,243           |
|                   | NIH      | Allergy, Immunology and Transplantation Research            | Vaccine and Treatment Evaluati                           | Emory University                       |   | UM1A1148684        |                      | 93.855 | -                        | 96,293              | 96,293            |
|                   | NIH      | Allergy, Immunology and Transplantation Research            | Leadership Group for an Infect                           | National Jewish Health                 |   | 20123803-CCHMC     |                      | 93.855 | -                        | 112,664             | 112,664           |
|                   | NIH      | Allergy, Immunology and Transplantation Research            | ADRN - LEADS: Longitudinal End                           | The Board of Regents Univ of Wisconsin |   | 000001464          |                      | 93.855 | -                        | 663,676             | 663,676           |
|                   | NIH      | Allergy, Immunology and Transplantation Research            | Childhood Asthma in Urban Sett                           | Johns Hopkins University               | University of Cincinnati  | 2004813187         |                      | 93.855 | 184,698                  | 642,813             | 827,511           |
|                   | CDC      | Allergy, Immunology and Transplantation Research            | New Horizons in the Prevention                           |  |   |                    |                      | 93.RD  | -                        | 377,797             | 377,797           |
|                   | CDC      | Allergy, Immunology and Transplantation Research            | A Prospective Observational St                           |  |   |                    |                      | 93.RD  | -                        | 119,253             | 119,253           |
|                   | CDC      | Allergy, Immunology and Transplantation Research            | Safety of Simultaneous versus                            |  |   |                    |                      | 93.RD  | -                        | 61,699              | 61,699            |
|                   | CDC      | Allergy, Immunology and Transplantation Research            | CISA Consult 1 year Bridge Con                           |  |   |                    |                      | 93.RD  | -                        | 286,770             | 286,770           |
|                   | CDC      | Allergy, Immunology and Transplantation Research            | Safety of simultaneous mRNA CO                           |  |   |                    |                      | 93.RD  | -                        | 113,420             | 113,420           |
|                   | CDC      | Allergy, Immunology and Transplantation Research            | Respiratory Virus Surveillance                           | Children's Hospital Boston             |   | GENFD000227664     |                      | 93.RD  | -                        | 103,090             | 103,090           |
|                   | CDC      | Allergy, Immunology and Transplantation Research            | Clinical Immunization Safety                             |  |   |                    |                      | 93.RD  | -                        | 41,126              | 41,126            |
|                   | CDC      | Allergy, Immunology and Transplantation Research            | CISA Clinical immunization Saf                           |  |   |                    |                      | 93.RD  | -                        | 197,867             | 197,867           |
|                   | NIH      | Allergy, Immunology and Transplantation Research            | A Molecular Atlas for Benchmar                           | Stanford University Medical Center     |   | 63008243-240857    |                      | 93.RD  | -                        | 375,145             | 375,145           |
|                   | NIH      | Allergy, Immunology and Transplantation Research            | Vaccine and Treatment Evaluation Units (VTEU) Protocol D |  |   |                    |                      | 93.RD  | -                        | 1,370,267           | 1,370,267         |
|                   | NIH      | Allergy, Immunology and Transplantation Research            | Vaccine and Treatment Evaluation Units (VTEU) Protocol D |  |   |                    |                      | 93.RD  | 144,918                  | 796,975             | 941,893           |
|                   | NIH      | Allergy, Immunology and Transplantation Research            | Mouse and Guinea Pig Models f                            | Pennington Biomedical Research Center  |   |                    |                      | 93.RD  | -                        | 26,144              | 26,144            |
|                   | NIH      | Allergy, Immunology and Transplantation Research            | Pharmacokinetics of Understudi                           | Duke University                        |   | 278589             |                      | 93.RD  | -                        | 26,144              | 26,144            |
|                   |          | Allergy, Immunology and Transplantation Research Total      |  |  |   |                    |                      |        | 5,088,623                | 28,448,598          | 33,537,221        |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Vega K23 - Resubmission - 1                              |  |   |                    |                      | 93.846 | -                        | 179,719             | 179,719           |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Mitochondrial regulation of ca                           |  |   |                    |                      | 93.846 | -                        | 20,235              | 20,235            |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Cincinnati Rheumatic Diseases                            |  |   |                    |                      | 93.846 | -                        | 649,224             | 649,224           |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Pediatric musculoSkeletal and                            |  | University of Cincinnati  |                    |                      | 93.846 | 917                      | 645,232             | 646,149           |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Deciphering mechanisms of myob                           |  |   |                    |                      | 93.846 | -                        | 716,336             | 716,336           |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Multi-site Randomized Clinical Trial of FIT Teens for Ju |  | Children's Hospital Boston  |                    |                      | 93.846 | 7,500                    | 339,286             | 481,490           |
|                   |          |   |  |  | Children's Mercy Hospital   |                    |                      |        | 32,575                   | -                   | -                 |
|                   |          |   |  |  | Connecticut Childrens Medical Center                              |                    |                      |        | 20,775                   | -                   | -                 |
|                   |          |   |  |  | Emory University  |                    |                      |        | 30,383                   | -                   | -                 |
|                   |          |   |  |  | Indiana University  |                    |                      |        | 29,507                   | -                   | -                 |
|                   |          |   |  |  | Nationwide Childrens Hospital                                     |                    |                      |        | 21,464                   | -                   | -                 |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | In vivo role of the fibroblast in muscular dystrophy     |  |   |                    |                      | 93.846 | -                        | 87,516              | 87,516            |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Transcription Factor Genetics                            |  | Boston University   |                    |                      | 93.846 | 46,385                   | 303,235             | 349,620           |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | GSK3 beta study in patients wi                           |  | Dayton Children's Hospital  |                    |                      | 93.846 | 14,115                   | 241,162             | 255,277           |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Identifying neural pathophysio                           |  | Universitat De Barcelona  |                    |                      | 93.846 | 93,437                   | 237,039             | 330,476           |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Epigenetic Determinants Influe                           |  | Children's Hospital of Philadelphia                               |                    |                      | 93.846 | 12,896                   | 261,870             | 343,247           |
|                   |          |   |  |  | Duke University   |                    |                      |        | 11,636                   | -                   | -                 |
|                   |          |   |  |  | Johns Hopkins University  |                    |                      |        | 11,447                   | -                   | -                 |
|                   |          |   |  |  | Stanford University   |                    |                      |        | 45,398                   | -                   | -                 |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | The Pediatric Lupus Nephritis                            |  | Albert Einstein College of Medicine                               |                    |                      | 93.846 | 3,000                    | 586,772             | 617,908           |
|                   |          |   |  |  | Ann & Robert H Lurie Children's Hospital                          |                    |                      |        | 3,737                    | -                   | -                 |
|                   |          |   |  |  | Children's Hospital Med Center of Akron                           |                    |                      |        | 3,000                    | -                   | -                 |
|                   |          |   |  |  | Medical College of Wisconsin                                      |                    |                      |        | 3,000                    | -                   | -                 |
|                   |          |   |  |  | Medical University South Carolina                                 |                    |                      |        | 3,000                    | -                   | -                 |
|                   |          |   |  |  | Nationwide Childrens Hospital                                     |                    |                      |        | 7,119                    | -                   | -                 |
|                   |          |   |  |  | Seattle Children's Hospital                                       |                    |                      |        | 5,280                    | -                   | -                 |
|                   |          |   |  |  | University of Colorado  |                    |                      |        | 3,000                    | -                   | -                 |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Pathogenesis of Systemic Juven                           |  |   |                    |                      | 93.846 | -                        | 598,417             | 598,417           |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Development of Foundational Co                           | Children's Hospital Boston             |   | GENFD0002512074    |                      | 93.846 | -                        | 9,484               | 9,484             |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Improving delivery of therapeu                           |  |   |                    |                      | 93.846 | -                        | 32,788              | 32,788            |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Electrical Coupling of Circula                           |  |   |                    |                      | 93.846 | -                        | 220,706             | 220,706           |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Cincinnati Training Program in                           |  |   |                    |                      | 93.846 | -                        | 180,462             | 180,462           |
|                   | NIH      | Arthritis, Musculoskeletal and Skin Diseases Research       | Towards personalized use of me                           | Oklahoma Medical Research Foundation   |   | 0352-02_CHMC_SH    |                      | 93.846 | -                        | 86,772              | 86,772            |
|                   |          | Arthritis, Musculoskeletal and Skin Diseases Research Total |  |  |   |                    |                      |        | 409,571                  | 5,396,255           | 5,805,826         |
|                   | BARDA    | Biomedical Advance Research and Development                 | Development, validation and us                           | University of Cincinnati               |   | 015548-00002:      | 75A50123C00052       | 93.RD  | -                        | 30,172              | 30,172            |
|                   |          | Biomedical Advance Research and Development Total           |  |  |   |                    |                      |        | -                        | 30,172              | 30,172            |
|                   | NIH      | Biomedical Research and Research Training                   | Mechanisms of cardiomyocyte dy                           |  |   |                    |                      | 93.859 | -                        | 192,463             | 192,463           |
|                   | NIH      | Biomedical Research and Research Training                   | Developing a Precision Medicin                           |  |   |                    |                      | 93.859 | -                        | 194,555             | 194,555           |
|                   | NIH      | Biomedical Research and Research Training                   | Role of Vpu, Tetherin, and Sig                           |  | University of Wisconsin System                                    |                    |                      | 93.859 | 26,245                   | 70,353              | 96,598            |
|                   | NIH      | Biomedical Research and Research Training                   | Mechanisms of Homocodomain Tran                          |  | University of Cincinnati  |                    |                      | 93.859 | 100,370                  | 415,882             | 516,252           |
|                   | NIH      | Biomedical Research and Research Training                   | Age-Dependent Mechanisms of Me                           |  |   |                    |                      | 93.859 | -                        | 47,965              | 47,965            |
|                   | NIH      | Biomedical Research and Research Training                   | Role of STAT3 in sepsis-induced adipose tissue browning  |  |   |                    |                      | 93.859 | -                        | 22,567              | 22,567            |
|                   | NIH      | Biomedical Research and Research Training                   | Functional characterization of                           |  | The Ohio State University- Spon Programs                          |                    |                      | 93.859 | 3,972                    | 138,068             | 142,040           |
|                   | NIH      | Biomedical Research and Research Training                   | Dynamic regulation of lineage                            |  |   |                    |                      | 93.859 | -                        | 296,006             | 296,006           |
|                   | NIH      | Biomedical Research and Research Training                   | Therapeutic resistance and agg                           | University of Cincinnati               |   | 014895-00002       |                      | 93.859 | -                        | 17,637              | 17,637            |
|                   | NIH      | Biomedical Research and Research Training                   | Finding Appropriate Subtypes i                           | Children's Hospital of Philadelphia    |   | FAST BOLUS         |                      | 93.859 | -                        | 229,501             | 229,501           |
|                   | NIH      | Biomedical Research and Research Training                   | Establishment of a multi-cente                           |  |   |                    |                      | 93.859 | -                        | 279,713             | 279,713           |
|                   | NIH      | Biomedical Research and Research Training                   | Leveraging multi-omics to maxi                           |  | Ann & Robert H Lurie Children's Hospital                          |                    |                      | 93.859 | 10,710                   | 165,699             | 201,062           |
|                   |          |   |  |  | Emory University  |                    |                      |        | 24,653                   | -                   | -                 |

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division                                  | Government Branch                               | Award Title  | Pass-Through Grantor                     | Subrecipient Name                        | Identifying Number        | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|---|---|--|--|--|---------------------------|----------------------|--------|--------------------------|---------------------|-------------------|
| NIH               | Biomedical Research and Research Training |   | Biobank of small extracellular                             |  |  |                           | R21GM151734          | 93.859 | \$ -                     | \$ 200,482          | \$ 200,482        |
| NIH               | Biomedical Research and Research Training |   | WE ENGAGE via Data and Stories to Improve Community Health |  | Miami University..                       |                           | R25GM129808          | 93.859 | 2,659                    | 149,307             | 154,840           |
|                   |   |   |  |  | University of Cincinnati                 |                           |                      |        | 2,874                    | -                   | -                 |
| NIH               | Biomedical Research and Research Training |   | #MyHealth: Training the Next G                             | University of Michigan                   |  | SUBK00013637              | R25GM137361          | 93.859 | -                        | 38,203              | 38,203            |
| NIH               | Biomedical Research and Research Training |   | Regulatory Mechanisms Governin                             |  |  |                           | R35GM140805          | 93.859 | -                        | 355,173             | 355,173           |
| NIH               | Biomedical Research and Research Training |   | How CHAF1B maintains cell stat                             |  |  |                           | R35GM142452          | 93.859 | -                        | 370,627             | 370,627           |
| NIH               | Biomedical Research and Research Training |   | Antibiotic Model-Informed Prec                             |  |  |                           | R35GM146701          | 93.859 | -                        | 448,688             | 448,688           |
| NIH               | Biomedical Research and Research Training |   | Method Development for Single-                             |  |  |                           | R35GM147283          | 93.859 | -                        | 26,585              | 26,585            |
| NIH               | Biomedical Research and Research Training |   | Novel regulators of macrophage                             | University of Cincinnati                 |  | 015245-00002              | R35GM149538          | 93.859 | -                        | 16,392              | 16,392            |
| NIH               | Biomedical Research and Research Training |   | Mechanisms regulating the bios                             |  |  |                           | R35GM150691          | 93.859 | -                        | 334,074             | 334,074           |
|                   |   | Biomedical Research and Research Training Total |  |  |  |                           |                      |        | 171,483                  | 4,009,940           | 4,181,423         |
| NIH               | Blood Diseases and Resources Research     |   | Sickle Cell Anemia, Splenic Pa                             | University of California                 |  | 705973                    | K23HL153763          | 93.839 | -                        | 163,539             | 163,539           |
| NIH               | Blood Diseases and Resources Research     |   | Validation of a pediatric thro                             | Children's Hospital Boston               |  | GENFD0002269955           | K23HL163330          | 93.839 | -                        | 96                  | 96                |
| NIH               | Blood Diseases and Resources Research     |   | Novel Strategies to Improve Bl                             |  |  |                           | P01HL158688          | 93.839 | -                        | 340,813             | 340,813           |
| NIH               | Blood Diseases and Resources Research     |   | The racial disparity in platelet                           |  |  |                           | R00HL136784          | 93.839 | -                        | 86,031              | 86,031            |
| NIH               | Blood Diseases and Resources Research     |   | Mechanisms of granulocyte home                             | The University of Chicago                |  | FP066598-A                | R01HL122661          | 93.839 | -                        | 448,824             | 448,824           |
| NIH               | Blood Diseases and Resources Research     |   | Chronic thrombus ablation with                             |  |  |                           | R01HL133334          | 93.839 | -                        | 51,092              | 51,092            |
| NIH               | Blood Diseases and Resources Research     |   | Small molecules targeting RhoA                             |  |  |                           | R01HL147536          | 93.839 | -                        | 119,638             | 119,638           |
| NIH               | Blood Diseases and Resources Research     |   | Linking Endotypes and Outcomes                             | Children's Hospital of Philadelphia      |  | 3201710624                | R01HL148054          | 93.839 | -                        | 66,074              | 66,074            |
| NIH               | Blood Diseases and Resources Research     |   | The role of mitochondria in he                             |  | Johns Hopkins University                 |                           | R01HL151654          | 93.839 | 17,536                   | 840,177             | 857,713           |
| NIH               | Blood Diseases and Resources Research     |   | The Role of Erythroblastic Isl                             |  | The Feinstein Institute Medical Research |                           | R01HL152099          | 93.839 | 330,440                  | 335,039             | 665,479           |
| NIH               | Blood Diseases and Resources Research     |   | Mechanisms whereby IFN-gamma s                             | University of Pittsburgh                 |  | AWD00003978               | R01HL153106          | 93.839 | -                        | 43,426              | 43,426            |
| NIH               | Blood Diseases and Resources Research     |   | Spatial control of myeloid dif                             |  |  |                           | R01HL153229          | 93.839 | -                        | 531,276             | 531,276           |
| NIH               | Blood Diseases and Resources Research     |   | MIDAS: Microangiopathy, Endoth                             | The Ohio State University Research Fnd   |  | 60078812                  | R01HL153723          | 93.839 | -                        | 116,946             | 116,946           |
| NIH               | Blood Diseases and Resources Research     |   | Functional characterization of                             | The University of Texas Southwestern     |  | GMO231108                 | R01HL153963          | 93.839 | -                        | 1,113               | 1,113             |
| NIH               | Blood Diseases and Resources Research     |   | Inflammatory Mechanisms in Pos                             | University of Cincinnati                 |  | 014082-00002              | R01HL155579          | 93.839 | -                        | 19,961              | 19,961            |
| NIH               | Blood Diseases and Resources Research     |   | Transfusion and Organ Dysfunct                             | Nationwide Children's Hospital           |  | 700277-0223-00            | R01HL157208          | 93.839 | -                        | 51,402              | 51,402            |
| NIH               | Blood Diseases and Resources Research     |   | Role of the local vascular mic                             |  |  |                           | R01HL158616          | 93.839 | -                        | 677,703             | 677,703           |
| NIH               | Blood Diseases and Resources Research     |   | The role of contact pathway fa                             |  |  |                           | R01HL160582          | 93.839 | -                        | 672,615             | 672,615           |
| NIH               | Blood Diseases and Resources Research     |   | Thrombosis Risk in Transgender                             |  |  |                           | R01HL161153          | 93.839 | -                        | 504,594             | 504,594           |
| NIH               | Blood Diseases and Resources Research     |   | Hematopoietic Stem Cell engraft                            |  |  |                           | R01HL162649          | 93.839 | -                        | 772,346             | 772,346           |
| NIH               | Blood Diseases and Resources Research     |   | The Darbepoetin Kindergarten D                             | RTI International                        |  | 3-312-0219253-67538L      | R01HL166254          | 93.839 | -                        | 95,775              | 95,775            |
| NIH               | Blood Diseases and Resources Research     |   | Preserving the bone marrow nic                             | University of Florida                    |  | SUB00003942               | R01HL166512          | 93.839 | -                        | 48,087              | 48,087            |
| NIH               | Blood Diseases and Resources Research     |   | Initiators of thrombotic micro                             |  |  |                           | R01HL171046          | 93.839 | -                        | 131,352             | 131,352           |
| NIH               | Blood Diseases and Resources Research     |   | The 11th Annual PTCTC Educatio                             |  |  |                           | R13HL173950          | 93.839 | -                        | 22,000              | 22,000            |
| NIH               | Blood Diseases and Resources Research     |   | Decoding innate immune signal                              |  |  |                           | R35HL166430          | 93.839 | -                        | 1,237,633           | 1,237,633         |
| NIH               | Blood Diseases and Resources Research     |   | Rho GTPase inhibitor for reflr                             | Orange Grove Bio LLC                     |  | SBIR_OGB4_Zheng_Y         | R44HL123103          | 93.839 | -                        | 88,588              | 88,588            |
| NIH               | Blood Diseases and Resources Research     |   | Decoding the Paradox of DDX41-                             |  |  |                           | R56HL169244          | 93.839 | -                        | 299,538             | 299,538           |
| NIH               | Blood Diseases and Resources Research     |   | Realizing Effectiveness Across                             |  | Baylor College of Medicine.              |                           | U01HL133883          | 93.839 | 9,313                    | 769,719             | 1,221,170         |
|                   |   |   |  |  | CEFA/Centre Hospitalier Monkole          |                           |                      |        | 83,527                   | -                   | -                 |
|                   |   |   |  |  | Hospital Pediatrico David Bernardino     |                           |                      |        | 122,073                  | -                   | -                 |
|                   |   |   |  |  | Mbale Regional Referral Hospital-Aclaim  |                           |                      |        | 135,384                  | -                   | -                 |
|                   |   |   |  |  | The Feinstein Institute Medical Research |                           |                      |        | 18,413                   | -                   | -                 |
|                   |   |   |  |  | University Health Network                |                           |                      |        | 19,975                   | -                   | -                 |
|                   |   |   |  |  | University of Oxford                     |                           |                      |        | 62,766                   | -                   | -                 |
| NIH               | Blood Diseases and Resources Research     |   | Sickle Cell Improvement: ENhan                             | The Nemours Foundation                   |  | PO010597                  | U01HL159850          | 93.839 | -                        | 62,333              | 62,333            |
|                   |   | Blood Diseases and Resources Research Total     |  |  |  |                           |                      |        | 799,427                  | 8,597,730           | 9,397,157         |
| NIH               | Cancer Biology Research                   |   | FA pathway activities in norma                             |  |  |                           | R01CA223790          | 93.396 | -                        | 156,954             | 156,954           |
| NIH               | Cancer Biology Research                   |   | The role of transcription elon                             |  |  |                           | R01CA234038          | 93.396 | -                        | 406,296             | 406,296           |
| NIH               | Cancer Biology Research                   |   | New activities of the human DE                             | University of Cincinnati                 | University of Kentucky Research Fnd      | 012828-002                | R01CA239605          | 93.396 | 21,609                   | 246,373             | 267,982           |
| NIH               | Cancer Biology Research                   |   | Defining genetic and metabolic                             |  |  |                           | R01CA239697          | 93.396 | -                        | 183,150             | 183,150           |
| NIH               | Cancer Biology Research                   |   | Patho-Genetic Analysis of Inva                             |  | Massachusetts General Hospital.          |                           | R01CA240317          | 93.396 | 98,817                   | 262,826             | 632,865           |
| NIH               | Cancer Biology Research                   |   | Modeling myelodysplasia                                    |  | University of Utah                       |                           |                      |        | 271,222                  | -                   | -                 |
|                   |   |   |  |  | Johns Hopkins University                 |                           | R01CA253981          | 93.396 | 56,636                   | 311,838             | 689,897           |
|                   |   |   |  |  | Yale University                          |                           |                      |        | 321,423                  | -                   | -                 |
| NIH               | Cancer Biology Research                   |   | Dissecting innate immune signa                             | Columbia University                      | New York University School of Medicine   | 1(GG016956-01)            | R01CA271455          | 93.396 | 320,766                  | 524,324             | 845,090           |
| NIH               | Cancer Biology Research                   |   | Mechanisms underlying gastric                              |  |  |                           | R01CA272903          | 93.396 | -                        | 431,127             | 431,127           |
| NIH               | Cancer Biology Research                   |   | The role of DNAJB1-PKAc-β-cate                             |  |  |                           | R01CA278834          | 93.396 | -                        | 663,066             | 663,066           |
| NIH               | Cancer Biology Research                   |   | Mechanisms coupling DEK to onc                             |  |  |                           | R37CA218072          | 93.396 | -                        | 421,491             | 421,491           |
| NIH               | Cancer Biology Research                   |   | Pathogenic Role of Foxl1 Hepa                              |  | Ann & Robert H Lurie Children's Hospital |                           | R37CA225807          | 93.396 | 8,862                    | 370,528             | 379,390           |
| NIH               | Cancer Biology Research                   |   | Therapeutic insights through p                             |  |  |                           | R50CA211404          | 93.396 | -                        | 210,774             | 210,774           |
| NIH               | Cancer Biology Research                   |   | Understanding the immune respo                             | Washington University                    |  | WU-24-0236                | U01CA275304          | 93.396 | -                        | 25,742              | 25,742            |
|                   |   | Cancer Biology Research Total                   |  |  |  |                           |                      |        | 1,099,335                | 4,214,489           | 5,313,824         |
| NIH               | Cancer Cause and Prevention Research      |   | Research Into Visual Endpoints                             | Vanderbilt University Medical Center     |  | VUMV67585                 | R01CA225005          | 93.393 | -                        | 10,347              | 10,347            |
| NIH               | Cancer Cause and Prevention Research      |   | Unbiased identification of spl                             |  |  |                           | R01CA226802          | 93.393 | -                        | 92,074              | 92,074            |
| NIH               | Cancer Cause and Prevention Research      |   | Strengthening epidermal defense                            |  |  |                           | R01CA228113          | 93.393 | -                        | 105,708             | 105,708           |
| NIH               | Cancer Cause and Prevention Research      |   | Investigating facilitator-driv                             | The University of Texas at Austin        |  | UTAUS-SUB00001294         | R01CA272757          | 93.393 | -                        | 15,490              | 15,490            |
| NIH               | Cancer Cause and Prevention Research      |   | Re-Engaging AYA Survivors in C                             | Children's Hospital of Philadelphia      |  | GRT-00003109              | R01CA273328          | 93.393 | -                        | 93,854              | 93,854            |
| NIH               | Cancer Cause and Prevention Research      |   | Towards an inclusive genomic r                             | Ohio State University Comprehensive Canc |  | SPC-1000012951   GR133524 | R01CA284595          | 93.393 | -                        | 195,315             | 195,315           |
| NIH               | Cancer Cause and Prevention Research      |   | A novel algorithm to compute a                             |  |  |                           | R21CA263704          | 93.393 | -                        | 184,555             | 184,555           |
| NIH               | Cancer Cause and Prevention Research      |   | A Pilot Feasibility Trial of a                             |  | Seattle Children's Hospital              |                           | R21CA268945          | 93.393 | 58,966                   | 168,280             | 255,498           |
|                   |   |   |  |  | St Jude Children's Research Hospital     |                           |                      |        | 28,252                   | -                   | -                 |
|                   |   | Cancer Cause and Prevention Research Total      |  |  |  |                           |                      |        | 87,218                   | 865,623             | 952,841           |

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division | Government Branch                             | Award Title  | Pass-Through Grantor                 | Subrecipient Name                    | Identifying Number        | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|----------|---|--|--------------------------------------|--------------------------------------|---------------------------|----------------------|--------|--------------------------|---------------------|-------------------|
|                   | NIH      | Cancer Detection and Diagnosis Research       | Integrated Informatic and Expe                           | University of Pennsylvania           |                                      | 577035                    | R01CA227485          | 93.394 | \$ -                     | \$ 297,566          | \$ 297,566        |
|                   | NIH      | Cancer Detection and Diagnosis Research       | Redefining hemophagocytic lym                            |                                      |                                      |                           | R21CA256390          | 93.394 | -                        | 48,316              | 48,316            |
|                   |          | Cancer Detection and Diagnosis Research Total |  |                                      |                                      |                           |                      |        | -                        | 345,882             | 345,882           |
|                   | NIH      | Cancer Research Manpower                      | Targeting MBNLI-mediated alter                           |                                      |                                      |                           | K08CA237753          | 93.398 | -                        | 155,383             | 155,383           |
|                   | NIH      | Cancer Research Manpower                      | Kinase-independent mechanism o                           |                                      |                                      |                           | K08CA270305          | 93.398 | -                        | 208,704             | 208,704           |
|                   | NIH      | Cancer Research Manpower                      | Dissecting the role of clonal                            |                                      |                                      |                           | R00CA252005          | 93.398 | -                        | 273,806             | 273,806           |
|                   | NIH      | Cancer Research Manpower                      | Pathways to Cancer Therapeutic                           | University of Cincinnati             |                                      | 1018713 & 1019848         | T32CA117846          | 93.398 | -                        | 88,320              | 88,320            |
|                   | NIH      | Cancer Research Manpower                      | Training Grant Bogdanov                                  | University of Cincinnati             |                                      |                           | 1019596 T32CA236764  | 93.398 | -                        | 42,661              | 42,661            |
|                   |          | Cancer Research Manpower Total                |  |                                      |                                      |                           |                      |        | -                        | 768,874             | 768,874           |
|                   | NIH      | Cancer Treatment Research                     | Linked regulation of tumor angiogenesis and chemo-resist | The University of Texas Southwestern |                                      |                           | R01CA207068          | 93.395 | -                        | 78,047              | 78,047            |
|                   | NIH      | Cancer Treatment Research                     | (PQ10) Role of Gut Microbiota                            |                                      |                                      | PO: 000001910A GMO 201112 | R01CA231303          | 93.395 | -                        | 147,513             | 147,513           |
|                   | NIH      | Cancer Treatment Research                     | Targeted Inhibition in Leukemi                           |                                      |                                      |                           | R01CA237016          | 93.395 | -                        | 372,014             | 372,014           |
|                   | NIH      | Cancer Treatment Research                     | Co-targeting S6 and TAM kinas                            | University of Cincinnati             |                                      | 12653-002                 | R01CA239657          | 93.395 | -                        | 10,731              | 10,731            |
|                   | NIH      | Cancer Treatment Research                     | Mechanism of Therapy in high-r                           |                                      |                                      |                           | R01CA250516          | 93.395 | -                        | 238,367             | 238,367           |
|                   | NIH      | Cancer Treatment Research                     | Therapeutic resistance and agg                           | University of Cincinnati             |                                      | 013734-00002              | R01CA255331          | 93.395 | -                        | 16,007              | 16,007            |
|                   | NIH      | Cancer Treatment Research                     | Therapeutic targeting of IRAK4                           | Albert Einstein College of Medicine  |                                      | 312231                    | R01CA275007          | 93.395 | -                        | 364,999             | 364,999           |
|                   | NIH      | Cancer Treatment Research                     | Rational targeting of Cdc42 to                           |                                      |                                      |                           | R01CA278756          | 93.395 | -                        | 273,575             | 273,575           |
|                   | NIH      | Cancer Treatment Research                     | Target the Dusp1 in Jak2 depen                           |                                      |                                      |                           | R21CA280723          | 93.395 | -                        | 392,140             | 392,140           |
|                   | NIH      | Cancer Treatment Research                     | The Pediatric Brain Tumor Cons                           | St Jude's Children's Hospital        |                                      | 110068210-7947557         | U01CA081457          | 93.395 | -                        | 61,906              | 61,906            |
|                   | NIH      | Cancer Treatment Research                     | BPTC-060: A Pilot Study of Saf                           | St Jude's Children's Hospital        |                                      |                           | U01CA081457          | 93.395 | -                        | 437                 | 437               |
|                   | NIH      | Cancer Treatment Research                     | Norris PHI-COG Associate Medic                           | Public Health Institute              |                                      | AR03186                   | U10CA180886          | 93.395 | -                        | 54,369              | 54,369            |
|                   | NIH      | Cancer Treatment Research                     | COMMITTEE LEADERSHIP: NIH Nati                           | Public Health Institute              |                                      | AR03217                   | U10CA180886          | 93.395 | -                        | 30,176              | 30,176            |
|                   | NIH      | Cancer Treatment Research                     | O'Brien PHI-COG Study Chair AA                           | Public Health Institute              |                                      | AR03402                   | U10CA180886          | 93.395 | -                        | 10,046              | 10,046            |
|                   | NIH      | Cancer Treatment Research                     | Study Chair  | Public Health Institute              |                                      | AR03413                   | U10CA180886          | 93.395 | -                        | 23,473              | 23,473            |
|                   | NIH      | Cancer Treatment Research                     | Study Chair  | Public Health Institute              |                                      | AR03426                   | U10CA180886          | 93.395 | -                        | 17,123              | 17,123            |
|                   | NIH      | Cancer Treatment Research                     | Study Chair AREN 1721 2021                               | Public Health Institute              |                                      | AR03450                   | U10CA180886          | 93.395 | -                        | 8,562               | 8,562             |
|                   | NIH      | Cancer Treatment Research                     | Study Chair  | Public Health Institute              |                                      | AR03451                   | U10CA180886          | 93.395 | -                        | 9,215               | 9,215             |
|                   | NIH      | Cancer Treatment Research                     | COG NCTN Network Group Operati                           | Public Health Institute              |                                      | AR04476                   | U10CA180886          | 93.395 | -                        | 5,539               | 5,539             |
|                   | NIH      | Cancer Treatment Research                     | AHEP 1531 (PHI managed)                                  | Public Health Institute              |                                      | AR04543/U10CA180886       | U10CA180886          | 93.395 | -                        | 18,240              | 18,240            |
|                   | NIH      | Cancer Treatment Research                     | COG NCTN Network Group Operati                           | Public Health Institute              |                                      | AR04575                   | U10CA180886          | 93.395 | -                        | 9,750               | 9,750             |
|                   | NIH      | Cancer Treatment Research                     | COG NCTN Network Group Operati                           | Public Health Institute              |                                      | AR04579                   | U10CA180886          | 93.395 | -                        | 3,799               | 3,799             |
|                   | NIH      | Cancer Treatment Research                     | Biomarker, Imaging and Quality                           | Public Health Institute              |                                      | AR04810                   | U10CA180886          | 93.395 | -                        | 8,833               | 8,833             |
|                   | NIH      | Cancer Treatment Research                     | COG Renal Tumor Committee Lead                           | Public Health Institute              |                                      | AR10915                   | U10CA180886          | 93.395 | -                        | 26,365              | 26,365            |
|                   | NIH      | Cancer Treatment Research                     | COG NCTN Network Group Operati                           | Public Health Institute              |                                      | AR61616                   | U10CA180886          | 93.395 | -                        | 4,609               | 4,609             |
|                   | NIH      | Cancer Treatment Research                     | PHI-COG Study Chair AALL2321                             | Public Health Institute              |                                      | AR66192                   | U10CA180886          | 93.395 | -                        | 11,238              | 11,238            |
|                   | NIH      | Cancer Treatment Research                     | COG NCTN Network Group Operati                           | Public Health Institute              |                                      | AR66195                   | U10CA180886          | 93.395 | -                        | 16,672              | 16,672            |
|                   | NIH      | Cancer Treatment Research                     | PHI-COG BIOSFP AHOD2131                                  | Public Health Institute              |                                      | AR67052                   | U10CA180886          | 93.395 | -                        | 1,794               | 1,794             |
|                   | NIH      | Cancer Treatment Research                     | COG Protocol Pathologist Revie                           | Public Health Institute              |                                      | AR69799                   | U10CA180886          | 93.395 | -                        | 1,999               | 1,999             |
|                   | NIH      | Cancer Treatment Research                     | 2023/24 STAR ACT Young Investi                           | Public Health Institute              |                                      | AR70344                   | U10CA180886          | 93.395 | -                        | 25,000              | 25,000            |
|                   | NIH      | Cancer Treatment Research                     | PHI-COG PCR Work Order 2021                              | Public Health Institute              |                                      | Norris_R_PHI/NIH          | U10CA180886          | 93.395 | -                        | 3,042               | 3,042             |
|                   | NIH      | Cancer Treatment Research                     | PHI-COG NCTN Work Order 2021                             | Public Health Institute              |                                      | U10CA180886               | U10CA180886          | 93.395 | -                        | 71,256              | 71,256            |
|                   | NIH      | Cancer Treatment Research                     | Childhood Cancer Survivor Stud                           | St Jude's Children's Hospital        |                                      | RFA-CA-20-052             | U24CA055727          | 93.395 | -                        | 243,183             | 243,183           |
|                   | NIH      | Cancer Treatment Research                     | Norris PHI-COG PEP-CTN WLI Cor                           | Public Health Institute              |                                      | AR06748                   | UM1CA228823          | 93.395 | -                        | 19,276              | 19,276            |
|                   |          | Cancer Treatment Research Total               |  |                                      |                                      |                           |                      |        | -                        | 2,579,295           | 2,579,295         |
|                   | NIH      | Cardiovascular Diseases Research              | GDF10 in Neonatal Heart Develo                           |                                      |                                      |                           | F31HL168819          | 93.837 | -                        | 4,585               | 4,585             |
|                   | NIH      | Cardiovascular Diseases Research              | Effects of early Retinoic Acid                           |                                      |                                      |                           | F31HL172346          | 93.837 | -                        | 3,521               | 3,521             |
|                   | NIH      | Cardiovascular Diseases Research              | The role of dendritic cells in                           |                                      |                                      |                           | F32HL168787          | 93.837 | -                        | 204                 | 204               |
|                   | NIH      | Cardiovascular Diseases Research              | The Role of PPARa in Cardiac Dysfuction in Sepsis        |                                      |                                      |                           | K08HL133377          | 93.837 | -                        | 8,810               | 8,810             |
|                   | NIH      | Cardiovascular Diseases Research              | Immune Response-Mediated Reg                             | The University of Texas Southwestern |                                      | GMO241017 - 241018        | P01HL160488          | 93.837 | -                        | 640,735             | 640,735           |
|                   | NIH      | Cardiovascular Diseases Research              | Uncovering compensatory mechan                           |                                      |                                      |                           | R00HL135258          | 93.837 | -                        | 22,798              | 22,798            |
|                   | NIH      | Cardiovascular Diseases Research              | Thrombospondin 4 regulates ada                           |                                      |                                      |                           | R01HL105924          | 93.837 | -                        | 96,125              | 96,125            |
|                   | NIH      | Cardiovascular Diseases Research              | Venous Malformations (VM): A M                           |                                      |                                      |                           | R01HL117952          | 93.837 | -                        | 648,134             | 648,134           |
|                   | NIH      | Cardiovascular Diseases Research              | Using MRI to visualize regiona                           | Duke University                      | University of Cincinnati             | A034671                   | R01HL126771          | 93.837 | 36,111                   | 123,937             | 160,048           |
|                   | NIH      | Cardiovascular Diseases Research              | Molecular examination of mitoc                           |                                      | Univ of Calif.-Davis-Mmrc            |                           | R01HL132831          | 93.837 | 218,921                  | 340,383             | 559,304           |
|                   | NIH      | Cardiovascular Diseases Research              | Molecular mechanisms of atrial                           |                                      |                                      |                           | R01HL137766          | 93.837 | -                        | 495,669             | 495,669           |
|                   | NIH      | Cardiovascular Diseases Research              | CelaI in Lung Development and Disease                    |                                      |                                      |                           | R01HL141229          | 93.837 | -                        | 189,585             | 189,585           |
|                   | NIH      | Cardiovascular Diseases Research              | Predictive Molecular Markers o                           |                                      |                                      |                           | R01HL142210          | 93.837 | -                        | 333,620             | 333,620           |
|                   | NIH      | Cardiovascular Diseases Research              | Cardiac fibroblasts in postnat                           |                                      |                                      |                           | R01HL142217          | 93.837 | -                        | 793,882             | 793,882           |
|                   | NIH      | Cardiovascular Diseases Research              | Mechanisms of Congenital Heart Valve Disease             |                                      |                                      |                           | R01HL143881          | 93.837 | -                        | 84,271              | 84,271            |
|                   | NIH      | Cardiovascular Diseases Research              | HDL composition/function and ca                          | University of Washington             |                                      | UWSC10977                 | R01HL144558          | 93.837 | -                        | 5,109               | 5,109             |
|                   | NIH      | Cardiovascular Diseases Research              | Molecular mechanisms underlyin                           |                                      |                                      |                           | R01HL144774          | 93.837 | -                        | 349,352             | 349,352           |
|                   | NIH      | Cardiovascular Diseases Research              | MRI Phenotyping of Early BPD a                           |                                      | University of Iowa                   |                           | R01HL146689          | 93.837 | 84,418                   | 75,618              | 160,036           |
|                   | NIH      | Cardiovascular Diseases Research              | Impact of Well-Timed vs. Mis-t                           |                                      | Rush University Medical Center       |                           | R01HL147915          | 93.837 | 30,979                   | 603,217             | 634,196           |
|                   | NIH      | Cardiovascular Diseases Research              | Novel Methods to Grow the Impa                           |                                      |                                      |                           | R01HL147957          | 93.837 | -                        | 298,286             | 298,286           |
|                   | NIH      | Cardiovascular Diseases Research              | Ultrasound-Mediated Controlled                           | University of Cincinnati             |                                      | 012268-003                | R01HL148451          | 93.837 | -                        | 203,548             | 203,548           |
|                   | NIH      | Cardiovascular Diseases Research              | Accelerating research to advan                           |                                      | Children's Hospital Boston           |                           | R01HL151604          | 93.837 | 199,191                  | 213,628             | 618,311           |
|                   |          |   |  |                                      | Vanderbilt University Medical Center |                           |                      |        | 205,492                  | -                   | -                 |
|                   | NIH      | Cardiovascular Diseases Research              | MINDS Imaging Ancillary Study                            | University of Pittsburgh             |                                      | AWD00002377 (134596-9)    | R01HL152740          | 93.837 | -                        | 14,207              | 14,207            |
|                   | NIH      | Cardiovascular Diseases Research              | Mechanisms underlying myxomato                           |                                      |                                      |                           | R01HL154522          | 93.837 | -                        | 580,881             | 580,881           |
|                   | NIH      | Cardiovascular Diseases Research              | Hypertrophic Cardiomyopathy: U                           | Brigham & Women's Hospital           |                                      | 2020A015252               | R01HL155568          | 93.837 | -                        | 5,608               | 5,608             |
|                   | NIH      | Cardiovascular Diseases Research              | Endothelial subpopulations in                            |                                      |                                      |                           | R01HL156270          | 93.837 | -                        | 481,560             | 481,560           |
|                   | NIH      | Cardiovascular Diseases Research              | Coronary Atherosclerosis and I                           | University of Cincinnati             |                                      | 014604-00002              | R01HL156779          | 93.837 | -                        | 117,710             | 117,710           |
|                   | NIH      | Cardiovascular Diseases Research              | Innate immune response signali                           |                                      |                                      |                           | R01HL156852          | 93.837 | -                        | 572,084             | 572,084           |
|                   | NIH      | Cardiovascular Diseases Research              | Pathogenesis and Treatment of                            |                                      |                                      |                           | R01HL156866          | 93.837 | -                        | 814,542             | 814,542           |
|                   | NIH      | Cardiovascular Diseases Research              | Lipoprotein Interactions in th                           | University of Cincinnati             |                                      |                           | R01HL157260          | 93.837 | 120,488                  | 261,660             | 382,148           |
|                   | NIH      | Cardiovascular Diseases Research              | Effect of reproductive history                           |                                      | Kaiser Foundation Res Institute      |                           | R01HL158100          | 93.837 | 2,370                    | 699,604             | 761,365           |
|                   |          |   |  |                                      | University of Cincinnati             |                           |                      |        | 43,693                   | -                   | -                 |
|                   |          |   |  |                                      | University of Pittsburgh             |                           |                      |        | 15,698                   | -                   | -                 |

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division | Government Branch                                      | Award Title  | Pass-Through Grantor                       | Subrecipient Name                       | Identifying Number        | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|----------|--|--|--|---|---------------------------|----------------------|--------|--------------------------|---------------------|-------------------|
|                   | NIH      | Cardiovascular Diseases Research                       | Microprotein Regulation of Mit   |  |   |                           | R01HL160569          | 93.837 | \$ -                     | \$ 397,217          | \$ 397,217        |
|                   | NIH      | Cardiovascular Diseases Research                       | Dissecting the role of the car   |  |   |                           | R01HL160765          | 93.837 | -                        | 636,606             | 636,606           |
|                   | NIH      | Cardiovascular Diseases Research                       | Thrombospondin1-regulated atro   |  |   |                           | R01HL162595          | 93.837 | -                        | 579,138             | 579,138           |
|                   | NIH      | Cardiovascular Diseases Research                       | Kids: Nocturnal Investigation  | Feinstein Institute for Medical Research   |   | AWD00001721_CR_Cincinnati | R01HL162912          | 93.837 | -                        | 58,280              | 58,280            |
|                   | NIH      | Cardiovascular Diseases Research                       | Role of SHE and ABL signaling  | University of Florida                      |   | 6145-1033-00-A            | R01HL163161          | 93.837 | -                        | 105,353             | 105,353           |
|                   | NIH      | Cardiovascular Diseases Research                       | Racial/Ethnic Influences on Ea   | Univ of California                         |   | 2022-1735                 | R01HL164823          | 93.837 | -                        | 55,245              | 55,245            |
|                   | NIH      | Cardiovascular Diseases Research                       | Harnessing novel glucocorticoid  |  |   |                           | R01HL166356          | 93.837 | -                        | 457,275             | 457,275           |
|                   | NIH      | Cardiovascular Diseases Research                       | Role of apoE in HDL-mediated e   |  | University of Cincinnati                |                           | R01HL167200          | 93.837 | 74,940                   | 425,522             | 500,462           |
|                   | NIH      | Cardiovascular Diseases Research                       | Pathogenesis of Vascular Anoma   |  |   |                           | R01HL167700          | 93.837 | -                        | 41,371              | 41,371            |
|                   | NIH      | Cardiovascular Diseases Research                       | Mechanisms governing the diffe   |  |   |                           | R01HL168790          | 93.837 | -                        | 392,782             | 392,782           |
|                   | NIH      | Cardiovascular Diseases Research                       | Developing DWORF gene therapy  |  |   |                           | R01HL171221          | 93.837 | -                        | 165,866             | 165,866           |
|                   | NIH      | Cardiovascular Diseases Research                       | Genetic Contributions to Valva   |  |   |                           | R03HL159537          | 93.837 | -                        | 180,640             | 180,640           |
|                   | NIH      | Cardiovascular Diseases Research                       | Finding the contribution of th   |  |   |                           | R21HL162572          | 93.837 | -                        | 58,505              | 58,505            |
|                   | NIH      | Cardiovascular Diseases Research                       | Intramuscular vs. Enteral Peni   |  | Murdoch Childrens Research Institute    |                           | R33HL166441          | 93.837 | 33,814                   | 138,289             | 384,739           |
|                   |          |  |  |  | Uganda Heart Institute                  |                           |                      |        | 210,214                  | -                   | -                 |
|                   |          |  |  |  | University of Washington                |                           |                      |        | 2,422                    | -                   | -                 |
|                   | NIH      | Cardiovascular Diseases Research                       | Intramuscular vs. Enteral Peni   |  | Children's Research Institute           |                           | R61HL166441          | 93.837 | 369,736                  | 277,136             | 811,184           |
|                   |          |  |  |  | Murdoch Childrens Research Institute    |                           |                      |        | 107,775                  | -                   | -                 |
|                   |          |  |  |  | The University of Melbourne             |                           |                      |        | 17,037                   | -                   | -                 |
|                   |          |  |  |  | University of Washington                |                           |                      |        | 39,500                   | -                   | -                 |
|                   | NIH      | Cardiovascular Diseases Research                       | Understanding Cardiovascular D   |  |   |                           | T32HL125204          | 93.837 | -                        | 270,881             | 270,881           |
|                   | NIH      | Cardiovascular Diseases Research                       | Administrative Coordinating Ce   |  | Children's Hospital Boston              |                           | U01HL131003          | 93.837 | 65,918                   | 4,332,754           | 5,015,073         |
|                   |          |  |  |  | Children's Hospital Los Angeles         |                           |                      |        | 50,000                   | -                   | -                 |
|                   |          |  |  |  | Columbia University                     |                           |                      |        | 52,537                   | -                   | -                 |
|                   |          |  |  |  | ICAHN School of Medicine at Mount Sinai |                           |                      |        | 6,694                    | -                   | -                 |
|                   |          |  |  |  | The University of Texas Science Center  |                           |                      |        | 34,482                   | -                   | -                 |
|                   |          |  |  |  | University of California                |                           |                      |        | 25,211                   | -                   | -                 |
|                   |          |  |  |  | University of Michigan                  |                           |                      |        | 85,889                   | -                   | -                 |
|                   |          |  |  |  | University of Pittsburgh                |                           |                      |        | 86,021                   | -                   | -                 |
|                   |          |  |  |  | University of Utah                      |                           |                      |        | 75,029                   | -                   | -                 |
|                   |          |  |  |  | University of Virginia                  |                           |                      |        | 33,454                   | -                   | -                 |
|                   |          |  |  |  | Yale University                         |                           |                      |        | 167,084                  | -                   | -                 |
|                   | NIH      | Cardiovascular Diseases Research                       | Lung Map submission with UC Sa   | University of California San Diego         |   | 125063615                 | U01HL148867          | 93.837 | -                        | 43,964              | 43,964            |
|                   | NIH      | Cardiovascular Diseases Research                       | Vascular Core for Dyslipidemia of Obesity Intervention T                       | New England Research Institutes            |   | NERI, Urina               | U24HL135691          | 93.837 | -                        | 5,524               | 5,524             |
|                   | NIH      | Cardiovascular Diseases Research                       | Single Institutional Review Bo   | New England Research Institutes            |   | NERI, Cnota, James        | U24HL135691          | 93.837 | -                        | 261,963             | 261,963           |
|                   | NIH      | Cardiovascular Diseases Research                       | PHN COVID/MUSIC Study Subcontr   | New England Research Institutes            |   | NERI, Taylor              | COVID-19 U24HL135691 | 93.837 | -                        | 4,500               | 4,500             |
|                   | NIH      | Cardiovascular Diseases Research                       | Impact of Race and Ethnicity o   | New England Research Institutes/HealthCore |   | NERI, Hills               | U24HL135691          | 93.837 | -                        | 74,000              | 74,000            |
|                   | NIH      | Cardiovascular Diseases Research                       | Pediatric Heart Network Prairieland Consortium                                 |  | Indiana University                      |                           | UG1HL135678          | 93.837 | 141,085                  | 117,563             | 258,648           |
|                   | NIH      | Cardiovascular Diseases Research                       | Multicenter Clinical Trial of  | Ann & Robert H Lurie Children's Hospital   |   | 901647-CCHMC              | UH3HL148318          | 93.837 | -                        | 9,201               | 9,201             |
|                   | NIH      | Cardiovascular Diseases Research                       | Pediatric Influence of Cooling   | University of Michigan                     |   | SUBK00017613              | UH3HL159134          | 93.837 | -                        | 49,373              | 49,373            |
|                   | NIH      | Cardiovascular Diseases Research                       | Pediatric Heart Network Joint  |  | University of Kentucky Research Fnd     |                           | UM1HL172717          | 93.837 | 55,419                   | 170,533             | 225,952           |
|                   |          | Cardiovascular Diseases Research Total                 |  |  |   |                           |                      |        | 2,691,622                | 18,392,354          | 21,083,976        |
|                   | NIH      | Child Health and Human Development Extramural Research | SMPD4: Role of a microcephaly  |  |   |                           | F31HD104350          | 93.865 | -                        | 14,219              | 14,219            |
|                   | NIH      | Child Health and Human Development Extramural Research | Child Health Research Career D   |  |   |                           | K12HD028827          | 93.865 | -                        | 534,221             | 534,221           |
|                   | NIH      | Child Health and Human Development Extramural Research | Clinical Pharmacology K12 Trai   |  | Midwestern University                   |                           | K12HD113190          | 93.865 | 30,517                   | 24,497              | 144,409           |
|                   |          |  |  |  | University of Colorado                  |                           |                      |        | 89,395                   | -                   | -                 |
|                   | NIH      | Child Health and Human Development Extramural Research | Surviving and Thriving in the  |  |   |                           | K23HD094855          | 93.865 | -                        | 27,316              | 27,316            |
|                   | NIH      | Child Health and Human Development Extramural Research | Electrophysiological Biomarker   |  |   |                           | K23HD101416          | 93.865 | -                        | 123,787             | 123,787           |
|                   | NIH      | Child Health and Human Development Extramural Research | Tracking early emergence of so   |  |   |                           | K23HD109375          | 93.865 | -                        | 155,083             | 155,083           |
|                   | NIH      | Child Health and Human Development Extramural Research | CLEAR consortium: Discovering  |  | Columbia University                     |                           | P01HD093363          | 93.865 | 170,947                  | 1,558,714           | 1,751,716         |
|                   |          |  |  |  | University of Texas at Austin           |                           |                      |        | 22,055                   | -                   | -                 |
|                   | NIH      | Child Health and Human Development Extramural Research | Pediatric HIV/AIDS Cohort Stud   | Harvard Medical School                     |   | 117267-0184-5119274       | P01HD103133          | 93.865 | -                        | 18,464              | 18,464            |
|                   | NIH      | Child Health and Human Development Extramural Research | C-Progress Pilot Grant for R03   | Frail Biomedical Research Institute        |   | 412579-19F99              | P2CHD101912          | 93.865 | -                        | 9,264               | 9,264             |
|                   | NIH      | Child Health and Human Development Extramural Research | The Indiana University-Ohio St   | Indiana University                         |   | 9600-9561 CCHMC           | P30HD106451          | 93.865 | -                        | 17,801              | 17,801            |
|                   | NIH      | Child Health and Human Development Extramural Research | Xenbase: a Xenopus Model Organ   |  | University of Calgary                   |                           | P41HD064556          | 93.865 | 625,620                  | 848,258             | 1,473,878         |
|                   | NIH      | Child Health and Human Development Extramural Research | Personalized Immunomodulation  |  | University of Utah                      |                           | PL1HD105462          | 93.865 | -                        | 11,409              | 11,409            |
|                   | NIH      | Child Health and Human Development Extramural Research | Establishment of the meiotic e   |  |   |                           | R00HD097285          | 93.865 | -                        | 303,319             | 303,319           |
|                   | NIH      | Child Health and Human Development Extramural Research | Genomic and functional analyse   |  |   |                           | R00HD104902          | 93.865 | -                        | 220,021             | 220,021           |
|                   | NIH      | Child Health and Human Development Extramural Research | Prenatal Genetic Diagnosis by  |  | Columbia University Medical Center      |                           | I(GG014633-01)       | 93.865 | -                        | 88,961              | 88,961            |
|                   | NIH      | Child Health and Human Development Extramural Research | Molecular signaling in uterine   |  |   |                           | R01HD068524          | 93.865 | -                        | 430,134             | 430,134           |
|                   | NIH      | Child Health and Human Development Extramural Research | Long-Term Outcomes of Intervene  | Oklahoma State University                  |   | 1-571918-CHMC             | R01HD074579          | 93.865 | -                        | 3,048               | 3,048             |
|                   | NIH      | Child Health and Human Development Extramural Research | A Cognitive Test Battery for I   | University of California-Davis             |   | 1580GYB180                | R01HD076189          | 93.865 | -                        | 188,700             | 188,700           |
|                   | NIH      | Child Health and Human Development Extramural Research | VIRTUUS Children's Study-Valid   | Children's Hospital of Philadelphia        |   | 3200880522                | R01HD091185          | 93.865 | -                        | 4,321               | 4,321             |
|                   | NIH      | Child Health and Human Development Extramural Research | The Effect of Emergency Depart   | Medical College of Wisconsin               |   | R01HD091302               | R01HD091302          | 93.865 | -                        | 5,120               | 5,120             |
|                   | NIH      | Child Health and Human Development Extramural Research | Vocational Fit Assessment and  | Colorado State University                  |   | R01HD092474               | R01HD092474          | 93.865 | -                        | 59,025              | 59,025            |
|                   | NIH      | Child Health and Human Development Extramural Research | Disorders/Differences of Sex Development (DSD) translational research network. | University of Michigan                     |   | SUBK00008039              | R01HD093450          | 93.865 | -                        | 26,154              | 26,154            |
|                   | NIH      | Child Health and Human Development Extramural Research | CES1 Genetic Variation Influen   | University of Florida                      |   | SUB00001726               | R01HD093612          | 93.865 | -                        | 5,103               | 5,103             |
|                   | NIH      | Child Health and Human Development Extramural Research | A multicenter collaborative cl   | Children's National Medical Center         |   | 30004927-01               | R01HD093622          | 93.865 | -                        | 8,856               | 8,856             |
|                   | NIH      | Child Health and Human Development Extramural Research | Early Childhood Communication  | University of California-Davis             |   | A19-0460-S002             | R01HD093654          | 93.865 | -                        | 394                 | 394               |
|                   | NIH      | Child Health and Human Development Extramural Research | Cognitive Outcome Measures in  |  | Colorado State University               |                           | R01HD093754          | 93.865 | 44,792                   | 108,014             | 152,806           |
|                   | NIH      | Child Health and Human Development Extramural Research | Improving the Detection of ST  | Children's National Medical Center         |   | R01HD094213               | R01HD094213          | 93.865 | -                        | 78,128              | 78,128            |
|                   | NIH      | Child Health and Human Development Extramural Research | Exploring vascular-mesenchymal   |  |   |                           | R01HD094698          | 93.865 | -                        | 25,828              | 25,828            |
|                   | NIH      | Child Health and Human Development Extramural Research | Dosing and Pilot Efficacy of 2   |  | Connecticut Childrens Medical Center    |                           | R01HD094862          | 93.865 | 43,094                   | 208,813             | 382,255           |
|                   |          |  |  |  | Nationwide Childrens Hospital           |                           |                      |        | 3,661                    | -                   | -                 |
|                   |          |  |  |  | The Broad Institute Inc.                |                           |                      |        | 106,402                  | -                   | -                 |
|                   |          |  |  |  | University of Cincinnati                |                           |                      |        | 20,285                   | -                   | -                 |
|                   | NIH      | Child Health and Human Development Extramural Research | Stress Hydrocortisone In Pedia   | Children's Hospital Boston                 |   | GENFD0001752112           | R01HD096901          | 93.865 | -                        | 185,556             | 185,556           |
|                   | NIH      | Child Health and Human Development Extramural Research | Deciphering the pathophysiology  |  |   |                           | R01HD098280          | 93.865 | -                        | 238,293             | 238,293           |
|                   | NIH      | Child Health and Human Development Extramural Research | Discovery of Molecular Targets   | UCLA School of Public Health               |   | R01HD098389               | R01HD098389          | 93.865 | -                        | 104,935             | 104,935           |
|                   | NIH      | Child Health and Human Development Extramural Research | Executive Function Outcome Mea   | Colorado State University                  |   | R01HD099150-01            | R01HD099150          | 93.865 | -                        | 104,063             | 104,063           |
|                   | NIH      | Child Health and Human Development Extramural Research | Improving the Effectiveness an   |  | University of Cincinnati                |                           | R01HD099775          | 93.865 | 71,636                   | 25,078              | 96,714            |
|                   | NIH      | Child Health and Human Development Extramural Research | Genomics of bone and body comp   | Children's Hospital of Philadelphia        |   | GRT-0000601               | R01HD100406          | 93.865 | -                        | 25,735              | 25,735            |

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division | Government Branch  | Award Title  | Pass-Through Grantor                            | Subrecipient Name                        | Identifying Number        | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|----------|--|--|---|--|---------------------------|----------------------|--------|--------------------------|---------------------|-------------------|
|                   | NIH      | Child Health and Human Development Extramural Research             | Enhancing Nursing Care Reliability                             | Ohio State University                           |  | 60077379                  | R01HD100455          | 93.865 | \$ -                     | \$ 96,886           | \$ 96,886         |
|                   | NIH      | Child Health and Human Development Extramural Research             | Development and persistence of Skeletal Health and Bone Marrow | North Carolina State University                 |  | 2020-2189-01              | R01HD101406          | 93.865 | -                        | 8,507               | 8,507             |
|                   | NIH      | Child Health and Human Development Extramural Research             | Pragmatic Pediatric Trial of B Integrating genomic studies of  | Children's Hospital Boston                      |  | Boston_Sub_TBD            | R01HD101421          | 93.865 | -                        | 313,816             | 313,816           |
|                   | NIH      | Child Health and Human Development Extramural Research             |  | Children's Hospital of Philadelphia             |  | PO# 20302538/GRT-00000762 | R01HD101528          | 93.865 | -                        | 41,483              | 41,483            |
|                   | NIH      | Child Health and Human Development Extramural Research             |  |   | University of California                 |                           | R01HD101669          | 93.865 | 68,034                   | 278,264             | 422,291           |
|                   |          |  |  |   | University of Exeter                     |                           |                      |        | 75,993                   | -                   | -                 |
|                   | NIH      | Child Health and Human Development Extramural Research             | An Injury Plausibility Assessment                              | Lurie Children's Hospital of Chicago            |  | 901615-CCHMC              | R01HD102428          | 93.865 | -                        | 1,191               | 1,191             |
|                   | NIH      | Child Health and Human Development Extramural Research             | A randomized controlled trial                                  | University of California-Davis                  |  | A21-0255-S001             | R01HD102571          | 93.865 | -                        | 72,813              | 72,813            |
|                   | NIH      | Child Health and Human Development Extramural Research             | Endocannabinoid Signaling during                               |   |  |                           | R01HD103475          | 93.865 | -                        | 496,005             | 496,005           |
|                   | NIH      | Child Health and Human Development Extramural Research             | Integration of spatiotemporal                                  |   |  |                           | R01HD103623          | 93.865 | -                        | 321,767             | 321,767           |
|                   | NIH      | Child Health and Human Development Extramural Research             | Automated Risk Assessment for                                  |   | University of Pittsburgh                 |                           | R01HD103630          | 93.865 | 193,947                  | 466,596             | 660,543           |
|                   | NIH      | Child Health and Human Development Extramural Research             | Leveraging the electronic health                               |   | Children's Hospital of Philadelphia      |                           | R01HD103654          | 93.865 | 443                      | 570,491             | 658,926           |
|                   |          |  |  |   | Tel Aviv Medical Center                  |                           |                      |        | 87,992                   | -                   | -                 |
|                   | NIH      | Child Health and Human Development Extramural Research             | Enhancement of Newborn Screening                               | University of Buffalo                           |  | R1304645                  | R01HD104814          | 93.865 | -                        | 17,940              | 17,940            |
|                   | NIH      | Child Health and Human Development Extramural Research             | Obesity Prevention Targets for                                 | Colorado State University                       |  | G-50243-01                | R01HD105233          | 93.865 | -                        | 224,251             | 224,251           |
|                   | NIH      | Child Health and Human Development Extramural Research             | Behavior Measure for Children                                  |   | University of Colorado                   |                           | R01HD105679          | 93.865 | 72,238                   | 372,180             | 444,418           |
|                   | NIH      | Child Health and Human Development Extramural Research             | Prevention of behavior problem                                 |   | Johns Hopkins University                 |                           | R01HD105727          | 93.865 | 27,697                   | 652,510             | 709,376           |
|                   |          |  |  |   | The Ohio State University                |                           |                      |        | 29,169                   | -                   | -                 |
|                   | NIH      | Child Health and Human Development Extramural Research             | Evaluating additive effects of                                 |   | Northeastern University                  |                           | R01HD106353          | 93.865 | 115,003                  | 410,390             | 639,258           |
|                   |          |  |  |   | Research Inst. at Nationwide Hospital    |                           |                      |        | 59,865                   | -                   | -                 |
|                   |          |  |  |   | University of Colorado                   |                           |                      |        | 54,000                   | -                   | -                 |
|                   | NIH      | Child Health and Human Development Extramural Research             | Using Dogs to Promote Therapeutic                              |   |  |                           | R01HD106416          | 93.865 | -                        | 322,213             | 322,213           |
|                   | NIH      | Child Health and Human Development Extramural Research             | Precision Alzementumab Therapy                                 |   |  |                           | R01HD107690          | 93.865 | -                        | 270,956             | 270,956           |
|                   | NIH      | Child Health and Human Development Extramural Research             | FX ENTRAIN: Perturbation of                                    |   | Brown University                         |                           | R01HD108222          | 93.865 | 23,633                   | 577,384             | 601,017           |
|                   | NIH      | Child Health and Human Development Extramural Research             | Human Milk as a Biological System                              | University of Cincinnati                        |  | 014666-00003              | R01HD109915          | 93.865 | -                        | 85,613              | 85,613            |
|                   | NIH      | Child Health and Human Development Extramural Research             | Screen to Prevent (S2P): Using                                 |   | Children's Hospital of Philadelphia      |                           | R01HD110321          | 93.865 | 120,790                  | 214,062             | 546,926           |
|                   |          |  |  |   | Children's National Medical Center       |                           |                      |        | 32,548                   | -                   | -                 |
|                   |          |  |  |   | Medical College of Wisconsin             |                           |                      |        | 66,605                   | -                   | -                 |
|                   |          |  |  |   | Nationwide Childrens Hospital            |                           |                      |        | 31,807                   | -                   | -                 |
|                   |          |  |  |   | University of Utah                       |                           |                      |        | 81,114                   | -                   | -                 |
|                   | NIH      | Child Health and Human Development Extramural Research             | Endotypes in Children with Severe                              | University of Michigan                          |  | SUBK00010627              | R01HL149910          | 93.865 | -                        | 8,214               | 8,214             |
|                   | NIH      | Child Health and Human Development Extramural Research             | ROR Plus: Randomized Trial of                                  |   |  |                           | R21HD102702          | 93.865 | -                        | 66,585              | 66,585            |
|                   | NIH      | Child Health and Human Development Extramural Research             | Developmental Pharmacology of                                  | Hasbro Children's Hospital                      |  | 7137746                   | R21HD107675          | 93.865 | -                        | 72,344              | 72,344            |
|                   | NIH      | Child Health and Human Development Extramural Research             | Addressing Sleep in Adolescent                                 |   |  |                           | R21HD110653          | 93.865 | -                        | 190,155             | 190,155           |
|                   | NIH      | Child Health and Human Development Extramural Research             | Pediatric Injury: Modules to Manage Medical Stress             | University of Utah                              |  | 1046978                   | R24HD096350          | 93.865 | -                        | 70,618              | 70,618            |
|                   | NIH      | Child Health and Human Development Extramural Research             | Evaluating Assessment and                                      |   | Univ of California-Davis-Mmrc            |                           | R33HD100934          | 93.865 | 41,741                   | 604,450             | 691,850           |
|                   |          |  |  |   | University of Pittsburgh                 |                           |                      |        | 45,659                   | -                   | -                 |
|                   | NIH      | Child Health and Human Development Extramural Research             | HEAL Initiative: Antenatal Opioid                              | RTI International                               |  | OBOE                      | RL1HD104254          | 93.865 | 6,964                    | 700,275             | 707,239           |
|                   | NIH      | Child Health and Human Development Extramural Research             | Enhancing Pediatric Treatment                                  |   |  |                           | T32HD068223          | 93.865 | -                        | 185,504             | 185,504           |
|                   | NIH      | Child Health and Human Development Extramural Research             | T32 Cincinnati Pediatric Clinical                              |   |  |                           | T32HD069054          | 93.865 | -                        | 169,387             | 169,387           |
|                   | NIH      | Child Health and Human Development Extramural Research             | dGTEX BPC Participation  | The Nat'l Disease Research Interchange          |  | 141143/1U24HD106537-01    | U24HD106537          | 93.865 | -                        | 52,085              | 52,085            |
|                   | NIH      | Child Health and Human Development Extramural Research             | Translational medicine and                                     |   | University of California, Riverside      |                           | U54HD104461          | 93.865 | 407,368                  | 779,101             | 1,910,741         |
|                   |          |  |  |   | University of Cincinnati                 |                           |                      |        | 41,212                   | -                   | -                 |
|                   |          |  |  |   | University of Oklahoma                   |                           |                      |        | 21,304                   | -                   | -                 |
|                   |          |  |  |   | University of Texas Southwestern         |                           |                      |        | 661,756                  | -                   | -                 |
|                   | NIH      | Child Health and Human Development Extramural Research             | NICHD Neonatal Research Network                                |   |  |                           | UG1HD027853          | 93.865 | -                        | 504,022             | 504,022           |
|                   | NIH      | Child Health and Human Development Extramural Research             | HEAL initiative: Neonatal Opioid                               |   |  |                           | UG1HD107616          | 93.865 | -                        | 296,036             | 296,036           |
|                   | NIH      | Child Health and Human Development Extramural Research             | Capitation - HEAL initiative:                                  | RTI International                               |  | 1U24HD107621              | UG1HD107616          | 93.865 | -                        | 19,470              | 19,470            |
|                   | NIH      | Child Health and Human Development Extramural Research             | Adolescent Medicine Trials Net                                 | Florida State University                        |  | R000003155                | UM2HD111102          | 93.865 | -                        | 137,333             | 137,333           |
|                   |          | Child Health and Human Development Extramural Research Total       |  |   |  |                           |                      |        | 3,595,286                | 15,461,529          | 19,056,815        |
|                   | ACL      | Developmental Disabilities Basic Support and Advocacy Grants       | Empowering Families  | Ohio Coalition for the Education of Children    |  | Riddle_OCECD              |                      | 93.630 | -                        | 21,857              | 21,857            |
|                   | ACL      | Developmental Disabilities Basic Support and Advocacy Grants       | Accommodations and Adaptations                                 | Florida Developmental Disabilities Council, Inc |  | FDDC #5045EM21            | Project Search       | 93.630 | -                        | 14,627              | 14,627            |
|                   |          | Developmental Disabilities Basic Support and Advocacy Grants Total |  |   |  |                           |                      |        | -                        | 36,484              | 36,484            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Identification of the genetic                                  |   |  |                           | F30DK123841          | 93.847 | -                        | 16,990              | 16,990            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Global Lipidomics Analysis                                     |   |  |                           | F31DK131885          | 93.847 | -                        | 18,878              | 18,878            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Elizabeth Coffey F32 Transfer                                  |   |  |                           | F32DK128979          | 93.847 | -                        | 65,621              | 65,621            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | The Role of DDX41 in Inherited                                 |   |  |                           | K01DK121733          | 93.847 | -                        | 136,180             | 136,180           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Role of VPS4A and ESCRT-III in                                 |   |  |                           | K01DK129270          | 93.847 | -                        | 147,592             | 147,592           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Microbial regulation of intestinal                             |   |  |                           | K01DK135647          | 93.847 | -                        | 168,638             | 168,638           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Bridging the gap of late gestational                           |   |  |                           | K08DK131259          | 93.847 | -                        | 170,117             | 170,117           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Commensal bacterial metabolism                                 |   |  |                           | K08DK134884          | 93.847 | -                        | 168,681             | 168,681           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Disrupted sleep architecture in                                |   |  |                           | K23DK135797          | 93.847 | -                        | 215,253             | 215,253           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Digestive Health Center (DHC):                                 |   |  |                           | P30DK078392          | 93.847 | -                        | 1,452,060           | 1,452,060         |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Personalized Cystic Fibrosis Treatment                         |   | University of Cincinnati                 |                           | P30DK117467          | 93.847 | 18,387                   | 808,983             | 827,370           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Critical Translational Studies in Pediatric Nephrology         |   |  |                           | P50DK096418          | 93.847 | -                        | 111,140             | 111,140           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Pediatric Kidney Single Cell Analysis                          | Washington University                           |  | WU-PCEN-03                | P50DK133943          | 93.847 | -                        | 41,684              | 41,684            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Immunologic Dysfunction in Bariatric                           |   | Univ of Texas Southwestern               |                           | R01DK064008          | 93.847 | 200,382                  | 19,061              | 219,443           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Adolescent Bariatric Surgery:                                  |   | Sanford Research North                   |                           | R01DK080020          | 93.847 | 10,380                   | 340,059             | 352,029           |
|                   |          |  |  |   | The CDM Group, Inc                       |                           |                      |        | 1,590                    | -                   | -                 |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Genetic basis of virus induced                                 |   |  |                           | R01DK091566          | 93.847 | -                        | 85,096              | 85,096            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Immunopathogenesis of non-alcoholic                            |   |  |                           | R01DK099222          | 93.847 | -                        | 456,875             | 456,875           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | On the regulation of hepatic glucose                           |   | University of Cincinnati                 | 014965-00002              | R01DK106364          | 93.847 | -                        | 59,509              | 59,509            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Advancing Treatment for Pancreatic                             |   | University of Minnesota                  | N005115002                | R01DK109124          | 93.847 | -                        | 36,559              | 36,559            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Epigenomic control of antimicrobial immunity in the intestine  |   |  |                           | R01DK114123          | 93.847 | -                        | 166,245             | 166,245           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Host integration of commensal                                  |   |  |                           | R01DK116868          | 93.847 | -                        | 452,392             | 452,392           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Molecular targets in cholestatic                               |   |  |                           | R01DK117266          | 93.847 | -                        | 212,870             | 212,870           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Manipulating DNA Damage-response                               |   |  |                           | R01DK117632          | 93.847 | -                        | 79,853              | 79,853            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Biomarkers for Urinary Tract Infection                         | University of Pittsburgh                        |  | AWD00000120 (132569-2)    | R01DK118033          | 93.847 | -                        | 130,586             | 130,586           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research       | Surgical or Medical Treatment                                  |   | Ann & Robert H Lurie Children's Hospital |                           | R01DK119450          | 93.847 | 5,714                    | 403,503             | 719,815           |
|                   |          |  |  |   | University of Colorado                   |                           |                      |        | 310,598                  | -                   | -                 |

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division | Government Branch  | Award Title  | Pass-Through Grantor                     | Subrecipient Name                      | Identifying Number      | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|----------|--|--|--|--|-------------------------|----------------------|--------|--------------------------|---------------------|-------------------|
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Molecular regulation of hepatic                          |  |  |                         | R01DK120765          | 93.847 | \$ -                     | \$ 145,229          | \$ 145,229        |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Regulation of functionally dis                           |  |  |                         | R01DK121062          | 93.847 | -                        | 280,277             | 280,277           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Diabetes Journey: From systema                           |  | University of Florida                  |                         | R01DK121295          | 93.847 | 154,595                  | 132,406             | 287,001           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Sox Proteins Modulate Genomic                            |  |  |                         | R01DK123092          | 93.847 | -                        | 442,314             | 442,314           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Role of extracellular vesicle                            |  | Vanderbilt University                  |                         | R01DK123181          | 93.847 | 41,279                   | 693,169             | 734,448           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Regulation of Niche Cell Differe                         | Case Western University                  |  | RESS16540               | R01DK123299          | 93.847 | -                        | 17,800              | 17,800            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Microbiota-mediated fibrotic r                           | University of North Carolina             |  | 5117429                 | R01DK124617          | 93.847 | -                        | 13,852              | 13,852            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Host and viral determinants of                           | Children's Hospital of Philadelphia      |  | 25460-GRT-00000414      | R01DK125418          | 93.847 | -                        | 317,634             | 317,634           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Extracellular vesicle cargo an                           | Translational Genomics Research Institut |  | DISTEFANO-22-01-CCHMC   | R01DK127015          | 93.847 | -                        | 6,291               | 6,291             |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Determinants of inception of i                           | Massachusetts General Hospital           |  | 239459                  | R01DK127171          | 93.847 | -                        | 79,964              | 79,964            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Changing Health And Lifestyle                            |  | University of Delaware                 |                         | R01DK128525          | 93.847 | 12,060                   | 282,814             | 294,874           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Structure, function, and modul                           |  |  |                         | R01DK131542          | 93.847 | -                        | 1,694               | 1,694             |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Contributions of the enterocyt                           | The University of Chicago                |  | AWD102456SUB00000571    | R01DK132043          | 93.847 | -                        | 300,754             | 300,754           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Role of Etv4 and Etv5 in the s                           |  |  |                         | R01DK132052          | 93.847 | 16,391                   | 385,365             | 401,756           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Multi-parametric quantitative                            |  |  |                         | R01DK132346          | 93.847 | -                        | 617,062             | 617,062           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Precise Infliximab Exposure an                           |  |  |                         | R01DK132408          | 93.847 | 43,736                   | 669,496             | 860,146           |
|                   |          |  |  |  | Indiana University                     |                         |                      |        | 7,442                    | -                   | -                 |
|                   |          |  |  |  | Medical College of Wisconsin           |                         |                      |        | 38,266                   | -                   | -                 |
|                   |          |  |  |  | Nationwide Childrens Hospital          |                         |                      |        | 50,963                   | -                   | -                 |
|                   |          |  |  |  | Nemours Children's Clinic              |                         |                      |        | 50,243                   | -                   | -                 |
|                   |          |  |  |  | Stanford University                    |                         |                      |        | -                        | -                   | -                 |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Targeting POGlut1 to promote b                           |  |  |                         | R01DK132751          | 93.847 | -                        | 121,785             | 121,785           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Diabetic Memory in Hematopoiet                           |  |  |                         | R01DK133145          | 93.847 | -                        | 525,973             | 525,973           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Cutaneous biomarkers of pediat                           |  | University of California, San Diego    |                         | R01DK133198          | 93.847 | 395,212                  | 452,442             | 847,654           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Artificial Intelligence to Pre                           | University of Alabama-Birmingham         |  | 000537127-SC002         | R01DK133539          | 93.847 | -                        | 22,122              | 22,122            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Oral Feeding Difficulty in Lar                           | The Nemours Foundation                   |  | R01DK134499             | R01DK134499          | 93.847 | -                        | 17,491              | 17,491            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | RNA silencing machinery in ext                           |  |  |                         | R01DK134646          | 93.847 | -                        | 238,433             | 238,433           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Organoid-guided Precision Hepa                           |  |  |                         | R01DK135478          | 93.847 | -                        | 137,383             | 137,383           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Genetic and Small Molecule Reg                           |  |  |                         | R01DK135479          | 93.847 | -                        | 67,094              | 67,094            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | A Novel Obesity Prevention Pro                           |  |  |                         | R01DK135497          | 93.847 | -                        | 298,072             | 298,072           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Liver-Gut-Microbiome Axis in P                           | Baylor College of Medicine               |  | R01DK135602             | R01DK135602          | 93.847 | -                        | 10,343              | 10,343            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | The role of serpins and LRP1 i                           |  |  |                         | R01DK136512          | 93.847 | -                        | 22,704              | 22,704            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Mechanistic and Therapeutic Ro                           | University of California-Davis           |  | A24-0282-S001           | R01DK136815          | 93.847 | -                        | 155,949             | 155,949           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | ROLE OF CIRCADIAN RHYTHM AND I                           |  |  |                         | R03DK130908          | 93.847 | -                        | 76,188              | 76,188            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Diabetes Timing and Types and                            |  |  |                         | R03DK131156          | 93.847 | -                        | 254,619             | 254,619           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Fibrosis Beyond the Core: A Ne                           |  |  |                         | R21DK133562          | 93.847 | -                        | 94,333              | 94,333            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | PAINED: Project Addressing INe                           | Children's National Medical Center       |  | 30007384-01             | R61DK135406          | 93.847 | -                        | 23,724              | 23,724            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Systems Biology of Bone Marrow                           | Children's Hospital Boston               |  | GENFD0001792995         | RC2DK122533          | 93.847 | -                        | 17,654              | 17,654            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | A generalizable framework for                            |  | University of Pittsburgh               |                         | RC2DK122376          | 93.847 | 148,177                  | 905,321             | 1,385,025         |
|                   |          |  |  |  | Yale University                        |                         |                      |        | 331,527                  | -                   | -                 |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Protein biomarkers to predict                            | University of Minnesota                  |  | N010838401              | R01DK138809          | 93.847 | -                        | 25,697              | 25,697            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Research Training in Pediatric                           |  |  |                         | T32DK007695          | 93.847 | -                        | 210,462             | 210,462           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Pediatric Gastroenterology and                           |  |  |                         | T32DK007727          | 93.847 | -                        | 557,409             | 557,409           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Research Training in Child Beh                           |  |  |                         | T32DK063929          | 93.847 | -                        | 423,819             | 423,819           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Non Alcoholic Steatohepatitis                            | Cleveland Clin Lerner Col of Med of CWRU |  | 1324-SUB                | U01DK061732          | 93.847 | -                        | 208,934             | 208,934           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Clinical Center for Cholestat                            |  |  |                         | U01DK062497          | 93.847 | -                        | 608,984             | 608,984           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | CKID IV (patient care and sala                           | Children's Mercy Hospital                |  | 18-0007                 | U01DK066143          | 93.847 | -                        | 37,077              | 37,077            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Limited Competition for Contin                           | Children's Mercy Kansas City             |  | 42189124                | U01DK066143          | 93.847 | -                        | 50,369              | 50,369            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | CUREGN 2.0 - Midwest Pediatric                           | Nationwide Children's Hospital           |  | 700198-0620-00          | U01DK100866          | 93.847 | -                        | 37,444              | 37,444            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Defining the intestinal stem c                           |  |  |                         | U01DK103117          | 93.847 | -                        | 518,637             | 518,637           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | INSPPIRE: A Longitudinal Cohor                           | University of Iowa                       |  | S02042-03               | U01DK108334          | 93.847 | -                        | 101,073             | 101,073           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Phosphate binder therapy and e                           | UCLA School of Public Health             |  | 1652 G YA029            | U01DK122013          | 93.847 | -                        | 21,731              | 21,731            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Pediatric Acute Liver Failure                            | Lurie Children's Hospital of Chicago     |  | 901628-CCH              | U01DK127995          | 93.847 | -                        | 33,900              | 33,900            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Clinical, imaging, and endosco                           |  |  |                         | U01DK134356          | 93.847 | -                        | 261,254             | 261,254           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Cincinnati Children's Clinical                           |  |  |                         | U01DK134976          | 93.847 | -                        | 130,889             | 130,889           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Limited Competition for the Co                           | City of Hope                             |  | 63054.2008523.669201    | U24DK085532          | 93.847 | -                        | 7,326               | 7,326             |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Cincinnati Cooperative Center                            |  |  |                         | U54DK126108          | 93.847 | -                        | 991,144             | 991,144           |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Modeling diabetes using an int                           |  | University of Illinois at Chicago      |                         | UH3DK119982          | 93.847 | 184,837                  | 194,686             | 651,519           |
|                   |          |  |  |  | University of North Texas              |                         |                      |        | 271,996                  | -                   | -                 |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Teen Longitudinal Assessment o                           | Lurie Children's Hospital of Chicago     |  | 901645-CHMC             | UM1DK072493          | 93.847 | -                        | 32,135              | 32,135            |
|                   | NIH      | Diabetes, Digestive, and Kidney Diseases Extramural Research                               | Teen Longitudinal Assessment of Bariatric Surgery (Teen- | University of Cincinnati                 |  | 010577-009              | UM1DK095710          | 93.847 | -                        | 87,196              | 87,196            |
|                   |          | Diabetes, Digestive, and Kidney Diseases Extramural Research Total                         |  |  |  |                         |                      |        | 2,293,775                | 18,332,342          | 20,626,117        |
|                   | NIH      | Discovery and Applied Research for Technological Innovations to Improve Human Health       | MRI and Deep Learning for Earl                           |  |  |                         | R01EB029944          | 93.286 | -                        | 560,993             | 560,993           |
|                   | NIH      | Discovery and Applied Research for Technological Innovations to Improve Human Health       | Quantification of Liver Fibros                           |  | New York University School of Medicine |                         | R01EB030582          | 93.286 | 25,206                   | 450,323             | 488,032           |
|                   |          |  |  |  | Univ of Michigan                       |                         |                      |        | 12,503                   | -                   | -                 |
|                   | NIH      | Discovery and Applied Research for Technological Innovations to Improve Human Health       | MRI-Compatible Robot for Real-                           | Children's National Medical Center       |  | 30006761-01             | R01EB031084          | 93.286 | -                        | 89,841              | 89,841            |
|                   | NIH      | Discovery and Applied Research for Technological Innovations to Improve Human Health       | Center for Innovative Diagnost                           | Johns Hopkins University                 |  | 2006251659              | U54EB007958          | 93.286 | -                        | 77,900              | 77,900            |
|                   |          | Discovery and Applied Research for Technological Innovations to Improve Human Health Total |  |  |  |                         |                      |        | 37,709                   | 1,179,057           | 1,216,766         |
|                   | NIH      | Drug Abuse and Addiction Research Programs   | Role of Siglec-1 in HIV Intera                           |  | University of Cincinnati               |                         | R01DA051895          | 93.279 | 14,728                   | 482,713             | 497,441           |
|                   | NIH      | Drug Abuse and Addiction Research Programs   | Modeling HIV and methamphetamine                         |  | University of Cincinnati               |                         | R01DA056903          | 93.279 | 19,515                   | 780,905             | 800,420           |
|                   | NIH      | Drug Abuse and Addiction Research Programs   | Automated Substance Use Detect                           |  |  |                         | R03DA054256          | 93.279 | -                        | 50,634              | 50,634            |
|                   | NIH      | Drug Abuse and Addiction Research Programs   | Omics analysis of HIV during s                           | University of Cincinnati                 |  | 014150-00002            | R33DA048439          | 93.279 | -                        | 25,143              | 25,143            |
|                   | NIH      | Drug Abuse and Addiction Research Programs   | SPRINT: Signature for Pain Rec                           | Stanford University                      |  | 63308247-144386         | R33NS114926          | 93.279 | -                        | 188,790             | 188,790           |
|                   | NIH      | Drug Abuse and Addiction Research Programs   | 4/6 HBCD Prenatal Experiences                            |  | University of Cincinnati               |                         | U01DA055342          | 93.279 | 122,274                  | 1,068,440           | 1,190,714         |
|                   | NIH      | Drug Abuse and Addiction Research Programs   | HEALTHy Brain and Child Develo                           | University of California San Diego       |  | KR 705046               | U24DA055325          | 93.279 | -                        | 65,947              | 65,947            |
|                   | NIH      | Drug Abuse and Addiction Research Programs   | A cohort study of pain, psycho                           | Yale                                     |  | CON-80004834 (GR122619) | UG1DA015831          | 93.279 | -                        | 48,014              | 48,014            |
|                   |          | Drug Abuse and Addiction Research Programs Total   |  |  |  |                         |                      |        | 156,517                  | 2,710,586           | 2,867,103         |

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division   | Government Branch | Award Title   | Pass-Through Grantor                    | Subrecipient Name                                     | Identifying Number | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|--|-------------------|---|---|---|--------------------|----------------------|--------|--------------------------|---------------------|-------------------|
| HRSA              | Emergency Medical Services for Children                                      |                   | Emergency Medicine Services fo  |   | Medical College of Wisconsin<br>Washington University |                    | U0322684             | 93.127 | \$ 119,299<br>168,605    | \$ 447,325<br>-     | \$ 735,229<br>-   |
|                   | Emergency Medical Services for Children Total                                |                   |   |   |   |                    |                      |        | 287,904                  | 447,325             | 735,229           |
| NIH               | Environmental Health   |                   | Internalizing Behaviors and Neuroimaging Outcomes: Impa                   |   | San Diego St. Univ. Research Foundation               |                    | R01ES027224          | 93.113 | -                        | 189                 | 189               |
| NIH               | Environmental Health   |                   | Contribution of Thirdhand Smoke to Overall Tobacco Smoke                  |   | University of Cincinnati                              |                    | R01ES027815          | 93.113 | 214,574                  | 43,096              | 269,878           |
| NIH               | Environmental Health   |                   | Developmental neurotoxicity of  | University of Pennsylvania              |   |                    | Chen NewFR R01       | 93.113 | -                        | 44,764              | 44,764            |
| NIH               | Environmental Health   |                   | Investigating the Impact of Ph  | University of North Carolina            |   |                    | 5129474              | 93.113 | -                        | 33,665              | 33,665            |
| NIH               | Environmental Health   |                   | Effects of DDE exposure on adi  | University of Southern California       |   |                    | 129965417            | 93.113 | -                        | 14,548              | 14,548            |
| NIH               | Environmental Health   |                   | ADVOCATE: Prevalence and Clini  |   | San Diego St. Univ. Research Foundation               |                    | R01ES030743          | 93.113 | 171,762                  | 450,287             | 634,502           |
| NIH               | Environmental Health   |                   | Epigenetics, Air Pollution, an  | University of Cincinnati                |   |                    | 1R01ES031054-01A1    | 93.113 | -                        | 157,809             | 157,809           |
| NIH               | Environmental Health   |                   | Maternal Exposure to Low Level  | Johns Hopkins University                |   |                    | 2005604948           | 93.113 | -                        | 3,047               | 3,047             |
| NIH               | Environmental Health   |                   | Longitudinal Impact of Air Pol  |   | Brown University                                      |                    | R01ES031621          | 93.113 | 47,887                   | 1,125,686           | 1,206,436         |
| NIH               | Environmental Health   |                   | Gene-pesticide interactions an  |   | University of Cincinnati                              |                    | R01ES032270          | 93.113 | 32,863                   | -                   | -                 |
| NIH               | Environmental Health   |                   | Gestational PFAS Mixture Expos  | Brown University                        |   |                    | 1R01ES032836-01      | 93.113 | -                        | 569,852             | 569,852           |
| NIH               | Environmental Health   |                   | Impact of pre- and postnatal c  | University of Pennsylvania              |   |                    | 582722               | 93.113 | -                        | 63,992              | 63,992            |
| NIH               | Environmental Health   |                   | OPEs and Adolescent Adiposity   | University of Nevada, Las Vegas         |   |                    | GR16780              | 93.113 | -                        | 173,276             | 173,276           |
| NIH               | Environmental Health   |                   | Investigating the Impact of Ph  | University of North Carolina            |   |                    | 5129586              | 93.113 | -                        | 141,848             | 141,848           |
| NIH               | Environmental Health   |                   | Childhood and In-Utero Exposur  | University of Cincinnati                |   |                    | 014646-00002         | 93.113 | -                        | 399,677             | 399,677           |
| NIH               | Environmental Health   |                   | Pre- and postnatal chemical mi  | University of Cincinnati                |   |                    | ULRF 22-1005-02      | 93.113 | -                        | 64,777              | 64,777            |
| NIH               | Environmental Health   |                   | A Residential Dust Control Int  | University of Louisville                |   |                    | 00002114             | 93.113 | -                        | 25,872              | 25,872            |
| NIH               | Environmental Health   |                   | Research Innovations using Sen  | Brown University                        |   |                    | R21ES034187          | 93.113 | -                        | 27,047              | 27,047            |
| NIH               | Environmental Health   |                   | Early Warning Systems for Chil  |   | University of Cincinnati                              |                    | R25ES034592          | 93.113 | 46,412                   | 78,110              | 124,522           |
| NIH               | Environmental Health   |                   | Training Grant  | Icahn School of Medicine at Mount Sinai |   |                    | 0001147              | 93.113 | -                        | 33,496              | 33,496            |
| NIH               | Environmental Health   |                   | Environmental Carcinogenesis a  | University of Cincinnati                |   |                    | 1019779              | 93.113 | -                        | 128,682             | 128,682           |
| NIH               | Environmental Health   |                   | Training Grant  | University of Cincinnati                |   |                    | 1018504              | 93.113 | -                        | 85,771              | 85,771            |
| NIH               | Environmental Health   |                   | David Ohayon T32 Billing Agree  | University of Cincinnati                |   |                    | 1019541              | 93.113 | -                        | 93,693              | 93,693            |
| NIH               | Environmental Health   |                   | Prenatal inflammatory exposures and neonatal immune deve                  | University of Cincinnati                |   |                    | 1018979              | 93.113 | -                        | 66,832              | 66,832            |
|                   | Environmental Health Total   |                   |   |   | Univ of Calif-Davis-Mmrc                              |                    | U01ES029234          | 93.113 | 272,653                  | -                   | 272,653           |
|                   |  |                   |   |   |   |                    |                      |        | 810,812                  | 3,826,016           | 4,636,828         |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Electrical Stimulation of Indu  | Kennedy Krieger Research Institute      |   |                    | 113126-0723-33B      | 93.853 | -                        | 200,827             | 200,827           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Towards biomarkers of resilien  |   |   |                    | K23NS117734          | 93.853 | -                        | 208,204             | 208,204           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Mitogenic Activities in Neurof  |   |   |                    | R01NS028840          | 93.853 | -                        | 608,407             | 608,407           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Comparison of Hemorrhagic and   | University of Cincinnati                |   |                    | 012830-00013         | 93.853 | -                        | 106,322             | 106,322           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Supraspinal Processing of Sens  |   | Universitat De Barcelona                              |                    | R01NS039426          | 93.853 | 10,207                   | 565,585             | 575,792           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Identification and reversal of  |   |   |                    | R01NS065200          | 93.853 | -                        | 278,288             | 278,288           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | A New Model to Identify Preter  |   |   |                    | R01NS094200          | 93.853 | -                        | 1,003,247           | 1,003,247         |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | MiR-155 and RUNX function in n  |   |   |                    | R01NS096053          | 93.853 | -                        | 58,140              | 58,140            |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Binding of Epstein Barr Virus   |   | The University of TX Health Science                   |                    | R01NS097233          | 93.853 | 54,196                   | 533,856             | 588,052           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Mechanisms of Biguanide Sensit  |   | Univ of Pennsylvania                                  |                    | R01NS099068          | 93.853 | 48,297                   | 490,366             | 538,663           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Distinct Mechanisms of Cognitive Behavioral Therapy Effects in Youth with |   | University of Cincinnati                              |                    | R01NS099162          | 93.853 | 34,778                   | 352,074             | 386,852           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Migraine: Insights from Neuroimaging and Quantitative Sensory Testing     |   |   |                    | R01NS101321          | 93.853 | -                        | 233,262             | 233,262           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | (The How and Why Youth with Headaches Get Better Study)                   |   |   |                    | R01NS103824          | 93.853 | -                        | 1,924               | 1,924             |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Assessing Population-based Rad  | University of Cincinnati                |   |                    | 011815-003           | 93.853 | -                        | 8,105               | 8,105             |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Progranulin:A Novel Gene in Gaucher Diseases                              | New York University                     |   |                    | R01NS103931          | 93.853 | -                        | 48,265              | 48,265            |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | A novel smart patch for the f   | University of Cincinnati                |   |                    | 012058-002           | 93.853 | -                        | 363,219             | 363,219           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Sensitization of developing sc  |   |   |                    | R01NS105715          | 93.853 | -                        | 12,347              | 12,347            |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Targeting the Hippo Signaling   | University of Houston                   |   |                    | R200017              | 93.853 | -                        | 246,601             | 246,601           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Mechanisms linking hemostatic   |   |   |                    | R01NS107258          | 93.853 | -                        | 300,365             | 300,365           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Functional analysis of the mic  |   |   |                    | R01NS107453          | 93.853 | -                        | 14,669              | 14,669            |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Headache Assessment of Childre  | The Trustees of Columbia University     |   |                    | PECARN Headache      | 93.853 | -                        | 33                  | 33                |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Neonatal Seizure Registry Deve  | UCSF Human Research Program             |   |                    | 11997sc              | 93.853 | -                        | 268,494             | 268,494           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Spinal circuitry for ventilato  |   |   |                    | R01NS111666          | 93.853 | -                        | 383,505             | 383,505           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Mechanisms of muscle afferent   |   |   |                    | R01NS113965          | 93.853 | -                        | 276,670             | 276,670           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Bystander gene deletions in ca  |   |   |                    | R01NS114074          | 93.853 | -                        | 295,084             | 295,084           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Uncovering treatment targets f  | University of Minnesota                 |   |                    | P008296601           | 93.853 | -                        | 429,459             | 429,459           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | CNS in congenital DMI: pathoge  |   |   |                    | R01NS115662          | 93.853 | -                        | 254,523             | 254,523           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Diagnostic validity and safety  | Johns Hopkins University                |   |                    | R01NS115929-01       | 93.853 | -                        | 48,420              | 48,420            |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Polyomic Predictors of Symptom  | Pennsylvania State University           |   |                    | CCHMCNS115942        | 93.853 | -                        | 126,644             | 126,644           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Role of mTOR in Circadian and   | University of Florida                   |   |                    | SUB00003646          | 93.853 | -                        | 152,286             | 152,286           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Circuit defects underlying in   | Univ of California Los Angeles          |   |                    | 1580 G YB180         | 93.853 | -                        | 425                 | 425               |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Seizures and Children's Outcom  | Univ of California San Francisco        |   |                    | 13490sc              | 93.853 | -                        | 13,834              | 13,834            |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | ROSE-LAWN   | University of Cincinnati                |   |                    | 013382-002           | 93.853 | -                        | 491,912             | 491,912           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Identification of novel pathwa  |   |   |                    | R01NS120892          | 93.853 | -                        | 634,209             | 634,209           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Anti-epileptogenic role of mTO  | Ntl Inst of Neuro Disorders & Stroke    |   |                    | R01NS121042          | 93.853 | -                        | 3,340               | 3,340             |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | NSR-GENE (Neonatal Seizure Reg  | University of California, San Francisco |   |                    | 13439sc              | 93.853 | -                        | 666,623             | 666,623           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Roles of Gsx factors in basal   |   |   |                    | R01NS124660          | 93.853 | -                        | 608,429             | 608,429           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Understanding the Impact of Yo  |   |   |                    | R01NS125316          | 93.853 | -                        | 34,102              | 34,102            |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | CMRO2 and Uncoupling of Oxidat  | University of Virginia                  |   |                    | AWD-004172.GR101205  | 93.853 | -                        | 338,244             | 338,244           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Midbrain pathways for visual h  |   |   |                    | R01NS126108          | 93.853 | -                        | 323,039             | 323,039           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Self-Management Intervention f  | Makerere Institute of Social Research   |   |                    | 11V2                 | 93.853 | -                        | 28,120              | 28,120            |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Defining the remote effects of  | University of Cincinnati                |   |                    | 014891-00002         | 93.853 | -                        | 38,641              | 38,641            |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | The title is Role of mmeningeal   | Yale University School of Medicine      |   |                    | CON-80004496         | 93.853 | -                        | 61,509              | 61,509            |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Advancing CNS drug delivery vi  |   | Indiana University                                    |                    | R01NS132504          | 93.853 | 50,727                   | 412,499             | 463,226           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | AT1C is a novel molecular targ  |   | University of Cincinnati                              |                    | R01NS132884          | 93.853 | 13,814                   | 134,320             | 161,513           |
| NIH               | Extramural Research Programs in the Neurosciences and Neurological Disorders |                   | Epigenetic mechanisms of disru  |   | University of North Carolina-Chapel Hill              |                    | R03NS133727          | 93.853 | 13,379                   | -                   | 47,830            |

(Continued)



**Children's Hospital Medical Center and Affiliates**

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division | Government Branch                           | Award Title   | Pass-Through Grantor                     | Subrecipient Name                    | Identifying Number | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|----------|---|---|--|--------------------------------------|--------------------|----------------------|--------|--------------------------|---------------------|-------------------|
|                   | NIH      | Lung Diseases Research                      | Role of lung endothelial cells                                |  | Indiana University                   |                    | R01HL158659          | 93.838 | \$ -                     | \$ 166,521          | \$ 166,521        |
|                   | NIH      | Lung Diseases Research                      | Risk stratification in pulmona                                |  |                                      |                    | R01HL160941          | 93.838 | 225,398                  | 242,177             | 467,575           |
|                   | NIH      | Lung Diseases Research                      | DLL4 in the Developing Lung an                                | Children's Mercy Hospital                |                                      | 42094127           | R01HL162937          | 93.838 | -                        | 12,158              | 12,158            |
|                   | NIH      | Lung Diseases Research                      | Derivation and Validation of t                                | Lurie Children's Hospital of Chicago     |                                      | A23-0051-S002-CHMC | R01HL163692          | 93.838 | -                        | 85,584              | 85,584            |
|                   | NIH      | Lung Diseases Research                      | Prdm3/16 Regulate Chromatin Ac                                |  |                                      |                    | R01HL164414          | 93.838 | -                        | 650,688             | 650,688           |
|                   | NIH      | Lung Diseases Research                      | Trajectories of Regional Cardi                                |  |                                      |                    | R01HL164420          | 93.838 | -                        | 666,146             | 666,146           |
|                   | NIH      | Lung Diseases Research                      | Defining PRC2 complex epigenom                                |  |                                      |                    | R01HL166245          | 93.838 | -                        | 566,631             | 566,631           |
|                   | NIH      | Lung Diseases Research                      | Elucidating the FOXF1 gene reg                                |  |                                      |                    | R01HL166283          | 93.838 | -                        | 631,591             | 631,591           |
|                   | NIH      | Lung Diseases Research                      | Early detection of pulmonary c                                |  |                                      |                    | R01HL166335          | 93.838 | -                        | 656,373             | 656,373           |
|                   | NIH      | Lung Diseases Research                      | Lung developmental defects cau                                | Univ of Arkansas for Medical Sciences    |                                      | 55852              | R01HL166748          | 93.838 | -                        | 60,149              | 60,149            |
|                   | NIH      | Lung Diseases Research                      | Role of alveolar fibroblasts i                                |  |                                      |                    | R01HL167030          | 93.838 | -                        | 620,688             | 620,688           |
|                   | NIH      | Lung Diseases Research                      | Human gene transfer and macrop                                |  | University of Cincinnati             |                    | R33HL156888          | 93.838 | 30,532                   | 1,430,203           | 1,721,264         |
|                   | NIH      | Lung Diseases Research                      | Pragmatic Research on Diuretic                                |  | University of South Florida          |                    |                      |        | 260,529                  | -                   | -                 |
|                   |          |   |   |  | Case Western Reserve University      |                    | R34HL158586          | 93.838 | 47,041                   | 103,661             | 255,057           |
|                   |          |   |   |  | Emory University                     |                    |                      |        | 26,916                   | -                   | -                 |
|                   |          |   |   |  | RTI International                    |                    |                      |        | 77,439                   | -                   | -                 |
|                   | NIH      | Lung Diseases Research                      | Transcriptional and epigenetic                                |  |                                      |                    | R35HL171346          | 93.838 | -                        | 196,182             | 196,182           |
|                   | NIH      | Lung Diseases Research                      | Stimulating Access to Research                                | University of Cincinnati                 |                                      | 013456-0002        | R38HL155775          | 93.838 | -                        | 3,865               | 3,865             |
|                   | NIH      | Lung Diseases Research                      | Commercial Translation of Biom                                |  |                                      |                    | R61HL154105          | 93.838 | -                        | 9,779               | 9,779             |
|                   | NIH      | Lung Diseases Research                      | Pulmonary Development and Dise                                |  |                                      |                    | T32HL007752          | 93.838 | -                        | 299,649             | 299,649           |
|                   | NIH      | Lung Diseases Research                      | Cincinnati Children's Summer M                                |  |                                      |                    | THL113229C           | 93.838 | -                        | 101,723             | 101,723           |
|                   | NIH      | Lung Diseases Research                      | ORBEX: Primary Prevention of Asthma and Wheezing in Children  | University of Arizona                    |                                      | PO 438886          | U01HL130045          | 93.838 | -                        | 394,513             | 394,513           |
|                   | NIH      | Lung Diseases Research                      | Editing Alveolar Progenitor Cells for Correction of Mono      |  | Boston University                    |                    | U01HL134745          | 93.838 | 35,638                   | 20,263              | 69,606            |
|                   |          |   |   |  | Johns Hopkins University             |                    |                      |        | 873                      | -                   | -                 |
|                   |          |   |   |  | National Jewish Health               |                    |                      |        | 65                       | -                   | -                 |
|                   |          |   |   |  | Univ of Pennsylvania                 |                    |                      |        | 2,687                    | -                   | -                 |
|                   |          |   |   |  | Washington University                |                    |                      |        | 10,080                   | -                   | -                 |
|                   | NIH      | Lung Diseases Research                      | LungMap Phase II - Building a                                 |  | Cedars-Sinai Medical Center          |                    | U01HL148856          | 93.838 | 2,351                    | 701,659             | 812,471           |
|                   |          |   |   |  | Massachusetts General Hospital.      |                    |                      |        | 108,461                  | -                   | -                 |
|                   | NIH      | Lung Diseases Research                      | Eliminating Monitor Overuse (E                                | Children's Hospital of Philadelphia      |                                      | GRT-00001474       | U01HL159880          | 93.838 | -                        | 51,322              | 51,322            |
|                   | NIH      | Lung Diseases Research                      | The LungMAP Data Coordination                                 |  | Battelle Memorial Institute          |                    | U24HL148865          | 93.838 | 50,000                   | 1,063,738           | 1,420,095         |
|                   |          |   |   |  | RTI International                    |                    |                      |        | 75,122                   | -                   | -                 |
|                   |          |   |   |  | The Broad Institute Inc.             |                    |                      |        | 104,890                  | -                   | -                 |
|                   |          |   |   |  | University of California, San Diego  |                    |                      |        | 50,000                   | -                   | -                 |
|                   |          |   |   |  | University of California, Santa Cruz |                    |                      |        | 26,345                   | -                   | -                 |
|                   |          |   |   |  | University of Rochester              |                    |                      |        | 50,000                   | -                   | -                 |
|                   | NIH      | Lung Diseases Research                      | Hydrocortisone for BPD Respiratory and Developmental Outcomes | Children's Hospital of Philadelphia      |                                      | 3200930818         | UG3HL137872          | 93.838 | -                        | 74,934              | 74,934            |
|                   | NIH      | Lung Diseases Research                      | Study (HYBRID Outcomes Study): Clinical Coordinating Center   | University of Arizona                    |                                      | 653083             | UH3HL147016          | 93.838 | -                        | 137,180             | 137,180           |
|                   | NIH      | Lung Diseases Research                      | AZInthromycin Therapy in Presc                                | Johns Hopkins University                 |                                      | 2006287179         | UH3HL151458          | 93.838 | -                        | 11,909              | 11,909            |
|                   |          |   | 1/2 Kids MoD PAH Trial: Mono-                                 |  |                                      |                    |                      |        | -                        | -                   | -                 |
|                   |          | Lung Diseases Research Total                |   |  |                                      |                    |                      |        | 3,101,228                | 16,951,875          | 20,053,103        |
|                   | NIH      | Medical Library Assistance                  | Reading Bees: Adapting and Tes                                |  |                                      |                    | G08LM014107          | 93.879 | -                        | 30,994              | 30,994            |
|                   | NIH      | Medical Library Assistance                  | Personal Health Record for You                                |  |                                      |                    | R01LM012816          | 93.879 | -                        | 12,551              | 12,551            |
|                   | NIH      | Medical Library Assistance                  | A Framework for Automated and                                 | Children's Hospital of Philadelphia      |                                      | GRT-00001468       | R01LM013222          | 93.879 | -                        | 349,179             | 349,179           |
|                   | NIH      | Medical Library Assistance                  | Situation Awareness to Improve                                |  |                                      |                    | R01LM013526          | 93.879 | -                        | 48,133              | 48,133            |
|                   |          | Medical Library Assistance Total            |   |  |                                      |                    |                      |        | -                        | 440,857             | 440,857           |
|                   | NIH      | Mental Health Research Grants               | A Family Navigator Interventio                                |  |                                      |                    | K23MH125138          | 93.242 | -                        | 157,037             | 157,037           |
|                   | NIH      | Mental Health Research Grants               | Molecular Mechanisms Controlli                                |  | University of Cincinnati             |                    | R01MH090740          | 93.242 | 8,066                    | -                   | 8,066             |
|                   | NIH      | Mental Health Research Grants               | 1/2 Anomalous Motor System Phy                                |  |                                      |                    | R01MH095014          | 93.242 | -                        | 448,369             | 448,369           |
|                   | NIH      | Mental Health Research Grants               | 4/7-Collaborative genomic stud                                |  |                                      |                    | R01MH115962          | 93.242 | -                        | 128,510             | 128,510           |
|                   | NIH      | Mental Health Research Grants               | Nationwide dissemination of a                                 |  |                                      |                    | R01MH118488          | 93.242 | -                        | 138,732             | 138,732           |
|                   | NIH      | Mental Health Research Grants               | Patient and Provider perspecti                                | University of North Carolina             |                                      | 5113985            | R01MH118955          | 93.242 | -                        | 162,541             | 162,541           |
|                   | NIH      | Mental Health Research Grants               | 1/3 Effectiveness Trial of the                                | Florida State University                 |                                      | R000002935         | R01MH121627          | 93.242 | -                        | 70,009              | 70,009            |
|                   | NIH      | Mental Health Research Grants               | Longitudinal Examination of SI                                |  |                                      |                    | R01MH122415          | 93.242 | -                        | 836,646             | 836,646           |
|                   | NIH      | Mental Health Research Grants               | Molecular Dissection of Synapt                                | The University of Massachusetts, Amherst |                                      | 21-015624 A00      | R01MH122519          | 93.242 | -                        | 5,446               | 5,446             |
|                   | NIH      | Mental Health Research Grants               | Parsing Neurobiological Bases                                 |  | Purdue University                    |                    | R01MH123831          | 93.242 | 18,379                   | 381,090             | 454,903           |
|                   |          |   |   |  | University of Cincinnati             |                    |                      |        | 55,434                   | -                   | -                 |
|                   | NIH      | Mental Health Research Grants               | Adaptive intervention to preve                                | University of Michigan                   |                                      | SUBK00020392       | R01MH126871          | 93.242 | -                        | 97,758              | 97,758            |
|                   | NIH      | Mental Health Research Grants               | Developing 3D brain circuits o                                |  |                                      |                    | R21MH132038          | 93.242 | 20,293                   | 136,224             | 156,517           |
|                   | NIH      | Mental Health Research Grants               | Airway inflammation and fear:                                 | University of Cincinnati                 |                                      | 014685-00002       | R56MH127043          | 93.242 | -                        | 86,154              | 86,154            |
|                   | NIH      | Mental Health Research Grants               | ADHD PreSMART: ADHD PreSMA Res                                |  |                                      |                    | R61MH135994          | 93.242 | -                        | 15,820              | 15,820            |
|                   |          | Mental Health Research Grants Total         |   |  |                                      |                    |                      |        | 102,172                  | 2,664,336           | 2,766,508         |
|                   | NIH      | National Center on Sleep Disorders Research | Circadian Clock Dysregulation                                 |  |                                      |                    | K08HL148551          | 93.233 | -                        | 143,269             | 143,269           |
|                   | NIH      | National Center on Sleep Disorders Research | Improving Outcomes in Pediatri                                |  |                                      |                    | R00HL144822          | 93.233 | -                        | 305,170             | 305,170           |
|                   | NIH      | National Center on Sleep Disorders Research | Treatment of Obstructive Sleep                                | Oregon Health Sciences University        |                                      | 1021452_Cincinnati | R61HL165345          | 93.233 | -                        | 255,363             | 255,363           |
|                   | NIH      | National Center on Sleep Disorders Research | Randomized Control Trial of ox                                |  | Brigham and Women's Hospital         |                    | R61HL165366          | 93.233 | 556,147                  | 755,374             | 2,814,845         |
|                   |          |   |   |  | Case Western Reserve University      |                    |                      |        | 131,038                  | -                   | -                 |
|                   |          |   |   |  | Children's Hospital Boston           |                    |                      |        | 134,208                  | -                   | -                 |
|                   |          |   |   |  | Children's Hospital Los Angeles      |                    |                      |        | 78,688                   | -                   | -                 |
|                   |          |   |   |  | Children's Hospital of Philadelphia  |                    |                      |        | 205,298                  | -                   | -                 |
|                   |          |   |   |  | Eastern Virginia Medical School      |                    |                      |        | 388,458                  | -                   | -                 |
|                   |          |   |   |  | Harvard Pilgrim Health Care, Inc.    |                    |                      |        | 78,836                   | -                   | -                 |
|                   |          |   |   |  | Oregon Health & Science University   |                    |                      |        | 43,828                   | -                   | -                 |
|                   |          |   |   |  | Seattle Children's Hospital          |                    |                      |        | 51,930                   | -                   | -                 |

(Continued)

**Children's Hospital Medical Center and Affiliates**

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division  | Government Branch   | Award Title  | Pass-Through Grantor                | Subrecipient Name                        | Identifying Number  | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|---|---|--|-------------------------------------|--|---------------------|----------------------|--------|--------------------------|---------------------|-------------------|
|                   |   |   |  |                                     | Univ of Michigan                         |                     |                      |        | \$ 154,382               | \$ -                | \$ -              |
|                   |   |   |  |                                     | University of Southern California        |                     |                      |        | 236,658                  | -                   | -                 |
|                   |   | National Center on Sleep Disorders Research Total   |  |                                     |  |                     |                      |        | 2,059,471                | 1,459,176           | 3,518,647         |
| HRSA              | National Research Service Award in Primary Care Medicine                                  |   | General Pediatrics Research Fe                           |                                     |  |                     | T3210027             | 93.186 | -                        | 568,498             | 568,498           |
|                   |   | National Research Service Award in Primary Care Medicine Total                                  |  |                                     |  |                     |                      |        | -                        | 568,498             | 568,498           |
| NIH               | Nursing Research  |   | A mixed methods approach to ex                           | Emory University                    |  | A567559             | K23NR020037          | 93.361 | -                        | 513                 | 513               |
| NIH               | Nursing Research  |   | Self-Management of Adolescent                            | Children's Hospital of Philadelphia |  | 3201511123          | R01NR017429          | 93.361 | -                        | 14,925              | 14,925            |
| NIH               | Nursing Research  |   | Fostering medication adherence                           |                                     | CHOC Children's Hospital                 |                     | R01NR017794          | 93.361 | 84,083                   | 244,081             | 483,882           |
|                   |   |   |  |                                     | Medical University South Carolina        |                     | R01NR017794          | 93.361 | 79,625                   | -                   | -                 |
|                   |   |   |  |                                     | North Carolina State University          |                     | R01NR017794          | 93.361 | 11,219                   | -                   | -                 |
|                   |   |   |  |                                     | Research Inst. at Nationwide Hos         |                     | R01NR017794          | 93.361 | 60,222                   | -                   | -                 |
|                   |   |   |  |                                     | University of Florida                    |                     | R01NR017794          | 93.361 | 4,652                    | -                   | -                 |
| NIH               | Nursing Research  |   | Randomized Controlled Trial of                           | Akron Children's Hospital           |  | 23-0001-A0001-SUB02 | R01NR019426          | 93.361 | 46,977                   | 501,617             | 548,594           |
| NIH               | Nursing Research  |   | Integrating clinician, caregiv                           |                                     | Children's Hospital of Philadelphia      |                     | R01NR020608          | 93.361 | -                        | 108,559             | 108,559           |
| NIH               | Nursing Research  |   | A socio-ecological approach fo                           |                                     | Nemours Children's Clinic, Jacksonville  |                     | R01NR020781          | 93.361 | 12,036                   | 379,841             | 401,047           |
|                   |   |   |  |                                     |  |                     |                      |        | 9,170                    | -                   | -                 |
| NIH               | Nursing Research  |   | Reducing Health Disparities th                           | University of Cincinnati            |  | 013513-002          | R21NR019126          | 93.361 | -                        | 26,068              | 26,068            |
|                   |   | Nursing Research Total  |  |                                     |  |                     |                      |        | 307,984                  | 1,275,604           | 1,583,588         |
| NIH               | Oral Diseases and Disorders Research  |   | Role of the Ciliary Protein C2                           |                                     |  |                     | F31DE030664          | 93.121 | -                        | 40,581              | 40,581            |
| NIH               | Oral Diseases and Disorders Research  |   | Developmental roles of Nr2f1 a                           |                                     |  |                     | F31DE032261          | 93.121 | -                        | 37,249              | 37,249            |
| NIH               | Oral Diseases and Disorders Research  |   | The role of Sonic hedgehog sig                           |                                     |  |                     | F31DE033565          | 93.121 | -                        | 21,791              | 21,791            |
| NIH               | Oral Diseases and Disorders Research  |   | Stottmann R01 Subaward from Na                           | Nationwide Children's Hospital      |  | 700262-0622         | R01DE027091          | 93.121 | -                        | 61,342              | 61,342            |
| NIH               | Oral Diseases and Disorders Research  |   | Regulation of Craniofacial Dev                           |                                     |  |                     | R01DE029417          | 93.121 | -                        | 758,009             | 758,009           |
| NIH               | Oral Diseases and Disorders Research  |   | Development and evaluation of                            | Indiana University                  |  | 9352-CHMC           | R01DE031259          | 93.121 | -                        | 34,512              | 34,512            |
| NIH               | Oral Diseases and Disorders Research  |   | Predicting Gli3 regulatory act                           | The Jackson Laboratory              |  | 210391-0323-02      | R01DE031750          | 93.121 | -                        | 353,354             | 353,354           |
| NIH               | Oral Diseases and Disorders Research  |   | Molecular Regulation of Palate                           |                                     |  |                     | R01DE033890          | 93.121 | -                        | 147,403             | 147,403           |
| NIH               | Oral Diseases and Disorders Research  |   | Tracing the origins of craniof                           |                                     |  |                     | R03DE030200          | 93.121 | -                        | 180,717             | 180,717           |
| NIH               | Oral Diseases and Disorders Research  |   | Function and Regulation of Sem                           |                                     |  |                     | R21DE030193          | 93.121 | -                        | 6,951               | 6,951             |
| NIH               | Oral Diseases and Disorders Research  |   | Molecular Basis of SIX2-relate                           |                                     |  |                     | R21DE032877          | 93.121 | -                        | 231,886             | 231,886           |
| NIH               | Oral Diseases and Disorders Research  |   | Harnessing the therapeutic potential of neural crest cel | Phoenix Children's Hospital         |  |                     | R35DE027557          | 93.121 | 20,805                   | 927,250             | 948,055           |
| NIH               | Oral Diseases and Disorders Research  |   | Velopharyngeal insufficiency f                           |                                     |  |                     | U01DE029750          | 93.121 | -                        | 49,008              | 49,008            |
| NIH               | Oral Diseases and Disorders Research  |   | Reduction of bloodstream infec                           |                                     | Brigham and Women's Hospital             |                     | UH3DE030401          | 93.121 | 25,246                   | 377,034             | 505,562           |
|                   |   |   |  |                                     | Dana Farber Cancer Institute             |                     |                      |        | 56,101                   | -                   | -                 |
|                   |   |   |  |                                     | University of Colorado                   |                     |                      |        | 47,181                   | -                   | -                 |
|                   |   | Oral Diseases and Disorders Research Total  |  |                                     |  |                     |                      |        | 149,333                  | 3,227,087           | 3,376,420         |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | The Patient and Parent Perspec                           |                                     |  |                     | K08HS026763          | 93.226 | -                        | 140,370             | 140,370           |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | AHRQ Mentored Clinical Scienti                           |                                     |  |                     | K08HS026975          | 93.226 | -                        | 138,785             | 138,785           |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Diagnosis and management of pe                           | Stanford University                 |  | 63291150-306760     | R01HS027619          | 93.226 | -                        | 32,620              | 32,620            |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Achieving Pediatric Health Equ                           |                                     |  |                     | R01HS027996          | 93.226 | -                        | 484,895             | 484,895           |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Examining the impact of health                           |                                     |  |                     | R01HS028589          | 93.226 | -                        | 387,804             | 387,804           |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Developing and Validating an A                           |                                     | Children's Hospital of Philadelphia      |                     | R01HS028976          | 93.226 | 5,690                    | 408,860             | 429,902           |
|                   |   |   |  |                                     | Massachusetts General Hospital,          |                     |                      |        | 15,352                   | -                   | -                 |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Comparing Family Decision Maki                           |                                     | University of Pittsburgh                 |                     | R01HS029152          | 93.226 | 6,534                    | 280,798             | 287,332           |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Standardization of Evaluation                            | University of Michigan              |  | SUBK00017768        | R01HS029313          | 93.226 | -                        | 35,920              | 35,920            |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Ambulatory Pediatric Safety Le                           | Children's Hospital Boston          |  |                     | RHS026644B           | 93.226 | -                        | 37,066              | 37,066            |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Spread of Safety Interventions                           | Children's Hospital Boston          |  |                     | RHS027401A           | 93.226 | -                        | 81,521              | 81,521            |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Re-engineering Patient and Fam                           | Children's Hospital Boston          |  |                     | RHS029346            | 93.226 | -                        | 237,743             | 237,743           |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Digital Innovation, Simulation                           |                                     | Children's Hospital Boston               |                     | R18HS029626          | 93.226 | 11,113                   | 338,729             | 349,842           |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | SAMURAI PICU: Situation Awaren                           |                                     | Seattle Children's Hospital              |                     | R18HS029630          | 93.226 | 1,930                    | 109,256             | 144,773           |
|                   |   |   |  |                                     | The University of Chicago                |                     |                      |        | 11,921                   | -                   | -                 |
|                   |   |   |  |                                     | Univ of Pennsylvania                     |                     |                      |        | 17,575                   | -                   | -                 |
|                   |   |   |  |                                     | Virginia Commonwealth University         |                     |                      |        | 4,091                    | -                   | -                 |
| AHRQ              | Research on Healthcare Costs, Quality and Outcomes  |   | Inform shared decision-making                            | Seattle Children's                  |  | 13080SUB            | R21HS029399          | 93.226 | -                        | 77,200              | 77,200            |
|                   |   | Research on Healthcare Costs, Quality and Outcomes Total  |  |                                     |  |                     |                      |        | 74,206                   | 2,791,567           | 2,865,773         |
| NIH               | Research Related to Deafness and Communication Disorders                                  |   | Clinical factors in aminoglyco                           | Creighton University                |  | 270753-7326         | R01DC016680          | 93.173 | -                        | 22,829              | 22,829            |
| NIH               | Research Related to Deafness and Communication Disorders                                  |   | Prevention of Ototoxicity with                           |                                     | Oregon Health & Science University       |                     | R01DC017867          | 93.173 | 258,516                  | 285,246             | 572,770           |
|                   |   |   |  |                                     | Portland VA Research Foundation          |                     |                      |        | 29,008                   | -                   | -                 |
| NIH               | Research Related to Deafness and Communication Disorders                                  |   | Technology-assisted language i                           |                                     | University of Colorado                   |                     | R01DC018550          | 93.173 | 247,655                  | 366,335             | 613,990           |
| NIH               | Research Related to Deafness and Communication Disorders                                  |   | Earliest predictors of languag                           | University of Cincinnati            |  |                     | R01DC018734          | 93.173 | 49,549                   | 683,283             | 732,832           |
| NIH               | Research Related to Deafness and Communication Disorders                                  |   | Neuroimaging Reveals Treatment                           | University of Toronto               |  | 2-515357            | R01DC019337          | 93.173 | -                        | 73,562              | 73,562            |
| NIH               | Research Related to Deafness and Communication Disorders                                  |   | Society of Ears, Nose, and Thr                           | Mayo Clinic Arizona                 |  | CIN-312896          | R13DC021115          | 93.173 | -                        | 13,936              | 13,936            |
| NIH               | Research Related to Deafness and Communication Disorders                                  |   | Mobile technologies for delive                           |                                     | University of Pretoria                   |                     | R21DC019598          | 93.173 | 33,175                   | 177,752             | 210,927           |
| NIH               | Research Related to Deafness and Communication Disorders                                  |   | Investigating the contribution                           |                                     | University of Illinois at Chicago        |                     | R21DC020242          | 93.173 | 2,810                    | 53,119              | 59,394            |
|                   |   |   |  |                                     | University of North Carolina-Chapel Hill |                     |                      |        | 3,465                    | -                   | -                 |
| NIH               | Research Related to Deafness and Communication Disorders                                  |   | Effects of Hypoglossal Nerve S                           | Massachusetts Ear & Eye Infirmary   |  | MassEyeEar_Heubi    | U01DC019279          | 93.173 | -                        | 7,248               | 7,248             |
|                   |   | Research Related to Deafness and Communication Disorders Total                                  |  |                                     |  |                     |                      |        | 624,178                  | 1,683,310           | 2,307,488         |
| SAMHSA            | Substance Abuse and Mental Health Services_Projects of Regional and National Significance |   | Pediatric Integrated Post-Trau                           | University of Utah                  |  | 10060285-03-CCHMC   | H79SM085051          | 93.243 | -                        | 8,559               | 8,559             |
|                   |   |   | Implementation of Screening, Brief                       |                                     | University of Cincinnati                 |                     | H79TI084035          | 93.243 | 23,427                   | 701,649             | 725,076           |
|                   |   | Substance Abuse and Mental Health Services_Projects of Regional and National Significance Total |  |                                     |  |                     |                      |        | 23,427                   | 710,208             | 733,635           |

(Continued)

**Children's Hospital Medical Center and Affiliates**

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division  | Government Branch | Award Title   | Pass-Through Grantor                   | Subrecipient Name                   | Identifying Number        | Federal Grant Number | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|---|-------------------|---|--|-------------------------------------|---------------------------|----------------------|--------|--------------------------|---------------------|-------------------|
| CDC               | Training and Clinical Skills Improvement Projects                                   |                   | Advancing the Epidemiology and US Enhanced Surveillance Netwo | Indiana University                     |                                     | 9782-CHMC                 | NU58IP000004         | 93.185 | \$ -                     | \$ 68,327           | \$ 68,327         |
| CDC               | Training and Clinical Skills Improvement Projects                                   |                   | US Enhanced Surveillance Netwo                                |  |                                     |                           | U01IP001155          | 93.185 | -                        | 2,489,278           | 2,489,278         |
| CDC               | Training and Clinical Skills Improvement Projects                                   |                   | US Enhanced Surveillance Netwo                                |  |                                     |                           | COVID-19 U01IP001155 | 93.185 | -                        | 7,518               | 7,518             |
|                   | Training and Clinical Skills Improvement Projects Total                             |                   |   |  |                                     |                           |                      |        | -                        | 2,565,123           | 2,565,123         |
| NIH               | Trans-NIH Research Support  |                   | Engineering multi-organs in a                                 | University of Wisconsin-Madison        |                                     | 000003023                 | DP2DK128799          | 93.310 | -                        | 604,269             | 604,269           |
| NIH               | Trans-NIH Research Support  |                   | ReSET: Restarting Safe Educati                                |  |                                     |                           | OT2HD107558          | 93.310 | -                        | 87,528              | 87,528            |
| NIH               | Trans-NIH Research Support  |                   | Cloud implementation of Xenbas                                |  |                                     |                           | P41HD064556          | 93.310 | -                        | 32,754              | 32,754            |
| NIH               | Trans-NIH Research Support  |                   | COVID-19 Network of Networks -                                | Rutgers                                |                                     | SUB000002754              | COVID-19 R33HD105619 | 93.310 | -                        | 42,386              | 42,386            |
| NIH               | Trans-NIH Research Support  |                   | NYU Pediatric Obesity, Metabolism and Kidney Cohort Cent      | NYU Sponsored Programs Administration  |                                     | 16-A0-00-006256           | UG30D023305          | 93.310 | -                        | 27,099              | 27,099            |
| NIH               | Trans-NIH Research Support  |                   | Children's Respiratory Research and Environment Workgrou      | University of Wisconsin-Madison        |                                     | 000002430                 | UG30D023282          | 93.310 | -                        | 314,248             | 314,248           |
| NIH               | Trans-NIH Research Support  |                   | Childhood Allergy and the NeOn                                | University of Wisconsin-Madison        |                                     | 000003219                 | UG30D035509          | 93.310 | -                        | 22,768              | 22,768            |
| NIH               | Trans-NIH Research Support  |                   | Capitation- Merhar - Developme                                | Northwell Health                       |                                     | AWD00001795_Cincinnati_CR | UG30D035513          | 93.310 | -                        | 90,453              | 90,453            |
| NIH               | Trans-NIH Research Support  |                   | Developmental Impact of NICU E                                | Albert Einstein College of Medicine    |                                     | 311397                    | UH30D023320          | 93.310 | -                        | 59,145              | 59,145            |
|                   | Trans-NIH Research Support Total  |                   |   |  |                                     |                           |                      |        | -                        | 1,280,650           | 1,280,650         |
| NIH               | Vision Research   |                   | Predicting uveitis onset in ch                                |  | Children's Hospital of Philadelphia |                           | R01EY030521          | 93.867 | 380                      | 319,947             | 422,713           |
| NIH               | Vision Research   |                   |   |  | Children's Mercy Hospital           |                           |                      |        | 9,200                    | -                   | -                 |
| NIH               | Vision Research   |                   |   |  | Emory University                    |                           |                      |        | 9,450                    | -                   | -                 |
| NIH               | Vision Research   |                   |   |  | Univ. of California                 |                           |                      |        | 75                       | -                   | -                 |
| NIH               | Vision Research   |                   |   |  | University of Utah                  |                           |                      |        | 455                      | -                   | -                 |
| NIH               | Vision Research   |                   |   |  | Wake Forest Univ School of Medicine |                           |                      |        | 83,206                   | -                   | -                 |
| NIH               | Vision Research   |                   | Light regulated vascular devel                                |  |                                     |                           | R01EY032029          | 93.867 | -                        | 341,045             | 341,045           |
| NIH               | Vision Research   |                   | dopamine/LKB1 project   | Baylor College of Medicine             |                                     | 5R01EY032566              | R01EY032566          | 93.867 | -                        | 213,797             | 213,797           |
| NIH               | Vision Research   |                   | Mechanisms of intrinsic light                                 |  | University of Alabama at Birmingham |                           | R01EY032752          | 93.867 | 134,323                  | 114,140             | 248,463           |
| NIH               | Vision Research   |                   | Genomic analysis of microphtha                                |  |                                     |                           | R01EY032976          | 93.867 | -                        | 482,389             | 482,389           |
| NIH               | Vision Research   |                   | Melanopsin-dependent light-evo                                |  |                                     |                           | R01EY034456          | 93.867 | -                        | 289,335             | 289,335           |
| NIH               | Vision Research   |                   | Optimizing methotrexate use fo                                |  | Children's Mercy Hospital           |                           | R01EY034565          | 93.867 | 365                      | 403,467             | 404,363           |
| NIH               | Vision Research   |                   |   |  | Children's Hospital Boston          |                           |                      |        | 531                      | -                   | -                 |
| NIH               | Vision Research   |                   | Microphthalmia, anophthalmia a                                |  |                                     |                           | R01EY035500          | 93.867 | -                        | 194,554             | 194,554           |
| NIH               | Vision Research   |                   | Cataract Surgery Outcome Registry                             | Jaeb Center for Health Res Fdn., Inc.  |                                     | U10EY011751               | U10EY011751          | 93.867 | -                        | 59,553              | 59,553            |
| NIH               | Vision Research   |                   | Adalimumab in Juvenile Idiopat                                | The Univ of California, San Francisco  |                                     | 11309se_FEX               | UG1EY029658          | 93.867 | -                        | 22,276              | 22,276            |
|                   | Vision Research Total   |                   |   |  |                                     |                           |                      |        | 237,985                  | 2,440,503           | 2,678,488         |
| NIH               | Human Genome Research   |                   | Engaging adolescents in decis                                 |  | Mayo Clinic Rochester               |                           | R01HG010166          | 93.172 | 63,695                   | 908,014             | 971,709           |
| NIH               | Human Genome Research   |                   | Virus-driven human gene misreg                                |  | Brigham and Women's Hospital        |                           | R01HG010730          | 93.172 | 146,339                  | 265,730             | 453,985           |
| NIH               | Human Genome Research   |                   |   |  | University of Cincinnati            |                           |                      |        | 41,916                   | -                   | -                 |
| NIH               | Human Genome Research   |                   | Epigenome-wide variations and                                 |  | University of Cincinnati            |                           | R01HG011411          | 93.172 | 13,337                   | 1,008,143           | 1,021,480         |
| NIH               | Human Genome Research   |                   | Post-Transcriptional Regulator                                | Memorial Sloan Kettering Cancer Center |                                     | PO #C22420604             | R01HG013328          | 93.172 | -                        | 72,459              | 72,459            |
| NIH               | Human Genome Research   |                   | Single-cell and single-molecul                                | The University of Chicago              |                                     | AWD103412 (SUB00000762)   | R21HG012423          | 93.172 | -                        | 102,657             | 102,657           |
| NIH               | Human Genome Research   |                   | SciDAP: next generation platfo                                | Datirium LLC                           |                                     | Datirium - Salomonis,Nath | R42HG011219          | 93.172 | -                        | 173,256             | 173,256           |
| NIH               | Human Genome Research   |                   | Inferring 1D and 3D epigenomes                                |  | University of Pittsburgh            |                           | R56HG012360          | 93.172 | 20,560                   | 35,707              | 56,267            |
| NIH               | Human Genome Research   |                   | Polygenic Risk Scores for Heal                                |  | Children's Hospital Boston          |                           | U01HG011172          | 93.172 | 39,968                   | 1,521,151           | 1,719,259         |
|                   | Human Genome Research Total   |                   |   |  |                                     |                           |                      |        | 158,140                  | -                   | -                 |
|                   | Human Genome Research Total   |                   |   |  |                                     |                           |                      |        | 483,955                  | 4,087,117           | 4,571,072         |
| NIH               | Alcohol Research Programs   |                   | Therapeutic and mechanistic si                                | University of Cincinnati               |                                     | 014707-00002              | R01AA030486          | 93.273 | -                        | 32,554              | 32,554            |
|                   | Alcohol Research Programs Total   |                   |   |  |                                     |                           |                      |        | -                        | 32,554              | 32,554            |
| CDC               | Injury Prevention and Control Research and State and Community Based Programs       |                   | Evaluation of Return to School                                | University of Oregon                   |                                     | 282080C                   | U01CE003163          | 93.136 | -                        | 34,775              | 34,775            |
| CDC               | Injury Prevention and Control Research and State and Community Based Programs       |                   | Development of a Mental health                                |  |                                     |                           | U01CE003570          | 93.136 | -                        | 263,382             | 263,382           |
|                   | Injury Prevention and Control Research and State and Community Based Programs Total |                   |   |  |                                     |                           |                      |        | -                        | 298,157             | 298,157           |
| NIH               | National Center for Advancing Translational Sciences                                |                   | NIH KL2TR001426 KL2   | University of Cincinnati               |                                     | 012846-000011             | KL2TR001426          | 93.350 | -                        | 392,906             | 392,906           |
| NIH               | National Center for Advancing Translational Sciences                                |                   | Urinary Lipidomic profile in F                                |  |                                     |                           | R03TR003916          | 93.350 | -                        | 64,329              | 64,329            |
| NIH               | National Center for Advancing Translational Sciences                                |                   | Modeling Progressive Familial                                 |  |                                     |                           | R03TR004601          | 93.350 | -                        | 69,565              | 69,565            |
| NIH               | National Center for Advancing Translational Sciences                                |                   | Structure-function analysis of                                | University of Cincinnati               |                                     | 015695-00002              | R03TR004875          | 93.350 | -                        | 16,285              | 16,285            |
| NIH               | National Center for Advancing Translational Sciences                                |                   | Clinical Trial Readiness - Pri                                | Seattle Children's                     |                                     | 12874SUB                  | R21TR004057          | 93.350 | -                        | 8,238               | 8,238             |
| NIH               | National Center for Advancing Translational Sciences                                |                   | Precision Medicine in the Diag                                | Tufts Medical Center                   |                                     | 5016131-SERV              | U01TR002271          | 93.350 | -                        | 17,316              | 17,316            |
| NIH               | National Center for Advancing Translational Sciences                                |                   | Instrumenting the Delivery Sys                                | Children's Hospital Boston             |                                     | GENFD0001706578           | U01TR002623          | 93.350 | -                        | 258,811             | 258,811           |
| NIH               | National Center for Advancing Translational Sciences                                |                   | Engaging Cooperative Sites for                                | Vanderbilt University Medical Center   |                                     | VUMC116723                | U24TR004437          | 93.350 | -                        | 100,022             | 100,022           |
| NIH               | National Center for Advancing Translational Sciences                                |                   | Data Management and Coordinati                                |  |                                     |                           | U2CTR002818          | 93.350 | 25,071                   | 5,609,173           | 5,634,244         |
| NIH               | National Center for Advancing Translational Sciences                                |                   | Primary Immune Deficiency Trea                                | Baylor College of Medicine             |                                     | UG3TR003908               | UG3TR003908          | 93.350 | -                        | 5,866               | 5,866             |
| NIH               | National Center for Advancing Translational Sciences                                |                   | Center for Clinical and Transl                                | University of Cincinnati               |                                     | 2UL1TR001425-05A1         | UL1TR001425          | 93.350 | -                        | 2,566,290           | 2,566,290         |
|                   | National Center for Advancing Translational Sciences Total                          |                   |   |  |                                     |                           |                      |        | 25,071                   | 9,108,801           | 9,133,872         |
| CDC               | Occupational Safety and Health Program  |                   | Workplace Violence in Outpatie                                | Baylor College of Medicine             |                                     |                           | R01OH011930          | 93.262 | -                        | 249,074             | 249,074           |
| CDC               | Occupational Safety and Health Program  |                   | Enhanced injury surveillance u                                |  |                                     |                           | R01OH011996          | 93.262 | -                        | 742,150             | 742,150           |
| CDC               | Occupational Safety and Health Program  |                   | Defining the Role and Occupati                                |  |                                     |                           | R21OH012679          | 93.262 | -                        | 120,227             | 120,227           |
| CDC               | Occupational Safety and Health Program  |                   | Newman UC sub T42 ERC Renewal                                 | University of Cincinnati               |                                     | 0001253                   | T42OH008432-16-00    | 93.262 | -                        | 10,217              | 10,217            |
|                   | Occupational Safety and Health Program Total  |                   |   |  |                                     |                           |                      |        | -                        | 1,121,668           | 1,121,668         |
| NIH               | Research and Training in Complementary and Alternative Medicine                     |                   | Dissecting Neural Mechanisms S                                | Wake Forest University                 |                                     | 1679-45117-1100000967     | R01AT010171          | 93.213 | -                        | 616,531             | 616,531           |
| NIH               | Research and Training in Complementary and Alternative Medicine                     |                   | Online Techniques and Educatio                                |  |                                     |                           | R01AT011502          | 93.213 | -                        | 48,320              | 48,320            |
| NIH               | Research and Training in Complementary and Alternative Medicine                     |                   | RELAXaHEAD: A Behavioral Appro                                | NYU Langone Health                     |                                     | 119664                    | R01AT011875          | 93.213 | -                        | 46,236              | 46,236            |

(Continued)

**Children's Hospital Medical Center and Affiliates**

Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024

| Government Agency | Division                       | Government Branch   | Award Title   | Pass-Through Grantor                   | Subrecipient Name                      | Identifying Number     | Federal Grant Number   | ALN    | Subrecipient Expenditure | Federal Expenditure | Total Expenditure |
|-------------------|--------------------------------|---|---|--|--|------------------------|------------------------|--------|--------------------------|---------------------|-------------------|
|                   | NIH                            | Research and Training in Complementary and Alternative Medicine   | Feasibility and acceptability   | The Research Instit at Nationwide Hosp |  | 700266-0622-00         | R34AT011218            | 93.213 | \$ -                     | \$ 26,645           | \$ 26,645         |
|                   | NIH                            | Research and Training in Complementary and Alternative Medicine   | Integrative Training Program f  | Emory University                       |  | A730969                | R61AT012421            | 93.213 | -                        | 182,830             | 182,830           |
|                   | NIH                            | Research and Training in Complementary and Alternative Medicine   |   |  | University of Colorado                 |                        | U01AT010132            | 93.213 | 118,301                  | 522,020             | 640,321           |
|                   | NIH                            | Research and Training in Complementary and Alternative Medicine   | Food-Body-Mind Intervention: P  | Michigan State University              |  | RC115611CCHMC          | UG3AT012521            | 93.213 | -                        | 37,947              | 37,947            |
|                   |                                | Research and Training in Complementary and Alternative Medicine Total   |   |  |  |                        |                        |        | 118,301                  | 1,480,529           | 1,598,830         |
|                   | NIH                            | Cancer Control  | Norris PHI-COG NCORP PCR Work   | Public Health Institute                |  | UG1CA189955-08         | UG1CA189955            | 93.399 | -                        | 260                 | 260               |
|                   |                                | Cancer Control Total  |   |  |  |                        |                        |        | -                        | 260                 | 260               |
|                   | HRSA                           | Healthy Start Initiative  |   |  | University of Cincinnati               |                        | H49MC27823             | 93.926 | 184,978                  | 1,010,412           | 1,195,390         |
|                   |                                | Healthy Start Initiative Total  |   |  |  |                        |                        |        | 184,978                  | 1,010,412           | 1,195,390         |
|                   | NIH                            | Research Infrastructure Programs  | Establish a novel mouse model   |  |  |                        | R21OD031906            | 93.351 | -                        | 551                 | 551               |
|                   | NIH                            | Research Infrastructure Programs  | Development of a mouse model o  |  | New York University School of Medicine |                        | R21OD031907            | 93.351 | -                        | 193,432             | 193,432           |
|                   | NIH                            | Research Infrastructure Programs  | A new mouse model to study GBA  |  |  |                        | R21OD033660            | 93.351 | 69,610                   | 134,343             | 203,953           |
|                   |                                | Research Infrastructure Programs Total  |   |  |  |                        |                        |        | 69,610                   | 328,326             | 397,936           |
|                   | CDC                            | Rare Disorders: Research, Surveillance, Health Promotion, and Education   | Woodward CDC NSBPR Registry 20  |  |  |                        | U01DD001279            | 93.315 | -                        | 65,604              | 65,604            |
|                   |                                | Rare Disorders: Research, Surveillance, Health Promotion, and Education Total   |   |  |  |                        |                        |        | -                        | 65,604              | 65,604            |
|                   | NIH                            | Minority Health and Health Disparities Research   | Model-Informed Evaluation of H  |  | University of California               |                        | K01MD017289            | 93.307 | -                        | 59,952              | 59,952            |
|                   | NIH                            | Minority Health and Health Disparities Research   | Linking pre- and post-natal psychosoc                                     |  |  |                        | R01MD013006            | 93.307 | 15,457                   | 497,139             | 512,596           |
|                   | NIH                            | Minority Health and Health Disparities Research   | Growing and Sustaining Communi  | University of Cincinnati               |  | 015322-0003            | R25MD019150            | 93.307 | -                        | 8,317               | 8,317             |
|                   |                                | Minority Health and Health Disparities Research Total   |   |  |  |                        |                        |        | 15,457                   | 565,408             | 580,865           |
|                   | AHRQ                           | National Research Service Awards_Health Services Research Training  | Describing ventilator weaning   | Children's Hospital of Philadelphia    |  | 3201350921 PO 20269160 | K12HS026393            | 93.225 | -                        | 32,923              | 32,923            |
|                   | AHRQ                           | National Research Service Awards_Health Services Research Training  | Toward Patient-Centered Clinic  | Children's Hospital of Philadelphia    |  | 3201350923             | K12HS026393            | 93.225 | -                        | 141,420             | 141,420           |
|                   |                                | National Research Service Awards_Health Services Research Training Total  |   |  |  |                        |                        |        | -                        | 174,343             | 174,343           |
|                   | ACL                            | Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health       | Parents Empowering Parents: Na  | Brandeis University                    |  | 404244                 | 90DPCP0012             | 93.433 | -                        | 17,393              | 17,393            |
|                   | ACL                            | Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health       | Accessible Pregnancy Action Pl  | Brandeis University                    |  | 404234                 | 90DPHF0011             | 93.433 | -                        | 18,011              | 18,011            |
|                   | ACL                            | Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health       | Enhancing Parenting Skills: Application of a web-based three-tiered model | University of Oregon                   |  | 239530A                | 90DPHF003-01-00        | 93.433 | -                        | 30,191              | 30,191            |
|                   | ACL                            | Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health       | Setting Families on a Positive  |  | Nationwide Childrens Hospital          |                        | 90IFRE0055             | 93.433 | 8,666                    | 92,621              | 127,713           |
|                   | ACL                            | Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health       | Impacts of Internalized, Inter  |  | Xavier University                      |                        | 90IFRE0062             | 93.433 | 26,426                   | -                   | -                 |
|                   | ACL                            | Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health       | A Randomized Trial of I-INTERA  |  |  |                        | 90IFRE0075             | 93.433 | -                        | 173,481             | 173,481           |
|                   |                                | Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health Total |   |  |  |                        |                        |        | -                        | 57,331              | 57,331            |
|                   |                                |   |   |  |  |                        |                        |        | 35,092                   | 389,028             | 424,120           |
|                   | NIH                            | Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders                            | Accelerating Delivery of rheum  |  | Children's Research Institute          |                        | R01HL164615            | 93.840 | 32,278                   | 368,834             | 713,881           |
|                   | NIH                            | Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders                            |   |  | Uganda Heart Institute                 |                        |                        |        | 287,805                  | -                   | -                 |
|                   | NIH                            | Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders                            |   |  | University of Washington               |                        |                        |        | 24,964                   | -                   | -                 |
|                   |                                | Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders Total                      |   |  |  |                        |                        |        | 345,047                  | 368,834             | 713,881           |
|                   | HRSA                           | Autism Collaboration, Accountability, Research, Education, and Support  | DBPNet ADHD Node CHOP SubIN RE  | Children's Hospital of Philadelphia    |  | GRT-00001441           | UTSMC42432-01-00       | 93.877 | -                        | 17,009              | 17,009            |
|                   |                                | Autism Collaboration, Accountability, Research, Education, and Support Total  |   |  |  |                        |                        |        | -                        | 17,009              | 17,009            |
|                   | CDC                            | Chronic Diseases: Research, Control, and Prevention   | Improving Pediatric Lupus Care  | University of Utah                     |  | 10064135-04-CCHMC      | U01DP006702            | 93.068 | -                        | 6,231               | 6,231             |
|                   |                                | Chronic Diseases: Research, Control, and Prevention Total   |   |  |  |                        |                        |        | -                        | 6,231               | 6,231             |
|                   |                                | Dept of Health and Human Serv Total   |   |  |  |                        |                        |        | 26,284,219               | 190,386,066         | 216,670,285       |
|                   | Office of Personnel Management | Intergovernmental Personnel Act (IPA) Mobility Program  | Mechanisms of liver failure   |  |  |                        | VA IPA Verma           | 27.011 | -                        | 5,728               | 5,728             |
|                   | OPM                            | Intergovernmental Personnel Act (IPA) Mobility Program  | Mechanisms of liver failure   |  |  |                        | VA IPA Subrumaniyam    | 27.011 | -                        | 9,191               | 9,191             |
|                   | OPM                            | Intergovernmental Personnel Act (IPA) Mobility Program  | Fadden IPA  |  |  |                        | VA IPA Fadden, Cather  | 27.011 | -                        | 20,001              | 20,001            |
|                   | OPM                            | Intergovernmental Personnel Act (IPA) Mobility Program  | Ho IPA  |  |  |                        | VA IPA Ho, Danielle    | 27.011 | -                        | 24,276              | 24,276            |
|                   | OPM                            | Intergovernmental Personnel Act (IPA) Mobility Program  | Tripathi IPA  |  |  |                        | VA IPA Tripathi, Pulak | 27.011 | -                        | 63,577              | 63,577            |
|                   |                                | Intergovernmental Personnel Act (IPA) Mobility Program Total  |   |  |  |                        |                        |        | -                        | 122,773             | 122,773           |
|                   |                                | Office of Personnel Management Total  |   |  |  |                        |                        |        | -                        | 122,773             | 122,773           |
|                   |                                | Research and Development Total  |   |  |  |                        |                        |        | 26,482,314               | 195,570,397         | 222,052,711       |
|                   | Department of Transportation   | NHTSA State and Community Highway Safety  | Occupant Protection Regional C  | Ohio Department of Health (ODH)        |  | 03130014BB0623         |                        | 20.600 | -                        | 17,596              | 17,596            |
|                   | NHTSA                          | State and Community Highway Safety  | Occupant Protection Regional C  | Ohio Department of Health (ODH)        |  | 03130014BB0124         |                        | 20.600 | -                        | 24,046              | 24,046            |
|                   |                                | State and Community Highway Safety Total  |   |  |  |                        |                        |        | -                        | 41,642              | 41,642            |
|                   |                                | Highway Safety Cluster Total  |   |  |  |                        |                        |        | -                        | 41,642              | 41,642            |

(Continued)

**Children's Hospital Medical Center and Affiliates**

**Supplementary Schedule of Expenditure of Federal Awards  
For the Year Ended June 30, 2024**

| Government Agency             | Division | Government Branch   | Award Title  | Pass-Through Grantor                               | Subrecipient Name                        | Identifying Number        | Federal Grant Number          | ALN    | Subrecipient |            | Federal     |             | Total |             |
|-------------------------------|----------|---|--|--|--|---------------------------|-------------------------------|--------|--------------|------------|-------------|-------------|-------|-------------|
|                               |          |   |  |  |  |                           |                               |        | Expenditure  |            | Expenditure |             |       |             |
| Department of Agriculture     | USDA     | Special Supplemental Nutrition Program for Women, Infants, and Children                             | Application Digital Accessibil                                   | Food Research & Action Center                      | University of Cincinnati                 | 238DC001M2003             | 238DC001M2003                 | 10.557 | \$           | 51,761     | \$          | 84,857      | \$    | 136,618     |
| Department of the Treasury    | TREAS    | Coronavirus State and Local Fiscal Recovery Funds   | Enhancing Public Health Data S                                   | Board of County Commissioners, Hamilton County, OH | The Health Collaborative                 | Hamilton County ARPA_Hart | COVID-19 Hamilton County ARPA | 21.027 |              | 99,422     |             | 232,848     |       | 332,270     |
| Department of the Treasury    | TREAS    | Coronavirus State and Local Fiscal Recovery Funds   | ARPA funding coming from OHMHA                                   | State of Ohio                                      |  | OMHAS - Promoting Wellnes | COVID-19 OMHAS                | 21.027 |              | -          |             | 252,486     |       | 252,486     |
| Department of the Treasury    | TREAS    | Coronavirus State and Local Fiscal Recovery Funds   | ECS-Maternal, Infant, and Early Childhood Home Visiting (MIECHV) | Northern Kentucky Ind Health Dis                   | St. Elizabeth Medical Center             | COVID-19 X11MC45273       | COVID-19 X11MC45273           | 21.027 |              | 135,677    |             | -           |       | 135,677     |
| Dept of Health and Human Serv | CDC      | Public Health Emergency Preparedness  | Poison Center Bioterrorism Pre                                   | Nationwide Children's Hospital                     |  | 720441-0623-00            | 34225-A4                      | 93.069 |              | -          |             | 67,126      |       | 67,126      |
| Dept of Health and Human Serv | CDC      | Environmental Public Health and Emergency Response  | ODH Asthma Home Assessment Pro                                   | Ohio Department of Health                          |  | ODH_Newman                | NUE1EH001385-02-00            | 93.070 |              | -          |             | 31,814      |       | 31,814      |
| Dept of Health and Human Serv | CDC      | Blood Disorder Program: Prevention, Surveillance and Research                                       | Community Counts: Public Healt                                   | Hemophilia Foundation of Michigan                  |  | NU27DD000020              | NU27DD000020                  | 93.080 |              | -          |             | 26,615      |       | 26,615      |
| Dept of Health and Human Serv | ACF      | Personal Responsibility Education Program   | Evaluation of Using the Connece                                  | Texas A & M  |  | M2200564                  | 90AP2702                      | 93.092 |              | -          |             | 215,649     |       | 215,649     |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Federal Consolidated Programs   | Region V East Comprehensive Care Network for Bleeding D          | Hemophilia Foundation of Michigan                  |  | H30MC24047                | H30MC24047                    | 93.110 |              | -          |             | 23,107      |       | 23,107      |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Federal Consolidated Programs   | IDF Severe Combined Immunodef                                    | University of California, San Francisco            |  | 12689sc                   | SC1MC31881                    | 93.110 |              | -          |             | 1,939       |       | 1,939       |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Federal Consolidated Programs   | Leadership Education in Neurod                                   | University of Cincinnati                           |  | 013719-0003               | T73MC00032                    | 93.110 |              | -          |             | 703,782     |       | 703,782     |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Federal Consolidated Programs   | Cincinnati Developmental-Behav                                   |  |  | T7749098                  | T7749098                      | 93.110 |              | -          |             | 277,743     |       | 277,743     |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Federal Consolidated Programs   | HRSA Central Region Thalassemi                                   | Ann & Robert H Lurie Children's Hospital           |  | 901639-CCHMC              | U1AMC41738                    | 93.110 |              | -          |             | 13,501      |       | 13,501      |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Federal Consolidated Programs   | Center for Pediatric Everyday                                    | University Hospital of Cleveland                   |  | DHHS HRSA-21-104 Regional | U1IMC43532                    | 93.110 |              | -          |             | 36,900      |       | 36,900      |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Federal Consolidated Programs   | Ohio Department of Health (ODH                                   | Ohio State University/ODH                          | University Hospitals of Cleveland        | SPC-1000012488 GR133169   | U7A50515                      | 93.110 | 68,761       |            |             | 33,076      |       | 101,837     |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Federal Consolidated Programs   | Newborn Screening Systems Qual                                   | Association of Public Health Laboratorie           | Nationwide Childrens Hospital            | 56300-600-158-22-24       | UG8MC31893                    | 93.110 | 1,238        |            |             | 14,309      |       | 15,547      |
| Dept of Health and Human Serv | CDC      | Health Program for Toxic Substances and Disease Registry  | Pediatric Environmental Health                                   | Univ of Illinois @ Chicago                         |  | 17852-00                  | NU61TS000296                  | 93.161 |              | -          |             | 38,784      |       | 38,784      |
| Dept of Health and Human Serv | CDC      | Disabilities Prevention   | Improving the Health of People                                   | Ohio State University                              |  | SPC - 1000005432          | NU27DD000032                  | 93.184 |              | -          |             | 40,902      |       | 40,902      |
| Dept of Health and Human Serv | HRSA     | Poison Center Support and Enhancement Grant Program   | Cincinnati Drug and Poison Inf                                   |  |  | H4BHS15468                | H4BHS15468                    | 93.253 |              | -          |             | 400,622     |       | 400,622     |
| Dept of Health and Human Serv | HRSA     | Sickle Cell Treatment Demonstration Program   | Sickle Treatment and Outcomes                                    |  | Children's Hosp & Clinics of Minnesota   | U1E27863                  | U1E27863                      | 93.365 |              | 66,515     |             | 659,769     |       | 1,136,701   |
| Dept of Health and Human Serv | HRSA     | Sickle Cell Treatment Demonstration Program   |  |  | Five Rivers Health Centers               |                           |                               |        |              | 8,510      |             | -           |       | -           |
| Dept of Health and Human Serv | HRSA     | Sickle Cell Treatment Demonstration Program   |  |  | Indiana Hemophilia & Thrombosis Ctr, Inc |                           |                               |        |              | 69,025     |             | -           |       | -           |
| Dept of Health and Human Serv | HRSA     | Sickle Cell Treatment Demonstration Program   |  |  | Medical College of Wisconsin             |                           |                               |        |              | 51,047     |             | -           |       | -           |
| Dept of Health and Human Serv | HRSA     | Sickle Cell Treatment Demonstration Program   |  |  | Sanford Research                         |                           |                               |        |              | 15,952     |             | -           |       | -           |
| Dept of Health and Human Serv | HRSA     | Sickle Cell Treatment Demonstration Program   |  |  | Sickle Cell Disease Assoc of America     |                           |                               |        |              | 30,438     |             | -           |       | -           |
| Dept of Health and Human Serv | HRSA     | Sickle Cell Treatment Demonstration Program   |  |  | University of Michigan                   |                           |                               |        |              | 56,928     |             | -           |       | -           |
| Dept of Health and Human Serv | HRSA     | Sickle Cell Treatment Demonstration Program   |  |  | University of Illinois at Chicago        |                           |                               |        |              | 178,517    |             | -           |       | -           |
| Dept of Health and Human Serv | HRSA     | Congressional Directives Discretionary  | Cincinnati Children's I29Xe Hy                                   |  |  | CE146670                  | CE146670                      | 93.493 |              | -          |             | 462,375     |       | 462,375     |
| Dept of Health and Human Serv | HRSA     | Congressional Directives Discretionary  | High End Cell Sorter   |  |  | CE152338                  | CE152338                      | 93.493 |              | -          |             | 630,000     |       | 630,000     |
| Dept of Health and Human Serv | HRSA     | Family to Family Health Information Centers   | Family Professional Partnership/CSHCN                            |  |  | H8428443                  | H8428443                      | 93.504 |              | -          |             | 85,511      |       | 85,511      |
| Dept of Health and Human Serv | ACL      | Developmental Disabilities Projects of National Significance  | National Center for Disability                                   |  | Autistic Self Advocacy Network Inc       | 90NCDE0001                | 90NCDE0001                    | 93.631 |              | 18,750     |             | 208,592     |       | 276,389     |
| Dept of Health and Human Serv | ACL      | Developmental Disabilities Projects of National Significance  |  |  | Kennedy Krieger Institute, Inc.          |                           |                               |        |              | 24,058     |             | -           |       | -           |
| Dept of Health and Human Serv | ACL      | Developmental Disabilities Projects of National Significance  |  |  | Morehouse School of Medicine Inc         |                           |                               |        |              | 24,989     |             | -           |       | -           |
| Dept of Health and Human Serv | ACL      | University Centers for Excellence in Developmental Disabilities Education, Research, and Service    | University Centers for Excell                                    | University of Cincinnati                           |  | 014723-00002              | 90DDUC0111                    | 93.632 |              | -          |             | 589,051     |       | 589,051     |
| Dept of Health and Human Serv | ACL      | University Centers for Excellence in Developmental Disabilities Education, Research, and Service    | Expanding the Public Health Wo                                   | University of Cincinnati                           |  | 014340-00002              | 90UCPH0030                    | 93.632 |              | -          |             | 30,760      |       | 30,760      |
| Dept of Health and Human Serv | HRSA     | Maternal, Infant, and Early Childhood Home Visiting (MIECHV)  | ECS-Maternal, Infant, and Early Childhood Home Visiting (MIECHV) | Ohio Department of Health                          | Best Point Edu & Behavioral Heath        | 03160191MH0523            | 03160191MH0523                | 93.870 | 126,264      |            |             | 1,408       |       | 127,672     |
| Dept of Health and Human Serv | HRSA     | Maternal, Infant, and Early Childhood Home Visiting (MIECHV)  | ECS-Maternal, Infant, and Early Childhood Home Visiting (MIECHV) | Ohio Department of Health                          | Best Point Edu & Behavioral Heath        | 03160191MH0724            | 03160191MH0724                | 93.870 | 393,340      |            |             | 7,094       |       | 400,434     |
| Dept of Health and Human Serv | HRSA     | Maternal, Infant, and Early Childhood Home Visiting (MIECHV)  | ECS-Maternal, Infant, and Early Childhood Home Visiting (MIECHV) | Northern Kentucky Ind Health Dis                   | St. Elizabeth Medical Center             | X10MC46867                | X10MC46867                    | 93.870 | 528,253      |            |             | -           |       | 528,253     |
| Dept of Health and Human Serv | HRSA     | Grants for Training in Primary Care Medicine and Dentistry  | Dental Faculty Loan Repayment Program Funding Opportun           |  |  | D87HP31252                | D87HP31252                    | 93.884 |              | -          |             | 201,276     |       | 201,276     |
| Dept of Health and Human Serv | ASPR     | National Bioterrorism Hospital Preparedness Program   | Bureau of Health Preparedness, Hospital                          | Ohio Department of Health                          |  | 6U3REP190583-04-01/6NU90T | U3REP190583                   | 93.889 |              | -          |             | 50,000      |       | 50,000      |
| Dept of Health and Human Serv | ASPR     | National Bioterrorism Hospital Preparedness Program   | Eastern Great Lakes Pediatric                                    | University Hospital of Cleveland                   |  | U3REP190615               | U3REP190615                   | 93.889 |              | -          |             | 118,135     |       | 118,135     |
| Dept of Health and Human Serv | CDC      | Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs | OPQC: Addressing gaps and equi                                   |  | The Ohio State University                | NU58DP007264              | NU58DP007264                  | 93.946 | 63,171       |            |             | 151,759     |       | 289,552     |
| Dept of Health and Human Serv | CDC      | Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs |  |  | University Hospitals of Cleveland        |                           |                               |        |              | 28,745     |             | -           |       | -           |
| Dept of Health and Human Serv | CDC      | Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs |  |  | University of Iowa                       |                           |                               |        |              | 45,877     |             | -           |       | -           |
| Dept of Health and Human Serv | SAMHSA   | Block Grants for Community Mental Health Services   | Suicide Prevention Caring Contacts                               | Nationwide Children's Hospital/OMHAS               |  | 720711-0623-00            | B09SM084002                   | 93.958 |              | -          |             | 20,000      |       | 20,000      |
| Dept of Health and Human Serv | HRSA     | Block Grants for Prevention and Treatment of Substance Abuse  | Substance Abuse Prevention and Treatment                         |  |  |                           | MHRSB Hamilton County         | 93.959 |              | -          |             | 202,623     |       | 202,623     |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Services Block Grant to the States  | Community Breastfeeding Ambass                                   | Ohio Department of Health                          |  | 03130011BH0224            |                               | 93.994 |              | -          |             | 116,481     |       | 116,481     |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Services Block Grant to the States  | Compassionate, Respectful, and                                   | Ohio Department of Health                          |  | 53702                     |                               | 93.994 |              | -          |             | 136,759     |       | 136,759     |
| Dept of Health and Human Serv | HRSA     | Maternal and Child Health Services Block Grant to the States  | Ohio Department of Health Cont                                   | Ohio Department of Health                          |  | 49688/0000215557-1        | B04MC40155-01-01              | 93.994 |              | -          |             | 8,941       |       | 8,941       |
| Grand Total                   |          |   |  |  |  |                           |                               |        | \$           | 28,569,552 | \$          | 201,788,633 | \$    | 230,358,185 |

(Concluded)

## Children’s Hospital Medical Center and Affiliates

Notes To Supplementary Schedule of Expenditures of Federal Awards  
For The Year Ended June 30, 2024

---

### 1. SCOPE OF AUDIT

All federal grant operations of Children’s Hospital Medical Center and Affiliates (“Cincinnati Children’s”, or the “Company”) are included in the scope of Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Single audits under the Uniform Guidance are performed in accordance with the provisions of the Office of Management and Budget (OMB)’s Compliance Supplement for Single Audits of Higher Learning Institutions and other Non-Profit Institutions (the “Compliance Supplement”). The Department of Health and Human Services has been designated as Cincinnati Children’s cognizant agency for the Single audit.

### 2. DE MINIMIS COST RATE

Cincinnati Children’s did not elect to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

**Basis of Presentation**—The accompanying Supplemental Schedule of Expenditures of Federal Awards (the “Schedule”) includes the federal grant activity of Cincinnati Children’s under programs of the federal government for the year ended June 30, 2024, and is presented on the accrual basis of accounting. This is consistent with the basis of accounting used in the preparation of the basic consolidated financial statements. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Guidance. Because the Schedule presents only a selected portion of the operations of Cincinnati Children’s, it is not intended to and does not present the financial position, changes in net assets or cash flows of Cincinnati Children’s.

**Negative Balances**—Negative amounts represent grants with deficit balances which were closed during fiscal 2024.

## **REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS***

### **INDEPENDENT AUDITOR'S REPORT**

To the Board of Trustees of  
Children's Hospital Medical Center and Affiliates  
Cincinnati, Ohio

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States ("*Government Auditing Standards*"), the consolidated financial statements of Children's Hospital Medical Center and Affiliates (the "Company"), which comprise the Company's consolidated balance sheet as of June 30, 2024, and the related consolidated statements of operations and changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements"), and have issued our report thereon dated September 30, 2024.

#### **Report on Internal Control Over Financial Reporting**

In planning and performing our audit of the financial statements, we considered the Company's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we do not express an opinion on the effectiveness of the Company's internal control.

*A deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. *A material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the Company's financial statements will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

## **Report on Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Company's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

### **Purpose of This Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

*Deloitte + Touche LLP*

September 30, 2024

## **REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE**

### **INDEPENDENT AUDITOR'S REPORT**

To the Board of Trustees  
Children's Hospital Medical Center and Affiliates  
Cincinnati, Ohio

#### **Report on Compliance for Each Major Federal Program**

##### ***Opinion on Each Major Federal Program***

We have audited Children's Hospital Medical Center and Affiliates' (the "Company") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Company's major federal programs for the year ended June 30, 2024. The Company's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Company complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2024.

##### ***Basis for Opinion on Each Major Federal Program***

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Company's compliance with the compliance requirements referred to above.

### ***Responsibilities of Management for Compliance***

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Company's federal programs.

### ***Auditor's Responsibilities for the Audit of Compliance***

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Company's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Company's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we

- exercise professional judgment and maintain professional skepticism throughout the audit
- identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Company's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances
- obtain an understanding of the Company's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

### ***Report on Internal Control Over Compliance***

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of

compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

***Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance***

We have audited the financial statements of the Company as of and for the year ended June 30, 2024, and have issued our report thereon dated September 30, 2024, which contained an unmodified opinion on those financial statements. Our audit was performed for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the financial statements as a whole.

*Deloitte + Touche LLP*

March 18, 2025

# Children's Hospital Medical Center and Affiliates

Schedule Of Findings and Questioned Costs  
For The Year Ended June 30, 2024

---

## SECTION I. SUMMARY OF AUDITOR'S RESULTS

### Financial Statements:

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

Internal control over financial reporting:

- Material weakness(es) identified?  Yes  No
- Significant deficiency(ies) identified?  Yes  None reported
- Noncompliance material to financial statements noted?  Yes  No

### Federal Awards:

Internal control over major programs:

- Material weakness(es) identified?  Yes  No
- Significant deficiency(ies) identified?  Yes  None reported

Type of auditor's report issued on compliance for major programs:

Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

Yes  No

Identification of Major Programs:

**ALN Number**

**Name of Federal Program or Cluster**

---

Various

Research and Development Cluster (R&D)

---

Dollar threshold used to distinguish between Type A and Type B programs?

\$ 3,000,000

Auditee qualified as low-risk auditee?

Yes  No

**SECTION II. FINANCIAL STATEMENT FINDINGS**

None

**SECTION III. FEDERAL AWARD FINDINGS AND QUESTIONED COSTS**

None

**SECTION IV. SUMMARY SCHEDULE OF PRIOR YEAR AUDIT FINDINGS**

None